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CHAPTER 1: SUMMARY 
 
Chronic kidney disease (CKD) is a clinical syndrome with a high prevalence both in human 
and veterinary medicine. Being able to formulate an early diagnosis of CKD can allow 
veterinarians to introduce a dietary and medical therapy, which can dramatically reduce 
progression towards end stage renal disease (ESRD)1. At the same time, strong evidences of a 
deep relationship between heart and kidney in the progression of CKD in humans, have led to 
a greater attention towards potential markers of prognosis and negative outcome of the 
disease, even in small animal population. The present research project has been organized in 
two sections2,3.  
 
FIRST SECTION 
The aim of the first part of the study has been to validate a glomerular filtration rate (GFR) 
method, at a low number of plasma samples, through the plasma clearance of iohexol in both 
CKD and clinically healthy cats.  
MATERIALS AND METHODS - After the owners’ informed consent, 53 clinically healthy and 14 
CKD cats have been submitted to a first blood sample (0) and to an eight-hour clearance 
study. Iohexol (Omipaque® 300 mgI/ml) has been intravenous injected at the dose of 64.7 
mg/kg body weight. Heparinised blood samples have been taken at 5 and 30 minutes and 1, 2, 
4, 6 and 8 hours from the completion of iohexol injection. Plasma has been obtained and each 
sample has been stored at -20 C° till extraction process and HPLC analysis. Pharmacokinetic 
analysis has been performed through the software Easy Fit® for Macintosh (Istituto Mario 
Negri, Milano, Italia) and, for each subject of HC and CKD group, plasma concentration of 
iohexol/time curves have been analyzed through a non-compartimental kinetic model. Then, a 
pharmacokinetic analysis has been carried on after the application of simplified models 
(Model A, Model B, Model C and Model D) with a lower number of blood samples. 
Statistical analysis has been performed by using the software GraphPad Prism 4 for 
Macintosh, USA. 
RESULTS – t-test analysis (p<0.05) between GFR of CH and CKD patients has shown a 
significant difference between the two groups of subjects, not only for reference method 
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(p=0.003), but also for Model A (p=0.0005), Model B (p=0.01), Model C (p=0.001) and 
Model D (p=0.004). Pearson correlation analysis (p<0.05) between each simplified model and 
reference method has shown a positive linear correlation with vey high values of Pearson r 
and R2.  
CONCLUSIONS - The present study has validated a safe, simple and accurate three-sample 
HPLC method (5’ – 30’ – 1 hour) for the determination of GFR through the plasma clearance 
of iohexol in feline patients. This model represents an attractive and cheap alternative to 
cumbersome plasma clearance methods, with a dramatic applicatory potential in different 
clinical settings. 
 
SECOND SECTION 
The aim of the second part of the study has been to assess serum ionized calcium, total 
calcium, calcium corrected for albumin (cCaAlb), calcium corrected for total proteins 
(cCaPt), Ca x P product (Ca x P), cardiac troponin I (cTnI), C-reactive proteine (CRP) and α-
tochopherol in CH and CKD canine patients at different stages of the disease.  
MATERIALS AND METHODS – serum ionized calcium, total calcium, cCaAlb and cCaPt have 
been determined in 301 CKD and 125 CH patients, while Ca x P, cTnI, CRP and α-
tochopherol have been assessed in 13 IRIS 1, 7 IRIS 2, 13 IRIS 3 and 11 IRIS 4 subjects. 
Ionized calcium has been determined through a selective ion method (STAT PROFILE® 
pHOx Plus, GEPA, Milano, Italy), cTnI through an immunometric method (IMMUNOLITE 
2000® Immunoassay System), CRP through an immunometric method (RANDOX 
immunoturbidimetric kit for CRP, Vet Med Lab, IDEXX, Germany) and α-tochopherol 
through HPLC (Chromosystems-Diagnostic Kit HPLC & LC/MS, Munchen, Germany). 
Statistical analysis has been performed by using the software GraphPad Prism 4 for 
Macintosh, USA. 
RESULTS – One-way ANOVA has reported a significant difference (p<0.0001) in ionized 
calcium concentration among CH, IRIS 1, IRIS 2, IRIS 3 and IRIS 4 and χ2 analysis has 
shown a significant difference (p<0.0001) in the number of patients with hyper, hypo and 
normocalcemia according to the progression of the disease. One-way ANOVA among CH 
subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients has reported a significant difference in 
the mean value of Ca x P (p<0.0001). No significant correlation has been found between Ca x 
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P and plasma creatinine in any of IRIS classes. The number of patients with Ca x P above 70 
mg/dl has been reported to increase significantly (p<0.0001) with the severity of CKD, as 
well as the number of dead patients (p<0.0008). Finally, Kaplan-Meier survival curve has 
shown a significantly higher percentage of survival (p<0.0002) of CKD patients with Ca x P 
below 70, compared to patients with Ca x P above 70. One-way ANOVA among CH subjects 
and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients has reported a significant difference in the 
mean value of cTnI (p<0.02). No significant correlation has been found between cTnI and 
plasma creatinine in any of IRIS classes. The number of patients with cTnI above 0.20 ng/ml 
has been reported to increase significantly (p<0.0001) with the severity of CKD, as well as 
the number of dead patients (p<0.02). Finally, Kaplan-Meier survival curve has shown a 
significantly higher percentage of survival (p<0.0002) of CKD patients with cTnI below 0.20 
ng/ml, compared to patients with cTnI above 0.20 ng/ml. One-way ANOVA among CH 
subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients has reported a significant difference in 
the mean value of CRP (p<0.0001). No significant correlation has been found between CRP 
and plasma creatinine in any of IRIS classes. The number of patients with CRP above 9.7 
mg/l has been reported to increase significantly (p<0.0001) with the severity of CKD, as well 
as the number of dead patients (p<0.0009). Finally, Kaplan-Meier survival curve has shown a 
significantly higher percentage of survival (p<0.001) of CKD patients with CRP below 9.7 
mg/l, compared to patients with CRP above 9.7 mg/l. One-way ANOVA among CH subjects 
and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients has reported a significant difference in the 
mean value of α-tochopherol (p<0.0002). A significant correlation (p=0.00) has been found 
between α-tochopherol and plasma creatinine in IRIS 2. The number of patients with α-
tochopherol below 21.6 ppm has been reported to increase significantly (p<0.0001) with the 
severity of CKD. No significant difference in the number of survived and dead patients has 
been found between subjects with α-tochopherol below and above 21.6 ppm. Finally, Kaplan-
Meier survival curve has shown no significant difference.  
CONCLUSIONS – The present study has demonstrated a significant increase in Ca x P, cTnI 
and CRP serum concentration according to the progression of CKD. Ca x P, cTnI and CRP 
have shown a prognostic, not IRIS stage-dependent, value and a significant correlation 
towards mortality. In CKD dogs, as well as in humans, alterations of calcium-phosphate 
metabolism, cardiovascular injury and inflammation seemed to play a significant role in the 
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progression and negative outcome of CKD. No correlation has been reported between 
mortality and α-tochopherol, although a significant serum reduction with the progression of 
CKD has been shown. 
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CHAPTER 2: PREFACE AND AIM OF THE STUDY 
 
Chronic kidney disease (CKD) is a complex clinical syndrome, with an even increasing 
prevalence in both human and veterinary medicine1,2. According to human guidelines, CKD 
has been defined as a pathological condition characterized by a persistent renal injury or a 
glomerular filtration rate (GFR) below 60 ml/min/1.73m2, lasting for four to more months, 
with or without evidence of kidney damage, irrespective of the cause. CKD is becoming a 
major public health problem worldwide, which affects about 7.2% of people below 30 years 
old and a 23.4% to 35.8% of people above 64 years old3. In human patients 
glomerulonephritis has been the leading cause of CKD since several decades ago, while, at 
present, infections have been showing an even lower importance in the pathogenesis of the 
disease, at least in the western world. On the contrary, the role of hypertension and diabetes in 
causing CKD has been increasing significantly. In addition, CKD presents wide 
interrelationships with other pathological diseases. Recent reports have underlined that CKD 
is an independent risk factor of cardiovascular disease and the American Heart Association 
stated that persons with CKD should be considered as the highest risk group for developing 
subsequent cardiovascular diseases3,5. The presence of a cardio-renal syndrome, characterized 
by a deep interconnection between kidney and heart injury, has been firstly postulated, then 
widely demonstrated. Oxidative stress, inflammation and alterations in calcium-phosphate 
metabolism have been reported both as risk factors and progressive elements of the cardio-
renal syndrome6.  
In veterinary medicine, as well, CKD represents an even more frequent reason of 
consultation. Its prevalence in feline and canine population has been estimated about 1-3% 
and 0.5-1.5% respectively. When geriatric patients are considered, the prevalence of CKD can 
reach 10% in dogs and 35% in cats. Moreover, recent reports have showed that, on a ten-year 
period of clinical activity, the 24% of canine patients, presented for consultation, were 
affected by CKD7. Since 2006, the International Renal Interest Society (IRIS) has introduced 
a standardized classification of CKD, based on serum creatinine. According to IRIS 
classification, both canine and feline patients can be classified in four stages of severity8. 
Previously reported epidemiologic studies have taken into consideration only the stages of 
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CKD with plasma creatinine above the reference range. So, no data are available about the 
prevalence of early phases. IRIS stage 1 is, in fact, a totally asymptomatic condition, which 
can be identified only by using GFR. Although in veterinary medicine, as well as in human 
medicine, haemodialysis and renal transplantation are becoming an interest reality all over the 
world, limitations due to high costs and low availability of specialized centers have focused 
the attention on early diagnosis. The establishment of an even earlier diagnosis of CKD can 
allow veterinarians to introduce a dietary and medical therapy, which can reduce the 
progression of patients towards end stage renal disease (ESRD). At the same time, strong 
evidences of a deep relationship between heart and kidney in the progression of CKD in 
humans, have led to an even more attention towards potential markers of prognosis and 
negative outcome of the disease, even in small animal population. 
 
 
In the first section of the present work, the aim of the study has been to identify a simplified 
GFR evaluation method by the plasma clearance of iohexol, based on a low number of plasma 
samples, in both clinically healthy and chronic kidney disease cats. 
In the second section of the research project, the aim of the study has been to evaluate the 
serum concentration of Ca x P product, cardiac troponin I, C-reactive protein and α-
tochopherol in canine patients at different stages of chronic kidney disease and to test their 
prognostic value. 
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CHAPTER 3: CHRONIC KIDNEY DISEASE (CKD): IMPORTANCE OF AN 
EARLY DIAGNOSIS 
 
Chronic kidney disease (CKD) refers to a pathological loss of functional renal tissue, 
characterized by a progressive and prolonged morbid event. Most forms of CKD are not 
reversible and, once acquired, they generally proceed to renal failure. The prevalence of CKD 
in the small animal population is estimated about 1-3% of cats and 0.5-1.5% of dogs and its 
incidence strongly increases with advancing age. In geriatric population the prevalence of 
CKD can reach a percentage of 10% of dogs and 35% of cats1. The vascular and tubular 
components of nephrons are strictly interdependent and CKD represents the end-point of an 
irreversible glomerular or tubular damage. Although the histopathological findings are often 
not process-specific, primary glomerular disorders have been identified as a frequent cause of 
CKD in dogs2.  
The major role of the kidneys is to maintain the normal volume and composition of the 
extracellular fluid by filtering the blood through the glomeruli and adjusting the concentration 
of the substances into the filtrate. At the same time kidneys control the local glomerular 
haemodynamics, sodium reabsorption and systemic blood pressure through the activity of the 
renin-angiotensin-aldosterone system (RAAS). Moreover, the production of erythropoietin 
(EPO) and the activation of calcitriol have to be enrolled among the renal functions. Kidneys 
are so involved in the stimulating activity of production of erythrocytes and in the intestinal 
absorption of calcium. As the kidney shows multiple functions, there is not a single test able 
to assess all of them simultaneously. Whereas many tests are currently available for the 
evaluation of the different renal functions, the clinician has to choose the most appropriate 
one, according to the purpose. In choosing the right test to use, it is essential to take into 
consideration the difference between kidney lesions and renal impairment. As a damaged 
kidney may have a normal function and CKD may show no visible lesions, it is possible that 
visible kidney injuries exist in the absence of renal dysfunction and vice versa. Patients 
affected by pre-renal acute renal failure (such as with a severe dehydration) can show a 
significant reduction of the GFR even though no lesions can be found in the renal tissue. 
Some tests are more useful than others depending on the course of the disease. Ultrasound and 
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renal biopsy can be more helpful in the diagnosis of ARF, while functional tests can play a 
fundamental role as diagnostic indexes of CKD1. Though the multiple renal functions cannot 
be assessed simultaneously, GFR is universally recognized as the most accurate marker of the 
overall renal function. GFR is a precise and direct test of glomerular filtration, which can 
detect a decreased kidney function before the onset of a CKD status3. GFR is directly related 
to the functional renal mass of the patient and allows a quantitative evaluation of the overall 
kidney function both in healthy and in nephropatic subjects. Canine and feline kidneys are 
constituted by a big number of nephrons, which work together side by side. It is possible that 
a loss of a certain number of nephrons occurs without any clinical evidence of renal failure. 
Kidneys show a great ability to compensate for a significant lack of renal mass by increasing 
the activity of the survived nephrons. More than 50% of the total renal tissue has to be 
destroyed before lacking the urinary concentration ability and more than 70% before 
developing clinical symptoms of CKD4,5.  
 
 
Glomerular filtration rate (GFR): gold standard test of overall renal function 
 
For a long period of time GFR has been estimated through the clearance of blood urea and 
creatinine. Although these parameters provide just a crude index of GFR they are still largely 
use for the diagnosis of CKD by the majority of veterinarians (6). Urea and creatinine show a 
very low sensibility in predicting GFR. Correlation studies performed between blood urea and 
GFR and between blood creatinine and GFR reported a significant dispersion, showing a poor 
ability to estimate GFR (7). The compensatory hyper-filtration of survived nephrons is 
responsible for a late haematic increase of creatinine and urea concentration. The blood value 
of creatinine starts to rise when more than 65-70% of the total functional renal mass has been 
definitely lost (6-8-9). GFR can be calculated through the evaluation of plasma or urinary 
clearance of a substance. An ideal marker of GFR should be freely filtered by the glomerulus 
(not protein bound) and not affected by tubular reabsorbing process or secretion or be 
metabolized elsewhere in the body. In addition the marker must not be toxic for the patient. 
At present, in veterinary medicine, GFR can be assessed through different methods, which 
present both advantages and disadvantages. In canine patients the urinary clearance of inulin 
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is considered the gold standard method for the GFR evaluation. Inulin does not bound to 
plasma proteins and shows no significant metabolism. This compound is freely filtrated 
through the glomerulus and not reabsorbed or secreted by the tubulus. Inulin shows a 
negligible toxicity and several studies reported no side effects in treated animals (9-10-11). 
Nevertheless, the urinary clearance of inulin is a cumbersome method, which requires an 
extremely accurate urine sampling. Moreover inulin is an expensive compound, not easily 
available in Europe, which needs special equipments to be analyzed. The urinary clearance of 
inulin, such as other urinary methods (endogenous and exogenous creatinine), shows several 
disadvantages due to urine collection. These methods require urine collection for a lengthy 
period (i.e. 24 hours) to minimize errors in the collection, thus necessitating indwelling 
catheters, repeated catheterization or metabolic cages. The use of urinary catheterization and 
metabolic cages can cause urinary infections and be extremely stressful for patients (10-6). 
Endogenous creatinine is freely filtered by the renal glomerulus and it derives from a constant 
breakdown of muscle creatine phosphate. Although no protein binding is present, endogenous 
creatinine clearance can be influenced by several factors, such as gender, age, season, 
biological rhythm, hydration, physical exercise and site of blood sample. Furthermore, plasma 
and serum contain other compounds, which are inappropriately measured as creatinine, when 
Jaffe reaction method is used. In addition, male dogs have shown a small degree of renal 
tubular secretion of creatinine. In order to reduce problems connected with endogenous 
creatinine clearance, methods based on exogenous creatinine clearance have been developed. 
Initially these methods have been performed through constant rate infusion or subcutaneous 
techniques, then a single intravenous bolus way has been proposed20. Constant infusion 
method has reported to underestimate GFR by as much as 18.8% in feline patients21. Single-
bolus plasma clearance of exogenous creatinine has been accepted as an accurate and simple 
method to determine GFR22,23. Anyway, it has to be underlined that, in order to obtain 
accurate measurements of GFR, this method should extend over a ten-hour period with a 
minimum of three to five samples24. Radioactive GFR markers, such as 51Cr-
ethylenediaminetetraacetic acid (EDTA) and 99mTc-diethylenetriaminepentaacetic acid 
(DTPA), fulfil all characteristics of ideal markers and can allow a contemporary renal 
scintigraphy, in order to assess overall and single renal function. Unfortunately these methods 
show multiple disadvantages, including low availability of laboratories, appropriate facilities 
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to conduct nuclear medicine-based tests and high intra-dog variability20. Radioactive markers, 
in fact, need gamma camera to be detected, so operator inexperience may cause significant 
lack in accuracy of GFR measurement25. Finally, GFR can be assessed through plasma 
clearance of iohexol. Iohexol is a low osmolality, non-ionic, iodinated contrast medium, 
which can be determined by using different techniques. High plasma stability of iodinated 
compounds allows them to be frozen for extended times. Although, different detecting 
techniques have shown significant differences in GFR result, according to quantification of 
endo- or exo-iohexol, high performance liquid chromatography (HPLC) system has 
demonstrated the more accurate and high reproducibility method26,27. Moreover, iohexol has 
been generally considered very safe even in severely nephropatic subjects 28,29. Plasma 
clearance of iohexol has been considered a valid method of GFR determination in both dogs 
and cats. At present, a two plasma sample and two-hour method in dogs and a two-hour 
plasma sample and three-hour method in cats, are considered the best compromise between 
accuracy and easy applicability of the method30. Very recently, an automated colorimetric 
gadolinium assay for GFR evaluation has been investigated in canine and feline patients31. 
Gadolinium contrast media are a high osmolality compounds, which have been widely used as 
contrast agents in magnetic resonance imaging (MRI) in both humans and companion 
animals. Anyway, their use in CKD patients is contraindicated. High osmolality contrast 
media gadopentetate have caused severe renal function depression, when injected into renal 
arteries. Radiographic contrast media, in fact, can cause an acute renal failure syndrome. The 
most important nephrotoxic mechanisms of such compounds have been identified in 
hyperosmolality and osmotic diuresis. High osmolality solutions, which are not able to cross 
cell membranes, can be responsible for a renal damage, which ranges from a transient 
depression of renal blood flow and GFR to extensive macro and microscopic changes with 
cessation of renal function. This action depends on the dose and the degree of 
hyperosmolality of the contrast media. Osmotic diuresis, instead, can be generated by contrast 
media molecules, once they have reached tubular lumen. As high osmolality contrast media 
compounds are not reabsorbed by renal tubules, they may act as osmotic diuretics. Osmotic 
load may be toxic for kidneys by activating the tubulo-glomerular feedback mechanism, 
which activates vasoconstrictive agents, by increasing oxygen demand for active reabsorption 
of the high tubular sodium load, by increasing intratubular pressure, with elevation of 
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interstitial pressure and secondary vascular compression beneath the rigid renal capsule32. At 
present, low osmolality contrast media are strongly preferred to high osmolality ones, due to 
significantly lower prevalence of side effects32. 
Urinary clearance methods requires the determination of both plasma and urinary 
concentration of the used marker. As a consequence, all urine must be collected over the 
entire clearance study. An incomplete or inaccurate urine collection leads to an 
underestimation of GFR. 24-hour urine collection and consequent required techniques, make 
these methods very difficult to be performed in companion animals. For this reason, plasma 
clearance methods have shown more utilized in veterinary medicine. In a plasma clearance 
study, GFR is obtained by determining the reduction in plasma concentration of a marker over 
time. Plasma clearance (CLplasma) of a marker is calculated by the formula CLplasma= D/AUC, 
where D corresponds to the dose of the injected marker and AUC to the area under the plasma 
concentration versus time curve. Plasma disappearance curve is determined by multiple 
plasma samples. The resultant total area under the plasma concentration versus time curve is 
affected by the kind of pharmacokinetic model used. One-compartment model produces a 
straight line plasma disappearance curve, which needs a limited number of samples to be 
determined, as the line between any two points is assumed to be constant. Anyway an 
immediate distribution of a marker through the body does not occur in reality, so this model 
may generate errors33. In two-compartment model plasma tracer is supposed to move initially 
from vasculature to body tissues, than to be eliminated by the body. Resultant plasma 
concentration versus time curve is constituted by an initial steep segment (corresponding to 
the initial tissue distribution of the marker), followed by a less steep portion (corresponding to 
the elimination phase). Two-compartment model is highly accurate, because it takes into 
consideration both the distribution and the elimination phase. Anyway, the resolution of the 
curve into two segments is not possible in patients with extracellular fluid volume is 
abnormal34. Multi-compartment model is similar to two-compartment model, with the 
exception that, for each conceptualized compartment, an equal number of straight lines is 
required. Finally, non-compartment model calculates the area under the curve, by adding the 
area of each trapezoid defined by the curve itself. In this model the terminal portion of the 
curve (from the last plasma sample to the time of theoretical zero plasma concentration) is 
estimated.  
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GFR can be expressed to body weight, body surface area or extra-cellular fluid volume. In 
dogs GFR is more related to metabolic rate than to body weight, so it is advisable to express 
GFR as ml/min/m2. Dogs have showed variable results depending on the utilized method of 
standardization, while most studies in cats have produced acceptable results for normalization 
with any method, probably due to their smaller range of body sizes20. 
 
 
 
	   18	  
CHAPTER 4: MATERIALS AND METHODS 
 
 
Treatment of animals 
 
The research project involved a total of 53 privately owned cats of different breed, gender, 
age and weight, presented to the Veterinary Teaching Hospital “Mario Modenato” between 
December 2008 and December 2010. 39 cats, presented for the annual general check up, 
resulted clinically healthy after clinical evaluation and showed no signs of 
polyuria/polydispsia (PU/PD). 14 cats were referred for nephrological consultation due to 
clinical signs of PU/PD, weight loss and plasma levels of creatinine > 1.6 mg/dl. After the 
owner’s informed consent, all cats were submitted to clinical evaluation and blood sampling 
(5 ml) for the evaluation of WBC, RBC, Hct, Hg, plasma urea and creatinine, serum total and 
ionized calcium, phosphate, albumin and total proteins. According to the plasma value of 
creatinine (> 1.6 mg/dl) and the presence of PU/PD, patients were divided in clinically 
healthy (HC) and chronic kidney disease cats (CKD). 53 patients belonged to the HC group, 
while 14 cats to the CKD group. Cats were submitted to a twelve-hour fasting period in order 
to perform the routine haematological and biochemical panel. Each cat was accurately 
weighted and provided with two intravenous catheters at the cephalic veins. A first blood 
sample (0) was taken from one the catheters before injecting the contrast medium and blood 
(0.5 ml) was put into a heparinised tube. The syringe containing iohexol was weighted before 
collecting the contrast medium (empty weight), full of iohexol (pre inoculation weight) and 
after the injection (post inoculation weight), in order to determine the exact injected dose. For 
each patient an identification report was filled in.  Iohexol (Omipaque® 300 mgI/ml) was 
slowly administered through the intravenous catheter at the dosage of 64.7 mg/kg in 60 
seconds. The completion of the injection represented time 0 (t0). Each patient was submitted 
to seven blood samples (0.5 ml) at 5 and 30 minutes and 1, 2, 4, 6 and 8 hours from t0 and 
blood was collected in heparinised tubes. Samples were taken from the intravenous catheter 
opposite to the one used for iohexol inoculation.  
 
	   19	  
Preparation of samples 
 
Blood samples were centrifuged at 3000 rpm for 10 minutes in order to obtain plasma. Each 
plasma sample was classified and stored at -20°C till HPLC analysis. Samples were submitted 
to extraction. 50 µl of plasma were added to 50 µl of iopentol water solution (50 µg/ml) and, 
after a 60 second vortex time, samples were extracted through 100 µl of dichloromethane 
(CH2Cl2) and 150 µl of distilled water. Solution was vortex for 60’’and centrifuged at 3000 
rpm for 10 minutes. Supernatant was centrifuged and injected in HPLC. 
 
Pharmacokinetic analysis 
Results were analyzed through the software Easy Fit® for Macintosh (Istituto Mario Negri, 
Milano, Italia). For each subject of the HC group and the CKD group plasma concentration of 
iohexol/time curves were analyzed through a non-compartimental kinetic model. Then 
pharmacokinetic analysis was performed for each subject after the application of simplified 
models (Model A, Model B, Model C and Model D) with a lower number of blood samples. 
Model A was based on four samples at 5’, 30’, 1 and 4 hours, Model B was based on four 
samples at 5’, 30’, 1 and 2 hours, Model C was based on four samples at 5’, 1, 2 and 4 hours 
and Model D was based on three samples at 5’, 30’ and 1 hour. Plasma concentration/time 
curves were analyzed by using a non-compartimental kinetic model.  
 
Materials 
Iohexol was used as intravenous water solution (Omnipaque® 300 mgI/ml-GE 
HEALTHCARE, GE Medical System, Milano, Italia). All solvents were suitable for a HPLC 
system (Baker Analyzed® Reagent, J.T. Baker, Deventer, Holland). Analytical water, used 
for reaching the right concentration of HPLC mobile phase, was filtered by using cellulose 
vinegar silicone proofed filters (PS Whatman®, Millipore Corporation, Maid Stone, 
England). All other reagents were bought from common commercial sources. 
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Tools 
HPLC system included a binary gradient pump SpectraSYSTEM® P2000 Thermo Finnigan, a 
UV-VIS detector SpectraSYSTEM® 3000 Thermo Finnigan and an automatic sampler 
SpectraSYSTEM® AS3000 Thermo Finnigan (Waltham, MA, USA). The chromatographic 
column (Waters SunFire® 250 x 4,60 mm), with a granulometry of 5 µm, and the pre-column 
(Waters Guard-Pack™, Waters, Milford, MA, USA) were packed through a C18 alkylic 
group-derived silica gel. An injection volume of 100 µl was used.  
 
Standard and stock solutions 
Standard solutions of iohexol were prepared from the commercial water solution 
Omnipaque® 300 mgI/ml (64.7 mg/ml of iohexol), by which a 2 mg/ml mother solution was 
obtained. Standard solutions were obtained from mother solution through different dilutions 
(5, 10, 25, 50, 100 and 200 µg/ml) and calibration line was determined by injecting 100 µl in 
the HPLC system. Standard solutions of iopentol were prepared from the commercial water 
solution Imagopaque® 300mgI/ml (658 mg/ml of iopentol), by which a 2 mg/ml mother 
solution was obtained. Standard solutions were obtained from mother solution through 
different dilutions (5, 10, 15, 50, 100 and 200 µg/ml). Iohexol and iopentol solutions were 
stored sheltered from the light at 4°C.  
 
Chromatographic conditions 
Mobile phase was made by water at a pH of 2.6 and acetonitrile in a 94/6 % v/v ratio. The 
water pH of 2.6 was reached by adding H3PO4 at 85%. A 1.3 ml/min flow was used. Mobile 
phase was degassed through a nitrogen flow. Every time that mobile phase had to be replaced 
with a new one, chromatographic equilibrium was restored before performing HPLC analysis. 
 
Calibration curves 
Calibration lines of iohexol and iopentol were obtained through injection of the standard 
solutions, according to chromatographic conditions. Each solution was injected three times 
and the equation of the calibration curve was determined through the software Graph Pad 
Prism® (Graph Pad Software Inc., IL, USA), by using the mean value of three measurements. 
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Area under chromatographic peaks was measured through the software ChromQuest 4.2 
(Thermo Finnigan, Waltham, MA, USA) and used as a quantitative parameter.  
 
Statistical analysis 
For both HC group and CKD group the average value of GFR (ml/min/kg) obtained by the 
application of the reference seven-sample method (reference method) and simplified models 
(Model A, Model B, Model C and Model D) was calculated. A t-test analysis between the 
GFR values of HC and CKD group was performed for GFR determined through the reference 
method and each of the four simplified models. For each group of patients (HC and CKD) 
Pearson correlation analysis (p<0.05) was carried out among reference GFR and the 
corresponding GFR value assessed through Model A, Model B, Model C and Model D. 
Similarly, a Bland-Altman analysis was performed among reference GFR and the 
corresponding GFR value determined through Model A, Model B, Model C and Model D in 
both HC and CKD patients. Statistical analysis was performed by using the software 
GraphPad Prism 4 for Macintosh, USA.  
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CHAPTER 5: RESULTS 
 
 
t-test analysis 
HC group was composed by 39 cats. Plasma creatinine ranged from a minimum of 0.80 mg/dl 
to a maximum of 1.58 mg/dl (mean: 1.24 mg/dl). Reference GFR ranged from a minimum of 
1.64 ml/min/kg to a maximum of 8.58 ml/min/kg, with a mean value of 3.25 ml/min/kg ± SE 
0.27. Model A GFR ranged from a minimum of 1.52 ml/min/kg to a maximum of 6.80 
ml/min/kg, with a mean value of 3.32 ml/min/kg ± SE 0.47. Model B GFR ranged from a 
minimum of 1.64 ml/min/kg to a maximum of 6.62 ml/min/kg, with a mean value of 3.28 
ml/min/kg ± SE 0.38. Model C GFR ranged from a minimum of 1.40 ml/min/kg to a 
maximum of 6.87 ml/min/kg, with a mean value of 3.08 ml/min/kg ± SE 0.41. Model D GFR 
ranged from a minimum of 1.51 ml/min/kg to a maximum of 7.24 ml/min/kg, with a mean 
value of 3.43 ml/min/kg ± SE 0.39.  
CKD group was composed by 14 cats with clinical signs of PU/PD and plasma creatinine 
above the reference range (1.6 mg/dl). Plasma creatinine ranged from a minimum of 1.87 
mg/dl to a maximum of 3.00 mg/dl (mean: 2.54 mg/dl). Reference GFR ranged from a 
minimum of 1.45 ml/min/kg to a maximum of 3.81 ml/min/kg, with a mean value of 2.30 
ml/min/kg ± SE 0.19. Model A GFR ranged from a minimum of 1.25 ml/min/kg to a 
maximum of 2.99 ml/min/kg, with a mean value of 2.11 ml/min/kg ± SE 0.17. Model B GFR 
ranged from a minimum of 1.49 ml/min/kg to a maximum of 4.17 ml/min/kg, with a mean 
value of 2.57 ml/min/kg ± SE 0.23. Model C GFR ranged from a minimum of 1.35 ml/min/kg 
to a maximum of 3.66 ml/min/kg, with a mean value of 2.28 ml/min/kg ± SE 0.19. Model D 
GFR ranged from a minimum of 1.36 ml/min/kg to a maximum of 4.24 ml/min/kg, with a 
mean value of 2.45 ml/min/kg ± SE 0.26. 
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 Plasma 
Cr  
(mean) 
Reference 
(GFR±SE) 
Model A 
(GFR±SE) 
Model B 
(GFR±SE) 
Model C 
(GFR±SE) 
Model D 
(GFR±SE) 
 
HC 
 
 
1.24 
 
3.25 ± 
0.27 
 
3.32 ± 
0.47 
 
3.28 ± 
0.38 
 
3.08 ± 
0.41 
 
3.43± 0.39 
 
CKD 
 
 
2.54 
 
2.30 ± 
0.19 
 
2.11 ± 
0.17 
 
2.57 ± 
0.23 
 
2.28 ± 
0.19 
 
2.45± 0.26 
Table 1: Mean values (ml/min/kg) of GFR and plasma creatinine (mg/dl) in HC group and CKD group. GFR is 
reported as mean value for reference method and for each simplified model (Model A, Model B, Model C and 
Model D). SE: standard error. 	  
The t-test analysis (p<0.05) among GFR values of HC group and CKD group, according to 
reference method, showed a significant difference (p=0.003) between the two groups of 
subjects. Similarly, t-test analysis between GFR of HC group and CKD group assessed 
through simplified models, reported a significant difference. The t-test analysis (p<0.05) 
among GFR values of HC group and CKD group, according to Model A, showed a significant 
difference (p=0.0005) between the two groups of subjects. The t-test analysis (p<0.05) among 
GFR values of HC group and CKD group, according to Model B, showed a significant 
difference (p=0.01) between the two groups of subjects. The t-test analysis (p<0.05) among 
GFR values of HC group and CKD group, according to Model C, showed a significant 
difference (p=0.001) between the two groups of subjects. The t-test analysis (p<0.05) among 
GFR values of HC group and CKD group, according to Model D, showed a significant 
difference (p=0.004) between the two groups of subjects. 
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Figure 1: t-test analysis between GFR of HC group and CKD group. GFR was significantly different (p=0.003) 
between HC and CKD patients. HC subjects showed a mean GFR of 3.25 ± SE 0.27 ml/min/kg while CKD 
subjects a value of 2.30 ± SE 0.19. 
 
Figure 2: t-test analysis between GFR of HC group and CKD group, according to Model A. GFR was 
significantly different (p=0.0005) between HC and CKD patients. HC subjects showed a mean GFR of 3.32 ± 
SE 0.47 ml/min/kg while CKD subjects a value of 2.11 ± SE 0.17. 
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Figure 3: t-test analysis between GFR of HC group and CKD group, according to Model B. GFR was 
significantly different (p=0.01) between HC and CKD patients. HC subjects showed a mean GFR of 3.28 ± SE 
0.38 ml/min/kg while CKD subjects a value of 2.57 ± SE 0.23. 
 
 
Figure 4: t-test analysis between GFR of HC group and CKD group, according to Model C. GFR was 
significantly different (p=0.001) between HC and CKD patients. HC subjects showed a mean GFR of 3.08 ± SE 
0.41 ml/min/kg while CKD subjects a value of 2.28 ± SE 0.19. 
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Figure 5: t-test analysis between GFR of HC group and CKD group, according to Model D. GFR was 
significantly different (p=0.004) between HC and CKD patients. HC subjects showed a mean GFR of 3.43± SE 
0.39 ml/min/kg while CKD subjects a value of 2.45± SE 0.26. 
 
 
 
 
Pearson analysis in clinically healthy (HC) cats 
Pearson correlation test (p<0.05) between GFR values obtained by reference method and 
Model A (5’ – 30’ – 1 and 4 hours) showed a positive linear correlation (p<0.0001) 
characterized by a value of R2 of 0.92 and a Pearson r of 0.95. Similarly, Bland-Altman 
analysis reported no significant clinical difference (bias=0.10) in average versus difference 
between GFR values assessed through reference method and Model A. Pearson correlation 
test (p<0.05) between GFR values obtained by reference method and Model B (5’ – 30’ – 1 
and 2 hours) showed a positive linear correlation (p<0.0001) characterized by a value of R2 of 
0.95 and a Pearson r of 0.97. Similarly, Bland-Altman analysis reported no significant clinical 
difference (bias=-0.39) in average versus difference between GFR values assessed through 
reference method and Model B. Pearson correlation test (p<0.05) between GFR values 
obtained by reference method and Model C (5’ – 1 – 2 and 4 hours) showed a positive linear 
correlation (p<0.0001) characterized by a value of R2 of 0.88 and a Pearson r of 0.94. 
Similarly, Bland-Altman analysis reported no significant clinical difference (bias=-0.04) in 
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average versus difference between GFR values assessed through reference method and Model 
C. Pearson correlation test (p<0.05) between GFR values obtained by reference method and 
Model D (5’- 30’ – 1 hour) showed a positive linear correlation (p<0.0001) characterized by a 
value of R2 of 0.83 and a Pearson r of 0.91. Similarly, Bland-Altman analysis reported no 
significant clinical difference (bias=-0.80) in average versus difference between GFR values 
assessed through reference method and Model D.  
 
Figure 6: Pearson correlation test between GFR assessed through reference method and Model A (5’-30’-1 and 
4 hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.92. 
 
Figure 7: Pearson correlation test between GFR assessed through reference method and Model B (5’-30’-1 and 
2 hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.95. 
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Figure 8: Pearson correlation test between GFR assessed through reference method and Model C (5’- 1 - 2 and 4 
hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.88. 
 
Figure 9: Pearson correlation test between GFR assessed through reference method and Model D (5’- 30’ and 1 
hour). Positive linear correlation (p<0.0001) characterized by R2 of 0.83. 	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Bland-Altman analysis in HC 	  
 
Figure 10: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model A. Bias of difference versus average was not clinically significant (0.10). 
 
Figure 11: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model B. Bias of difference versus average was not clinically significant (-0.39). 
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Figure 12: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model C. Bias of difference versus average was not clinically significant (-0.04). 
 
Figure 13: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model D. Bias of difference versus average was not clinically significant (-0.80). 
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Pearson analysis in chronic kidney disease (CKD) cats 
Pearson correlation test (p<0.05) between GFR values obtained by reference method and 
Model A (5’ – 30’ – 1 and 4 hours) showed a positive linear correlation (p<0.0001) 
characterized by a value of R2 of 0.92 and a Pearson r of 0.97. Similarly, Bland-Altman 
analysis reported no significant clinical difference (bias=0.20) in average versus difference 
between GFR values assessed through reference method and Model A. Pearson correlation 
test (p<0.05) between GFR values obtained by reference method and Model B (5’ – 30’ – 1 
and 2 hours) showed a positive linear correlation (p<0.0001) characterized by a value of R2 of 
0.95 and a Pearson r of 0.99. Similarly, Bland-Altman analysis reported no significant clinical 
difference (bias=-0.31) in average versus difference between GFR values assessed through 
reference method and Model B. Pearson correlation test (p<0.05) between GFR values 
obtained by reference method and Model C (5’ – 1 – 2 and 4 hours) showed a positive linear 
correlation (p<0.0001) characterized by a value of R2 of 0.98 and a Pearson r of 0.99. 
Similarly, Bland-Altman analysis reported no significant clinical difference (bias=0.05) in 
average versus difference between GFR values assessed through reference method and Model 
C. Pearson correlation test (p<0.05) between GFR values obtained by reference method and 
Model D (5’- 30’ – 1 hour) showed a positive linear correlation (p<0.0032) characterized by a 
value of R2 of 0.59 and a Pearson r of 0.77. Similarly, Bland-Altman analysis reported no 
significant clinical difference (bias=-0.18) in average versus difference between GFR values 
assessed through reference method and Model D. 
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Figure 14: Pearson correlation test between GFR assessed through reference method and Model A (5’-30’-1 and 
4 hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.97. 
 
Figure 15: Pearson correlation test between GFR assessed through reference method and Model B (5’-30’-1 and 
2 hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.98. 
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Figure 16: Pearson correlation test between GFR assessed through reference method and Model C (5’- 1 - 2 and 
4 hours). Positive linear correlation (p<0.0001) characterized by R2 of 0.98. 
 
Figure 17: Pearson correlation test between GFR assessed through reference method and Model D (5’- 30’ and 
1 hour). Positive linear correlation (p<0.0032) characterized by R2 of 0.59. 	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Bland-Altman analysis in CKD 	  
 
Figure 18: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model A. Bias of difference versus average was not clinically significant (0.20). 
 
Figure 19: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model B. Bias of difference versus average was not clinically significant (-0.31). 
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Figure 20: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model C. Bias of difference versus average was not clinically significant (0.05). 
 
Figure 21: Bland-Altman plot of difference versus average of GFR assessed through reference method and 
through Model D. Bias of difference versus average was not clinically significant (-0.18). 	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CHAPTER 6: DISCUSSION 
 
 
 
CKD represents a complex clinical syndrome with an even more increasing prevalence in 
small animal population. Recent reports showed, in fact, that CKD plays an important 
epidemiological role in canine and feline population. Epidemiological studies concern only 
IRIS stages 2, 3 and 4 in which plasma values of creatinine are above the reference range and, 
at present, no data about the prevalence of the disease in IRIS stage 1 are reported. Both in 
dogs and cats, IRIS 1 is an asymptomatic and subclinical stage characterized by plasma levels 
of creatinine within the normal range, which cannot be detected without using GFR. The 
importance of early diagnosis in slowing down the progression of CKD has been widely 
demonstrated both in human and in veterinary medicine1. CKD is inexorably doomed to 
develop end-stage renal disease (ESRD). At this point just haemodialysis and renal 
transplantation are effective treatments. Because of the high costs and low availability of 
these treatments, the early onset of a conservative nutritional and medical therapy shows a 
dramatic importance in postponing ESRD. Unfortunately, although GFR is universally 
considered the gold standard test to evaluate overall renal function, its use in veterinary 
clinical practice is still uncommon, due to technical difficulties, high number of samples and 
low availability of markers. Plasma clearance methods seem to be easier to be performed 
compared to urinary clearance ones and can represent an attractive way of GFR 
determination2.  Iohexol is an iodinate contrast medium that has been shown to be a good 
alternative to inulin and radioactive tracers in human, pig, horse, dog, donkey and cat2,3,4,5. 
The advantages of iohexol, over other markers, include lack of radiation hazard and 
associated radiation protection measures, easy commercial availability and assay, and low 
price2. The development of an accurate three-hour and four-sample GFR method in canine 
patients, by using plasma clearance of iohexol, encouraged us to evaluate different sampling 
schemes even in cats. The low compliance of feline patients, compared to dogs, led us to 
develop blood-sampling combinations with the smallest number of samples. The present 
study presented a fast, accurate and relatively simple method for GFR determination in feline 
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patients. Currently available HPLC systems to determine plasma iohexol concentration were 
proven to give reliable data, but they still present some disadvantages to be routinely used for 
the early diagnosis of CKD in a clinical setting. The method investigated in the present study 
combined an easy sample preparation and a rapid HPLC run with a simple mobile phase. 
Analysis were performed with inexpensive, not dangerous and readily available chemicals. 
The robustness of the method made easy for operators to learn the technique and to generate 
reproducible results. The method indeed showed itself to be very economical, with an 
approximate cost per sample of less than two Euros for supplies and materials. In fact, a 
single analytical column, under the assay condition, lasted for the entire period of method 
validation and clinical study. Furthermore, the stability test indicated that plasma samples can 
be frozen or sent by mail, and this would be attractive for general practitioners, who could 
send serum samples to a reference laboratory. This HPLC method required very small 
volumes of plasma samples (50 µl). Such limited amounts of plasma may be a significant 
advantage in a feline clinical setting, especially when anaemic or dehydrated animals are 
involved. At the dosage (64.7 mg/kg) used in this study, iohexol can be safely utilized even in 
debilitated or severely azotemic subjects6,7. Furthermore, no one of the enrolled cats showed 
immediate or subsequent side effects. In the the Author’s experience the use of two 
intravenous catheters (one utilized for iohexol injection and the other one to take blood 
samples) increased the compliance of owners and patients and should be preferred to several 
blood samples. The short time required for the GFR test and the small volume of blood 
needed made the use of an intravenous catheter to take blood easily. All the four analyzed 
models (Model A, Model B, Model C and Model D) offered a dramatic simplification of 
reference method, in terms of time and number of blood samples. Accuracy of GFR 
determination was not compromised by a reduction of the number of plasma samples. Pearson 
correlation analysis (p<0.05) between reference method and each of the simplified models 
showed a positive linear correlation, with very high values of R2 and Pearson r. Similarly, 
Bland-Altman analysis of difference versus average reported very low values of bias, which 
showed a clinically irrelevant difference between reference method and each simplified 
model. Mean GFR value of clinically healthy subjects (mean ± SEM, 3.40 ± 0.29 ml/min/kg) 
was in agreement with previously reported data for plasma clearance of iohexol in feline 
patients8 and it differed significantly from mean GFR of CKD patients, both using reference 
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method (p=0.003) and simplified Model A (p=0.0005), Model B (p=0.01), Model C 
(p=0.001) and Model D (p=0.004). In CKD cats, GFR showed a mean value of 2,38±0.23 
ml/min/kg, with a minimum of 1.36 ml/min/kg and a maximum of 3.47 ml/min/kg. Clinically 
healthy cats, instead, presented a wider range of GFR with a mean value between a minimum 
of 1.21 ml/min/kg and a maximum of 8.62 ml/min/kg. No one of CKD patients showed a 
GFR above 3.50 ml/min/kg. According to the guidelines of the International Renal Interest 
Society (IRIS), IRIS 1 patients present plasma values of creatinine within the normal range 
and are generally asymptomatic. So, there is no way to identify these patients without using 
GFR. UP/UC and systolic blood pressure (included into IRIS guidelines) only represent risk 
factors of CKD and they are not sufficient for a correct identification of IRIS 1 subjects9. 
According to these considerations, it was supposed that cats enrolled in the present study as 
clinically healthy, with a GFR below 2.00 ml/min/kg, may have been in an early stage of 
CKD. This hypothesis was suggested by the fact that the group of cats belonging to the HT 
group and with a GFR below 2.00 ml/min/kg showed a plasma iohexol decay pattern more 
similar to CKD than HT subjects. This group was composed by 11 subjects with a mean GFR 
of 1.14 ± 0.09 ml/min/kg, within a minimum of 1.04 ml/min/kg and a maximum of 1.99 
ml/min kg. Their mean GFR appeared significantly more related to CKD than to HT group. 
These data led us to the conclusion that this group of subjects was very probably composed by 
asymptomatic IRIS 1 patients. Although a wider number of subjects would be recommended 
for an accurate establishment of GFR range, present data and reference reports strongly 
suggest that feline patients with a GFR below 2.00 ml/min/kg should be considered in an 
early stage of CKD. The use of a seven-sample method to estimate plasma clearance of a 
tracer is an extremely accurate way of performing curve fitting with nonlinear regression 
analysis, but it is too time-consuming and expensive and it could be excessively stressful for 
feline patients. Furthermore, the high number (seven) of blood samples required is too 
cumbersome to be used in a clinical setting. Limited sampling strategies for plasma clearance 
procedures were investigated extensively in humans10, and more recently in animals11,2, to 
establish a quick, inexpensive, and clinically accurate value of GFR. All simplified models 
(Model A, Model B, Model C and Model D), that were taken into consideration in the present 
study, showed a high accuracy in determining GFR, both in healthy and in CKD patients, and 
represented a significant simplification of the reference method. Anyway, among different 
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models, Model D (5’- 30’ -1 hour) showed the best solution because it combined an accurate 
GFR determination with a very quick and easy to perform method. The extremely good 
correlation between Model D and reference method was demonstrated by high levels of R2 
and Pearson P, both in HC (R2=0.83, p<0.0001) and CKD patients (R2=0.59, p<0.0032).  
In conclusion, the present study validated a safe, simple and accurate three-sample HPLC 
method (5’ – 30’ – 1 hour) for the determination of GFR through the plasma clearance of 
iohexol in feline patients. This model represents an attractive and cheap alternative to 
cumbersome plasma clearance methods, with a dramatic applicatory potential in different 
clinical settings. The accuracy of HPLC analysis, the possibility to mail plasma samples to a 
referring laboratory and the high compliance of this method, would lead general practitioners 
to an easier diagnosis of subclinical stages of CKD and to a better management of the disease. 
After owners’ informed consent, 53 clinically healthy and 14 CKD cats have been submitted 
to an eight-hour clearance study.  	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CHAPTER 7: CALCIUM-PHOSPHATE METABOLISM IN CKD: TOTAL 
CALCIUM, IONIZED CALCIUM, CORRECTED CALCIUM AND CA X P 
PRODUCT 
 
Researches in human medicine have been focusing on the importance of mineral metabolism 
disorders and metabolic bone diseases in the progression of CKD1,2,3. For this reason a new 
classification of CKD has been proposed by the Kidney Disease Improving Global Outcomes 
(KDIGO), in order to consider even bone and mineral disorders. The new Chronic Kidney 
Disease – Bone and Mineral Disorders (CKD-BMD) staging has been accepted by the 
nephrology community and should be taken into consideration for a more accurate 
classification of the CKD patient. Recent epidemiologic and clinical acquisitions reported an 
increased mortality risk in the CKD population affected by disturbances of mineral 
metabolism. High levels of serum phosphate, enhanced by elevated blood calcium 
concentrations, would be responsible for an amplification of vascular calcification and would 
be related to an increased risk of cardiovascular mortality1,2,3,4. CKD patients are often 
affected by secondary hyperparathyroidism (SHPT) as a consequence of a condition of 
hyperphosphatemia, hypocalcemia and decreased concentration of 1,25-dihydroxy-vitamin 
D3. SHPT in CKD shows a complex pathogenesis which involves phosphate retention, 
hyperphosphatemia, low serum ionized calcium (iCa), elevated parathyroid hormone (PTH), 
vitamin D deficiency, intestinal calcium malabsorption, reduction of vitamin D and calcium-
sensing receptors in the parathyroid glands and altered mRNA-binding protein modulating 
PTH transcripts16. Serum PTH concentration depends on both the release of PTH stored into 
the parathyroid glands and on the synthesis of new hormone. PTH can be rapidly released by 
the parathyroid glands in hypocalcemia through the interaction between iCa and calcium 
sensing receptors (CaSR)16. CaSR are located on the surface of parathyroid cells and regulate 
PTH release in response to changes in the concentration of iCa. In physiologic conditions, as 
the serum calcium concentration falls, stored PTH is released into the blood stream. PTH 
increases the renal tubular calcium absorption through activation of the kidney calcium 
channels TRPV5 and it stimulates the activity of the renal-25-hydroxy-vitamin-D1-alpha 
hydroxilase leading to increment of the plasma concentration of 1-25-(OH)2D3. The action of 
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1-25-(OH)2D3 promotes an increased absorption of calcium from the small intestine by 
stimulating a transcriptional regulation of calcium channels TRPV6. These actions have the 
combined effect of raising the concentration of serum calcium. Alternatively, an increase in 
iCa concentration determines an inhibiting activity of CaSR on PTH release. CaSR are also 
present in thyroid tissue where they have been shown to regulate calcitonin release. Calcitonin 
acts mostly by inhibiting osteoclastic activity and, therefore, the release of calcium from 
bone18. The biological importance of CaSR in the homeostasis of iCa has been demonstrated 
by discovering familial hypercalcemic or hypocalcemic conditions due to a inactivating or 
activating mutation of CaSR. Transcription of CaSR is not influenced by iCa but by the 
concentration of vitamin D in the parathyroid glands, kidneys and thyroid C cells. CKD 
patients show reduced amounts of CaSR as a result of parathyroid hyperplasia and low serum 
levels of vitamin D. The reduction in CaSR concentration in the parathyroid glands attenuates 
the responsiveness of the gland to iCa and contributes to develop SHPT16. At the same time a 
reduction in number of vitamin D receptors (VDR) modifies the transcription of CaSR and 
PTH. In addition, CKD subjects can present changes in the amount of mRNA encoding PTH 
binding proteins. SHPT is a complex metabolic condition due to the onset of multiple 
abnormalities that are able to enhance the rate of PTH release and synthesis16. Homeostasis of 
calcium and phosphate is tightly linked and this relationship is best illustrated in diseases like 
CKD and SHPT18. The attempt to avoid SHPT led to the formulation of specific guidelines, 
which try to prevent an overstimulation of the parathyroid glands6. A strict relationship 
between a long-term exposure to high serum levels of calcium and phosphate and an 
increased risk of mortality has been widely documented and it is considered the main target of 
a conservative therapy. In human CKD patients, in fact, cardiovascular complications 
represent the most frequent cause of mortality. It is not clear if there is a direct causal 
relationship between bone health and calcification or if this is a common calcification 
pathway as part of the CKD-MBD disease process17. A calcium- phosphate imbalance can 
increase the risk of vascular calcification in end stage renal disease (ESRD) patients. The 
ongoing debate about the predominant origin of the vascular calcifications in this category of 
patients is trying to clarify if they are caused by an atherosclerotic or an arteriosclerotic injury 
or both. Although the differentiation between atherosclerosis and arteriosclerosis is essential 
for a correct prognosis and treatment, it can be hard to differentiate even using advanced 
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imaging techniques7,8,9. Both processes are characterized by a vessel calcification, which 
shows a different pathogenesis. 
Atherosclerosis is determined by a patchy calcification of the arterial intima around lipid 
deposits and it can be a common report of the Aorta and other large arteries in 
hyperlipidaemia and in advanced age. In human patients atherosclerosis begins as early as the 
second decade of life and small aggregates of crystalline calcium have been documented 
within the lipid core of coronary artery plaques of young adults10. Calcium phosphate 
represents the predominant form in arterial calcium deposits and it is secreted in a similar way 
to what found in osteogenesis and bone remodelling. Vesicles containing calcium phosphate 
are secreted by arterial wall cells (vascular smooth muscle cells and pericytes) as matrix 
vesicles do from condrocytes during bone developing8. Microvascular endothelial 
dysfunctions seem to play a fundamental role in the pathogenesis of atherosclerosis in renal 
failure. Glomerular endothelial injuries may develop in the early stages of renal disease 
hypertension, before the onset of blood pressure elevation. Endothelial dysfunction presents 
multifactor causes that are strictly related, like increased oxidative stress, dyslipidemia and 
inflammation.  CKD patients become progressively malnourished showing low levels of 
albumin, prealbumin and transferrin, that have been supposed to be activating factors of 
inflammation. Anyway, the often concomitant presence of diabetes and hypertension makes 
difficult to understand the direct role of early stage renal failure in promoting inflammation. 
CKD dyslipidemia is characterized by a progressive increase of high-density lipoproteins 
(HDL) and decrease of low density lipoproteins (LDL). In particular, the synthesis of Hepatic 
apolipoprotein A-I reduces and Apolipoprotein C-III (competitive inhibitor of liporpotein 
lipase) increases, resulting in serum accumulation of triglycerides. The relative low serum 
concentration in HDL is responsible for a reduction in antioxidant power and in endothelial 
protective effect towards proinflammatory cytokines10. Oxidative stress may involve 
activation of reduced nicotinamide adenine dinucleotide (NAD(P)H) oxidase, xanthine 
oxidase, uncoupled endothelial NO synthase, myeloperoxidase (MPO) and mitochondrial 
oxidase. Increased production of reactive oxygen species (ROS) by uncoupled endothelial NO 
synthase as well as their reduced inactivation by the antioxidant system may accelerate 
atherosclerosis. Moreover the activation of the renin-angiotensin system, frequently reported 
in CKD patients, can stimulate NAD(P)H oxidase, leading to generation of superoxide anion 
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able to cause endothelial injuries. The interaction between angiotensin II and AT1 receptor 
stimulates production of ROS and other enzyme systems that determine up-regulation of 
inflammatory mediators such as cytokines, chemokines, adhesion molecules, plasminogen 
activator inhibitor 1 and superoxide scavenging of nitric oxide (NO). Reduced bioavailability 
of NO is considered one of the main factors involved in CKD-associated endothelial 
dysfunction, due to increased oxidative stress in the vascular wall15. Asymmetric dimetyl 
arginine (ADMA), competitive inhibitor of NO synthase, may decrease the synthesis of NO. 
High plasma levels of ADMA are associated with endothelial injury and atheroslerosis and 
they have been reported predictors of cardiovascular complications and mortality in ESRD10.  
Arteriosclerosis, instead, is characterized by a metabolite-induced calcification of the arterial 
media of large vessels in the absence of lipid concretions10. Increased serum calcium-
phosphate levels can cause vascular changes that lead to an up-regulation of the osteogenic 
differentiation of vascular smooth muscle cells. The concentric media thickening of muscular 
arteries is responsible for a not age-related vascular stiffening which has been shown also in 
ESRD children and animal models7,8,9. The arterial stiffening occurring in arteriosclerosis 
involves an active calcium phosphate transport through the action of cotransporter PiT-1. The 
stimulation of PiT-1 activity is determined by both a phenotypic switch of vascular smooth 
muscle cells into osteoblast-like cells, as a consequence of high intracellular concentrations of 
calcium and phosphate, and by a functional impairment of calcification inhibitors10. An in 
vitro study demonstrated that elevated concentrations of calcium or phosphate promote 
calcification of human vascular smooth muscle cells. This process was started by release of 
membrane-bound matrix vesicles and apoptotic bodies. Vesicles released by cells exposed to 
calcium and phosphate calcified to an important degree, but those released in the presence of 
serum were just minimally calcified and were found to contain calcification inhibitors11. 
Arteriosclerosis appears as a result of an imbalance between the serum concentration of 
calcification promoters and inhibitors. In human medicine the following inhibitors of 
calcification were identified: fetuin-A, MGP, Osteoprotegerin, BMP-7 and pyrophosphate 
(PPi). Fetuin-A forms stable colloidal spheres with calcium and phosphate and becomes part 
of a high molecular mass complex containing calcium, phosphate and matrix GLA protein 
(MGP). A reduction in Fetuin-A serum concentration was related to an increased risk of 
vascular calcification. MGP belongs to a family of proteins that requires a vitamin K-
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dependent gamma carboxylation for its biological activity and the gamma carboxylated form 
is carried in plasma by Fetuin-A. MGP is a modulator of the activity of bone morphogenetic 
protein-2 (BMP-2). Mice lacking MGP developed spontaneous calcification of arteries and 
cartilage. On the other hand, high levels of MGP were found in the vicinity of atherosclerotic 
plaques and were associated with in vitro calcification of smooth muscular cells. The ability 
of MGP to reduce or increase calcification seems to depend to availability of BMP-2. MGP 
inhibits calcification of calcifying vascular cells with high relative concentration of BMP-2, 
while it stimulates calcification with low relative levels of BMP-210,12. Osteoprotegerin is a 
modulator of osteoclast activation which mechanism of action has not been clearly elucidated. 
A deficiency of Osteoprotegerin in mice was related to an increased vascular calcification, 
while high serum concentration, especially when associated with elevated levels of C-reactive 
protein (CRP), correlates with increased calcification and mortality in haemodialysis patients. 
ESRD subjects are generally characterized by elevated serum concentrations of 
Osteoprotegerin10,13,14. PPi is synthesized by the nucleotide pyrophosphatase phospho-
diesterase-1 and its deficiency is associated with a proliferation of altered vascular smooth 
muscle cell phenotype and increased calcification. Calcium phosphate deposits may also 
result from enhanced activity of the membrane-bound tissue-nonspecific alkaline 
phosphatase, which degrades PPi to P. PPi deficiency can occur in ESRD patients as a 
consequence of haemodialysis removal. BMP-7 is part of the BMP family of regulators of 
bone formation. Despite BMP-2 and BMP-4, BMP-7 is an inhibitor of vascular calcification, 
which is expressed mainly in the kidney. BMP-7 causes up regulation of a alpha-smooth 
muscle actin through induction of p21 and up regulation of Smad 6 and 7. A reduction in 
BMP-7 affects bone metabolism, determining an increase in serum phosphate, which induces 
phenotypic changes in vascular smooth muscle cells and metastatic calcification10. Although 
the debate about the role of atherosclerosis and artherosclerosis on cardiovascular 
complications in CKD patients is still open, a recent study7 did not find any correlation among 
long-term calcium phosphate exposure in ESRD subjects and intima-media thickness (IMT) 
and ankle-brachial index (ABI), both early markers of atherosclerosis.  
Finally, there is also a specific dialysis-related type of vascular calcification called 
calciphylaxis or uremic arteriopathy, which is characterized by diffuse calcification of the 
tunica media of small to medium arteries and arterioles. Patients affected by calciphylaxis 
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show even intimal proliferations and trombosis that can lead to skin ulcers and life-
threatening skin necrosis or gangrene. Calciphylaxis develops in a condition of elevated 
serum calcium – phosphate product (Ca x P) without the presence of an active osteogenic 
process and it differs from other forms of skin calcification that do not affect blood vessels.  
Kidneys play a key role in maintaining calcium and phosphate homeostasis through different 
and closely integrated processes. Despite calcium is filtered by the glomerulus, less than 3% 
of the filtered load is eliminated through urine. Calcium is, in fact, submitted to an intense 
tubular reabsorption, which occurs both passively and actively. The majority of calcium 
reabsorption is passive and it occurs in the proximal tubule. Within the proximal tubule 
calcium strictly follows sodium movements. Active reabsorption takes place in the thick 
ascending limb of the loop of Henle, in the distal convolute tubule and in the connecting 
tubule. In the thick ascending limb of the loop of Henle calcium is associated to the sodium-
potassium pump. The potassium movement towards tubule lumen determines a concentration 
gradient, which facilitates calcium reabsorption through the paracellular protein paracellin. In 
the distal convoluted tubule and in the connecting tubule calcium reabsorption follows 
different steps. Firstly calcium enters cells through apical TRPV5 calcium channel. The 
binding between calcium and the binding protein calbindin-D28k is responsible for a 
cytosolic transfer to the basolateral membrane. Calcium can then re-enter the extracellular 
compartment through the action of the Na+/Ca2+ exchanger (NCX1) and the Ca2- pump 
(PMCAlb). TRPV5 activity, trafficking and endosomal recycling are regulated by several 
proteins and ions, among which klotho, tissue kallikrein factor, pH, estrogens and intracellular 
Ca2- concentration. Klotho is an antiaging hormone which stimulates TRPV5 activity, leading 
to an increase of calcium intake. Tissue kallikrein is synthesized in the distal nephron. After 
its release into tubular filtrate tissue, kallikrein binds to kinin receptors and, through a protein 
kinase C pathway, increases TRPV5 expression resulting in augmented calcium reabsorption. 
PH can directly interact with TRPV5 receptors by regulating their expression in response to 
conditions of alkalosis or acidosis.  This mechanism is supposed to be due to a pH-controlled 
insertion of TRPV5 containing vesicles in the apical plasma membrane, which is able to 
stimulate hypo- or hypercalciuria according to pH modifications. Estrogens have a stimulating 
effect on TRPV5 receptors, which is vitamin vitamin D3 independent. Finally, TRPV5 can be 
modulated by calcium itself, which is responsible for a negative feedback towards the 
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receptors18. The majority of filtered phosphate is reabsorbed in renal proximal tubule 
epithelial cells through a sodium-coupled transport. This process is driven by basolateral Na-
K-ATPases and apical Na/Pi type II cotransporters. Although the Na/Pi II cotransporters have 
three isoforms, just type IIa and type IIc are present in the renal proximal tubular cell apical 
membrane, while type IIb is primary located in the small intestine. Studies in mice 
demonstrated that the majority of renal phosphate reabsorption is due to type IIa 
cotransporter, while type IIc plays a lesser role. Anyway recent acquisitions in human 
medicine underlined a certain importance of cotransporter type IIc. Renal phosphate 
reabsorption is influenced by different hormonal and non-hormonal factors, that can interact 
with Na/Pi cotransporters. PTH leads to an increased urinary excretion of phosphate by 
reducing the quantity of type IIa cotransporters in the apical brush border membrane of renal 
proximal tubule cells, through a PTH-induced endocytosis. In a similar way, high dietary 
phosphate intake is responsible for a down-regulation of type II cotransporters. On the 
contrary, low dietary phosphate intake stimulates increased expression of these cotransporters 
both through enhanced stability and increased insertion at the apical membrane. Elevated 
serum phosphate concentration also inhibits the synthesis of vitamin D3. In addition to PTH 
and phosphate there are other factors, termed phosphotonins, able to modulate renal 
reabsorption of phosphate. The phosphotonin FGF-23 has been showed to promote renal 
phosphate wasting by impairing the expression of type II cotransporters and by reducing the 
production of vitamin D3 and increasing its metabolism. FGF-23 both reduces the expression 
of the 1 alpha(OH)ase  enzyme reducing the production of vitamin D3 and increases the 
expression of 24-hydroxylase which metabolizes vitamin D3 into less biologically active 
forms. As increasing levels of vitamin D3 appear to augment FGF-23 concentration, the 
inhibiting activity of FGF-23 towards vitamin D3 has been supposed to be part of a negative 
feed-back mechanism. High levels of FGF-23 have been reported in some diseases like 
tumor-induced osteomalacia and autosomal dominant hypophosphatemic rickets. The anti-
aging hormone klotho has recently been suggested to be a necessary cofactor for FGF-23 
action. Other phosphotonins, like secreted frizzled-related protein 4 (sFRP-4), matrix 
extracellular phosphoglycoprotein and fibroblast growth factor 7, have been shown to reduce 
renal proximal tubular uptake of phosphate. sFRP-4 seems to act by impairing the expression 
of type II cotrasporters and by inhibiting vitamin D3 production, similarly to FGF-2318. Total 
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plasma calcium (tCa) consists of two major forms: protein-bound and unbound part. The 
protein bound fraction (pCa) is mainly associated to albumin, while the unbound part can be 
further divided into a freely ionized (iCa) and a portion complexed to anionic species (cCa). 
Each of these forms is in equilibrium with the others according to different factors like protein 
level, pH, concentration of citrate, sulphate, biacarbonate, lactate and phosphate1. In clinically 
healthy dogs, iCa, pCa and cCa account for approximately 56%, 34% and 10%. Sick dogs 
may present disturbances in calcium homeostasis and a tCa concentration within the reference 
range does not ensure that calcium is distributed among the fractions as would normally be 
expected. In dogs affected by CKD, in fact, cCa and pCa are significantly different (20.21% 
and 25.61% respectively) from the concentration reported in clinically healthy population, 
while iCa shows a similar value (54.32%)20. iCa is the biologically active form and the gold 
standard in the evaluation of the calcemic status. In CKD metabolic acidosis usually develops 
as a consequence of the low excretion of acid radicals (protons) and phosphate and sulphate 
compounds through the kidneys, as well as because of low renal absorption of bicarbonate 
and a decrease in renal ammoniagenesis. In metabolic acidosis iCa can increase in relation to 
the fact that calcium binds to the same albumin carboxyl group at which H+ usually binds. 
Thus, in the presence of acidosis, H+ radicals do not dissociate easily from the albumin 
carboxyl group and calcium shows a lower opportunity to bind to albumin. As a result plasma 
iCa concentration can increase23despite of a decrease in pCa fraction. Anyway a recent study 
reported that only the 24% of CRF dogs in metabolic acidosis showed high concentrations of 
iCa, while the 56% presented low levels of iCa. The role of metabolic acidosis in predicting 
reduced concentrations of plasma iCa in CKD dogs was not already documented23. Albumin 
represents the major calcium-binding protein and its concentration can vary significantly in 
CKD, leading to fluctuations of pCa. The binding of calcium to albumin can also be 
influenced by plasma pH. Previous studies conducted in human medicine showed that there 
was no calcium binding to albumin at a pH of 5.5 and that binding steadily increased up to a 
pH of 8.0 with an almost linear rise through the physiologic pH range1,21. In human beings a 
fall of pH of 1 unit causes approximately a 0.4 mmol/L increase in iCa concentration5. By the 
way no correlation between pH and iCa was observed in CKD dogs23. Although alterations in 
calcium homeostasis are common in critically ill humans and dogs, hypocalcemia often goes 
unrecognized in intensive care unit (ICU) human patients because it is assumed that tCa 
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concentration is falsely low due to low level of albumin. Human studies have, in fact, 
demonstrated that the use of tCa or calcium corrected for albumin cannot be used in an ICU 
setting to reliably monitor the calcium status. Recent acquisitions in veterinary medicine 
showed that iCa is the only accurate indicator to assess calcemic status in ICU dogs and that 
calcium corrected for albumin or total protein leads to overestimation of normocalcemia and 
underestimation of hypocalcemia22. In CKD dogs a discordance of 55% between iCa and tCa 
was detected, showing that iCa should always be assessed for an accurate evaluation of 
calcemic status23. Although a variety of correcting formulae have been proposed in veterinary 
and human medicine to permit calculation of the albumin-corrected or iCa from the total 
calcium and protein concentration, no data support the use of such algorithms in CKD 
patients5. One reason for the poor correlation between adjusted calcium and iCa may be the 
lack of correction for other molecules able to bind calcium5. The amount of cCa in CKD 
patients can widely vary and in human patients serum cCa is often increased. Calcium, in fact, 
may form complexes with bicarbonate, citrate, oxalate, citrate and sulphate and high 
concentrations of these molecules were found in CKD subjects. A recent report on the serum 
calcium fractions in CKD dogs suggested that the disparity between iCa and tCa was not 
attributable to differences in pCa or iCa but in cCa20. In another veterinary study a slightly 
significant negative correlation between iCa and phosphate concentration may partially 
suggest that hyperphosphatemia could contribute to the increase in cCa and decrease in iCa23. 
However a report conducted in 23 dogs with CKD showed that phosphate concentration 
cannot be used to predict cCa20. Serum phosphate concentration increases the cCa 
concentration and an inverse correlation between iCa and serum phosphate was 
demonstrated5. Available evidences in human beings, cats and dogs showed that calcium and 
phosphate abnormalities in CKD lead to negative effects on kidney function and survival. In 
human patients in haemodialysis serum phospate > 6.5 mg/dL increases significantly the risk 
of mortality. In feline CKD patients, for each 1 mg/dL increase in serum phosphate at time of 
diagnosis, there is a 11.8% increase in mortality risk. Similarly in dogs hyperphosphatemia 
has been associated to a rapid progression of CKD and decreased survival24. The sequence of 
events which leads to hyperphosphatemia starts with a reduction in GFR and in renal 
phosphate excretion. Excess of serum phosphate inhibits the activity of renal 1-alpha 
hydroxylase, determining a reduction in vitamin D3 and iCa concentration. As a response 
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PTH secretion is stimulated. The increase in PTH concentration diminishes tubular phosphate 
reabsorption, increasing phosphaturia. Initially, this mechanism restores vitamin D3 and iCa 
concentration but at expenses of a still high activity of PTH. Every time PTH returns to its 
initial concentration further phosphate retention occurs. On the contrary, each time GFR 
decreases the mechanism restarts preserving phosphate balance. Once maximal inhibition of 
tubular phosphate reabsorption is exceeded and GFR continues to decrease, vitamin D3 
remains low despite of a persistently high PTH concentration and severe hyperphosphatemia. 
In human beings phosphate retention starts at the early stages of CKD. In these patients, in 
fact, serum PTH begins to increase when serum phosphate concentration is still within the 
reference range. Available data suggest that hyperphosphatemia is a common finding even in 
CKD canine patients, showing a prevalence between 44.2% and 94.9%. A recent study 
reported that SHPT represents the most common abnormality of calcium-phosphate 
metabolism, affecting the 75.9% of CKD dogs and that this value increases with the severity 
of the disease. The prevalence of SHPT was > 96% in stage 3 and 4 and serum elevation of 
PTH can anticipate the onset of hyperphosphatemia. This finding is in agreement with a study 
performed in cats where the prevalence of SHPT was about 84%. Anyway some dogs can 
present phosphate retention at early stages of CKD as it occurs in humans24.  
Vascular calcification in CKD can be determined by different mechanisms such as passive 
precipitation of calcium phosphate due to high extracellular concentrations, increased activity 
of osteogenic inducers and deficiency of calcification inhibitors10. C x P product represents a 
clinically relevant tool to estimate cardiovascular risk in CKD and it can be accurately 
assessed through total or ionized calcium. High serum Ca x P product levels are responsible 
for a major risk of ectopic calcifications that can contribute to soft-tissue calcium phosphate 
deposits. Chronic kidney disease-mineral and bone disorder (CKD-MBD) defines a triad of 
interrelated abnormalities of serum biochemistry, bone and vasculature often associated with 
CKD17. In human medicine the relative risk of death for ESRD patients increases significantly 
with serum phosphorus higher than 6.5 mg/dL. This increased risk was not diminished by 
statistical adjustment for coexisting medical conditions, delivered dose of dialysis, nutritional 
parameters, or markers of noncompliance. The Ca x P product shows a mortality risk trend 
similar to that seen with serum phosphorus alone. In patients presenting a Ca x P product >72 
mg/dL the relative mortality risk was 1.34 relative to those with products of 42 to 52 mg/dL25. 
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The new human guidelines for a correct management of the CKD patient underlined the 
importance of a constant monitoring of serum phosphate and calcium for a more correct 
management of the CKD patient. Phosphate represents, in fact, a central molecule in the 
pathogenesis of CKD-MBD and vascular calcification. Frequent monitoring of serum 
phosphate and treatment of disorders of calcium-phosphate metabolism is essential for 
reducing the progression of CKD17. 
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CHAPTER 8: CARDIOVASCULAR DAMAGE IN CKD: ROLE OF CARDIAC 
TROPONIN I (CTNI) 	  
Cardiovascular diseases represent the leading cause of morbidity and mortality in ESRD 
patients, accounting for more than 50% of all deaths1. ESRD subjects show the highest risk 
group for subsequent cardiovascular events with a mortality rate 10-30 times the general 
population2. The importance of cardiovascular disorders in human patients has been 
demonstrated by the fact that the majority of CKD subjects dies before reaching ESRD. 
Patients with a reduced GFR show, in fact, a risk of fatal cardiovascular event much higher 
than the risk of developing ESRD. According to a recent report of the United States Renal 
Data System cardiac disease accounts for 43% of all-cause mortality in patients submitted to 
haemodialysis or peritoneal dialysis. Sudden cardiac death associated with arrhythmia or 
cardiac arrest can reach a 25% of all deaths in ESRD population4. CKD patients can be 
affected by three different forms of cardiovascular disease: atherosclerosis, arteriosclerosis 
and cardiomiopathy. Atherosclerosis is characterized by focal processes of plaque formation 
resulting in luminal narrowing and occlusive disease of the vasculature. On the contrary, 
arteriosclerosis is a non-occlusive remodelling degeneration of the vasculature, characterized 
by diffuse dilatation and hypertrophy of large arteries, with loss of arterial elasticity and 
reduced arterial compliance. Arteriosclerosis can determine different clinical manifestations, 
like left ventricular hypertrophy (LVH), decreased coronary perfusion, high systolic blood 
pressure and pulse pressure. Cardiomiopathy represents the final step of an adaptation 
mechanism of the heart towards pressure or volume overload. As heart workload increases, 
augmented oxygen demand by the hypertrophied left ventricle may exceed its perfusion, 
leading to ischemia and myocyte death. Initial physiology is often consistent with diastolic 
dysfunction but, as this process goes on, myocardial fibrosis may develop. The association of 
myocardial fibrosis and pressure and volume overload may determine the onset of dilated 
cardiomyopathy. Traditional and non-traditional risk factors of cardiovascular alterations have 
been identified both in general population and CKD patients7.  
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Traditional Risk Factors 
 
 
Non-traditional Risk Factors 
 
- Older age 
- Male gender 
- Hypertension 
- High LDL 
- Low HDL 
- Diabetes 
- Smoking 
- Physical inactivity 
- Menopause 
- Family history of coronary disease 
- LVH 
- White race 
 
CKD patients 
 
- Anemia 
- Volume overload 
- Abnormal mineral metabolism 
- Electrolyte imbalance 
- Albuminuria 
 
 
General population 
 
- Lipoprotein and Apo isoforms and 
lipoprotein remnants 
- Homocystein 
- Oxidative stress/inflammation 
- Malnutrition 
- Thrombogenic factors 
- Sleep disturbances 
- High sympathetic tone 
- Altered nitric oxide/endothelin balance 
 
Table 1: traditional and non-traditional risk factors of cardiovascular disease in human CKD 
patients and in general population. LDL: low-density lipoproteins. HDL: high-density 
lipoproteins. LVH: left ventricular hypertrophy. 
 
The risk of cardiovascular mortality in ESRD patients has been calculated ≥ 10 to 100 fold 
higher compared with the age-, sex- and race-matched general population. This category of 
patients presents, in fact, an increased prevalence of risk factors such as inflammation, high 
Ca X P product, uremic toxins, anaemia and fluid overload. The pathogenesis of the high 
cardiovascular injury risk in ESRD patients is multifactor. Anaemia shows a high prevalence 
in CKD subjects and it is mainly caused by erythropoietin deficiency, erythropoietin 
hyporesponsiveness and iron deficiency. In patients submitted to haemodialysis, anaemia is 
frequently associated with eccentric LVH, ventricular dilatation, heart failure and mortality. 
Mineral metabolism disorders can contribute to vascular calcification and arteriosclerosis, 
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even though the exact mechanism of action is not completely understood. Conditions of 
hyperphosphatemia, SHPT, vitamin D3 deficiency and alterations of calcification promoters 
and inhibitors are responsible for differentiation of vascular smooth muscle cells into 
osteoblast-like cells, able to synthesize proteins that increase vascular calcification. 
Arteriosclerosis, associated with alterations of calcium-phosphate metabolism, can play an 
important role in stimulating arterial stiffening and vascular and valvular calcifications3. 
Modifications of arterial elasticity have been indicated as predictive factors of obstructive 
coronary artery disease responsible for myocardial ischemia. Diseased myocardium secondary 
to coronary ischemia, together with myocardial fibrosis and/or hypertrophy, provides 
additional substrate for an increased electric instability, which may cause sudden 
cardiovascular death in uremic subjects. Systolic hypertension and arterial stiffness can 
determine LVH and represent significant independent predictive risk factors of sudden death3. 
Sodium retention and activation of the renin-angiotensin system are firstly involved in the 
mechanism of elevation of blood pressure. Human CKD patients, in fact, often show 
hypertension and elevated plasma concentrations of catecholamines4. Anomalies of left 
ventricular structure and function are very frequent in CKD. Among ESRD patients nearly 
15% presents systolic dysfunction, 40% has heart failure and more than 70% LVH. Several 
studies showed an elevated prevalence of LVH in non-uremic CKD patients. The prevalence 
of LVH in this category of subjects ranged from 34% to 78%, showing an increasing trend 
with declining renal function. The wide heterogeneity in the prevalence of LVH in different 
reports can be attributed to several differences, with regard to the characteristics of the studied 
population, the method of estimation of GFR, the GFR cut off used to enrol the patients and 
the exact definition of LVH. Left ventricular wall thickness and diameters generally increase 
significantly with the progression of renal failure and, in CKD stage 5, a very pronounced left 
ventricular growth takes place. When left ventricular mass (LVM) is greater than 28% of the 
value predicted by using an equation including blood pressure, stroke volume, height and 
gender, LVM is considered not appropriate. Inappropriate left ventricular mass (ILVM) is 
defined as the value of ventricular mass exceeding the amount needed to adapt to stroke work, 
according to individual gender and body size and it can be the result of the simultaneous 
increase of left ventricular diameters and wall thickness. The onset of an ILVM reported a 
negative impact on cardiovascular prognosis of hypertensive patients. CKD subjects showed a 
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prevalence of ILVM significantly higher (52.6%) than normal renal function hypertensive 
patients (30.5%). The prevalence of ILVM appeared to increase with lessening renal function, 
reaching values of 38% in stage 2, 47.5% in stage 3, 51.35% in stage 4 and 80.7% in stage 5. 
Although the pathogenesis of LVH is considered to be multifactor, hypertension, alterations 
of fluid and electrolyte balance and anaemia are the major determinants. LVH represents an 
adaptive remodelling process, which tries to compensate for an increase in cardiac work, due 
to volume or/and pressure overload. While hypertension causes concentric hypertrophy, 
volume overload is responsible for eccentric hypertrophy. Both processes are frequent in 
CKD patients and a mixed pattern, characterized by increase of both diameters and wall 
thickness, is often reported. Along with the worsening of CKD, concentric and mixed LVH 
become more frequent than eccentric hypertrophy. Among hemodynamic factors of LVH, 
even increased arterial stiffness plays a significant role. Other factors, such as inappropriate 
activation of renin-angiotensin-aldosterone system, oxidative stress and inflammation have 
been demonstrated to be involved in the pathogenesis of LVH5,6. Increased plasma 
concentrations of inflammatory markers like CRP, white blood cells and fibrinogen are 
associated with adverse cardiovascular outcomes in IRIS stage 3 and 4 CKD patients. An 
independent association between inflammation and risk of cardiovascular disease was found 
in human patients submitted to haemodialysis. Vitamin E administration was, in fact, related 
to a lower incidence of cardiovascular problems. At the same time, a reduction in oxidative 
stress may improve outcomes. Imbalance between pro-oxidant substances and antioxidants 
leads to increased tissue damage. Inflammation, malnutrition, uremic toxins and dialysis 
procedures are responsible for stimulating oxidative stress, while plasma protein-associated 
free thiols reduce oxidant defenses7. In advanced renal dysfunction, the reduced clearance of 
some growth factors has been supposed to take part in the developing of LVH. Carboxy-
terminal propeptide of collagen type I (PICP) and cardiotrophyn-1 (CT-1) are involved in the 
pathogenesis of LVH in hypertensive heart disease. Although PICP seems to depend only on 
hepatic function and its plasma concentration not to be influenced by renal clearance, a recent 
study showed higher values of PICP and CT-1 in CKD subjects comparing to normal renal 
function-hypertensive patients. Moreover, CKD subjects affected by LVH presented 
significantly higher concentrations of PICP and CT-1 than those without LVH. 
Sodium/potassium ATPase inhibitors may play a certain role in developing LVH in CKD5,6. 
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Very recent acquisitions reported that fibroblast growth factor-23 (FGF-23) shows an 
independent relationship with LVH (particularly concentric LVH). FGF-23 is a recently 
discovered hormone secreted by osteoblasts and ostecytes, which helps in maintaining a 
normal plasma phosphate concentration in CKD. FGF-23 stimulates urinary phosphate 
excretion and decreases intestinal phosphate absorption by inhibiting vitamin D3 synthesis. It 
has been hypothesized that elevated plasma concentrations of FGF-23 in CKD patients are 
responsible for a non-selective binding of FGF-23 with FGF receptors, normally activated by 
other factors. This activation could stimulate myocardial fibrosis and contribute to myocardial 
ischemia, due to a reduction in capillary density and coronary reserve. Increased myocardial 
fibrosis shows a central role in the pathogenesis of alterations of diastolic function. Recently, 
a significant correlation between impaired coronary flow and subclinical renal damage has 
been demonstrated. Left ventricular dysfunction is very frequent among CKD patients and 
may be associated with the subsequent development of heart failure and mortality. It has been 
also reported that in ESRD patients diastolic function reduces in parallel with the progression 
of LVH. However, alterations of diastolic function may occur even in early stages of CKD 
and in absence of LVH4. Early identification of ESRD patients at high risk of cardiovascular 
disease may improve prognostic accuracy and facilitate more aggressive and focused 
treatment1. Among different candidates, cardiac contractile and regulatory proteins have been 
demonstrated to be more cardiac-specific and sensitive indicators of myocardial injury. 
Myofibrillar proteins of striated muscle are expressed as tissue-specific isoforms and these 
antigens can be differentiated by immunologic methods. Cardiac myosin light chains, cardiac 
beta-type myosin heavy chains, cardiac alpha-actin, cardiac tropomyosin, as well as cardiac 
troponin C, are co-expressed in slow-twitch skeletal muscle fibers. Therefore, these proteins 
cannot be used as specific markers of cardiac injury. Troponins are structural proteins of 
cardiac and skeletal muscles9. Troponin I and Troponin T are present in three different 
isoforms with an unique structure: one for slow-twitch skeletal muscle, one for fast-twitch 
skeletal muscle and one for myocardium. The three isoforms are encoded by three different 
genes8. Cardiac Troponin presents two diagnostically relevant forms (cTnI and cTnT), which 
regulate heart contraction, and it is released into the circulation by injured myocardiocytes 
within hours. Cardiac Troponin’s plasma peak is reached within 2 days and its concentration 
remains elevated for as long as the injury continues. After acute myocardial injury, cTnI and 
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cTnT increase in parallel within three to six hour. The early elevation of cTnI and cTnT can 
be explained by the presence of soluble unbound Troponin pools inside the sarcoplasma, 
which may be rapidly released after myocardial damage and which account for about 5% 
amount of cTnI and cTnT in cardiomyocytes. Cardiac Troponins usually peak in parallel, 
except for patients without reperfusion, in whom cTnI increases about one day and cTnT 
three to four days after the onset of acute myocardial injury. Although both cardiac Troponins 
remain increased for at least a four to five day period, cTnT tends to stay elevated longer than 
cTnI. Reperfusion therapy strongly influences cTnT and cTnI time courses, leading to more 
rapid increase, higher rate of increase and early peak value8. cTnI is not expressed in skeletal 
muscle during fetal development or in adult skeletal muscle in response to any pathological 
stimuli. On the contrary, cTnT is expressed in small amounts in skeletal muscle during fetal 
development but it is not present in adult skeletal muscle. cTnT has been found in 
regenerating or denervated rat skeletal muscle, probably due to reversion to a fetal-like pattern 
of expression of Troponin isoforms. This protein is the “gold standard” biomarker of 
myocardial injury in humans because of its high tissue specificity, diagnostic sensitivity, low 
basal blood concentration, rapid release and persistence in the blood10. Although Troponin is 
considered a useful marker of myocardial infarction, it is important to underline that elevated 
plasma concentrations of Troponin reflect a myocardial damage, which may have a different 
pathogenesis.  
 
 
 
Myocardial Infarction 
 
 
Pathogenesis 
 
- Type 1 
 
- Type 2 
 
- Type 3 
 
- Type 4a 
 
- Type 4b 
 
- Type 5 
 
 
- Ischemia due to plaque rupture 
 
- Supply-demand imbalance 
 
- Sudden unexpected cardiac death 
 
- Percutaneous coronary intervention 
 
- Stent thrombosis 
 
- Coronary artery bypass grafting 
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Table 2: human classification of myocardial infarction according to pathogenesis15. Type 1 is 
due to plaque rupture, Type 2 to supply-demand imbalance, Type 3 to sudden unexpected 
cardiac death, Type 4a to percutaneous coronary intervention, Type 4b to stent thrombosis 
and Type 5 to coronary artery bypass grafting. 
 Plaque rupture with superimposed thrombosis within a coronary artery, resulting in 
myocardial cell death, is the most common mechanism of myocardial infarction in humans. 
However, plasma Troponin can increase even for conditions of pulmonary embolism, renal 
failure, sepsis, hypotension and other causes. In patients affected by pulmonary embolism, 
strain in the right side of the heart and myocardial necrosis are believed to determine 
Troponin elevation. In sepsis, systemic hypotension causes suboptimal coronary artery blood 
flow and cytokine release, which are supposed to be responsible for Troponin leakage from 
myocytes15.  Among CKD humans, cardiac Troponin is often elevated in the absence of acute 
coronary syndrome and cTnT is more frequently increased than cTnI in asymptomatic ESRD 
patients. High cTnT concentration shows, in fact, a prevalence between 30% and 85%, 
towards a value between 5% and 18% for cTnI. Although both cardiac Troponins tend to 
increase with progression of CKD, cTnT was strongly predictive of poor short prognosis 
regardless of creatinine clearance. cTnT seems to have greater prognostic importance among 
patients affected by mild to moderate degrees of CKD. Anyway, the lower incidence of cTnI 
elevation and lack of expression in non-cardiac tissue, led to the suggestion that cTnI may be 
a more specific diagnostic and prognostic marker of myocardial injury. The increase in cTnT 
in ESRD patients is very unlikely caused by decreased renal clearance. Both free and bound 
cTnT are, in fact, relatively large molecules of 37 kD and 77 kD respectively. Moreover, 
improvement of renal function after kidney transplantation does not seem to reduce pre-
existing elevated plasma concentration of cardiac Troponins. High cTnT concentration in 
asymptomatic ESRD subjects indicates subclinical myocardial necrosis or injury. In uremic 
cardiac hypertrophy, myocardial capillary growth is unable to keep pace with cardiomyocyte 
hypertrophy, resulting in increased oxygen diffusion distance and diminished ischemic 
tolerance of the heart. This condition predisposes patients to subclinical myocardial ischemia 
and to cellular Troponins leakage. Increased mechanical stress would be responsible for an 
altered membrane permeability of cardiomyocite, which led to Troponins leakage. 
Furthermore, the leak of cardiac Troponins from hyperthrophic cardiomyocytes in patients 
affected by LVH may show the presence of microvascular heart injuries in uremia. Anyway, 
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the use of cardiac magnetic resonance imaging indicated that high plasma values of cTnT 
cannot be explained solely by previous subclinical myocardial necrosis of LVH. Additional 
myocardial alterations, such as fibrosis, may be involved in plasma cTnT elevation16. In 
human patients, even minimally elevated plasma concentrations of cTnT have been related to 
a significant increase in cardiovascular risk and the higher the elevation of cTnT is, the higher 
the cardiovascular risk1 is.  
Recently veterinary publications12,13,17 have reported increased cTnI concentrations in dogs 
affected by different cardiac congenital and acquired diseases, including arrhythmogenic right 
ventricular cardiomyopathy in Boxer dogs, pericardial effusion, cardiac contusion, 
experimental infarction, cardiac injury caused by pacing, positive inotropic and cardiotoxic 
drug administration and neoplasia11. cTnI is part of the Troponin complex (Troponin I, C and 
T) within the sarcomere in myocardial cells and it is important for excitation-contraction 
coupling. The majority of cTnI is bound within the thin filaments of the contractile apparatus, 
whereas a small part of the protein remains free in the cytosol. In case of myocardial injury, 
cTnI is released into the blood stream and its concentration starts to rise within two hours, 
with a peak after 12-24 hours. A persistent increase in cTnI plasma concentration is 
suggestive of irreversible and active cardiomyocite damage. Furthermore, in dog models of 
acute coronary occlusion cTnI concentration correlates with infarct size, suggesting a 
potential role of cTnI as a marker for the extent of myocardial injury. Canine patients with 
acquired cardiac diseases and high plasma values of cTnI reported shorter survival times. 
Long survival times were associated with low cTnI concentrations, which indicate absence of 
significant active cardiomyocyte damage. Dogs affected by cardiac diseases with different 
surviving times showed different cTnI concentrations. Dogs surviving more than 1 year, 2 
years and 3 years presented median cTnI levels of 0.18 ng/mL, 0.07 ng/mL and 0.05 ng/mL 
respectively11. Elevated plasma values of cTnI are associated with many cardiac diseases like 
congestive heart failure, cardiomyopathy, ventricular arrhytmias, pericardial effusion, 
valvular disease, sub-aortic stenosis, experimentally-induced infarction, third-degree heart 
block, endocarditis and white muscle disease10. A particular correlation between high cTnI 
and mixomatous mitral valve disease (MMVD) has been found in dogs. Plasma cTnI 
concentration increases with increasing severity of MMVD. Cardiac release of cTnI starts in 
the early stages of MMVD. Because the half-life of cTnI is < 70 minutes, the increased cTnI 
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concentration is mainly due to an ongoing release of cTnI, caused by a continuous 
remodelling process, rather than an acute mechanism14. A significant increase in cTnI has 
been reported even in pathologic conditions other than cardiac diseases, like severe 
respiratory diseases, pancreatitis, moderate-to-marked anaemia, Addison’s and Cushing’s 
disease, advanced renal failure and neoplasia. Although the underlying cause of myocardial 
injury in these conditions remains unclear, ischemia and hypercatecholaemia seemed to be 
involved.  
 
Primary cardiac disease/injury 
 
 
Infectious disease 
 
- congestive heart failure 
- cardiomyopathy 
- ventricular arrhythmia 
- pericardial effusion 
- valvular disease 
- sub-aortic stenosis 
- experimentally-induced cardiac 
infarction  
- third-degree heart block 
- endocarditis 
- white muscle disease 
- cardiac pacing 
- cardiac surgery 
 
 
- babesiosis 
- ehrlichiosis 
- leptospirosis 
- foot and mouth disease 
- sepsis 
- endotoxaemia 
 
 
Toxicity 
 
 
Miscellaneous 
 
- Adrenergics (phenylpropanolamine, 
isoproterenol) 
- Anthraquinones (doxorubicin, 
daunorubicin) 
- Monensin 
- Fumonisisn B1 
- Viper envenomation 
 
 
- Trauma 
- Gastric dilatation/volvulus 
- Severe respiratory disease 
- Heat stroke 
- Severe exertion 
- Renal failure 
- Anaemia 
- Ageing 
- Pancreatitis 
- Lymphoma 
- Visceral neoplasia 
- Addison’s disease 
- Cushing’s disease 
- Severe colic 
- Significant weight loss 
- Downer cow syndrome 
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Table 3: diseases associated with elevated plasma concentrations of cardiac Troponins in 
veterinary medicine. 
 
Elevated plasma cTnI concentration is a well-recognized sensitive and specific marker of 
active cardiac damage but it doesn’t provide any information about the pathogenetic 
mechanism. Dogs and cats may even present an age-related increase in cTnI concentration, 
presumably due to a sub-clinical age-associated deterioration of cardiac function. This 
dysfunction is more common in older dogs than in cats and no association between cTnI 
concentration and breed has been reported. Anyway transient release of cTnI can occur after 
reversible cardiac injury, caused by intense exercise11.  Although approximately 78% of dogs 
and 72% of cats affected by CKD presented high plasma levels of cTnI, the exact 
pathogenesis is still unknown. Despite cTnI being eliminated by the kidney, the severity of 
CKD does not correlate with the cTnI concentration. The possible causes of the elevation of 
cardiac Troponins in ESRD patients are multiple and often discordant, according to different 
studies. Among different hypothesis, uremic myopathy, expression of fetal cardiac Troponins 
in skeletal muscle, altered protein clearance, abnormal protein metabolism, silent myocardial 
injury, microinfarctions, LVH and uremic toxins have been taken into consideration9. In 
human medicine the most reliable hypothesis reports that high plasma levels of cTnI in CKD 
patients are caused by a concomitant coronary artery disease. As coronary artery disease is 
not a feature in veterinary medicine, the relationship between CKD and elevated cTnI 
concentrations should be further investigated17. 	  	  	  	  	  	  	  	  
	   61	  
CHAPTER 9: ACUTE-PHASE INFLAMMATION AND CKD PROGRESSION: 
ROLE OF C-REACTIVE PROTEIN (CRP) 	  
Acute phase proteins (APPs) enclose a group of proteins the plasma concentration of which 
changes rapidly in response to the action of different stressors. APPs are divided into positive 
and negative proteins according to an increase or decrease of their plasma levels during 
inflammation. C-reactive protein (CRP), haptoglobin (Hp), ceruloplasmin (Cp), serum 
amyloid A (SAA), alpha-1 acid glycoprotein (AGP) and fibrinogen are considered positive 
APPs, while albumin and transferrin negative ones1. The majority of APPs is produced by the 
liver, through the stimulating activity of pro-inflammatory cytokines, such as IL-1, IL-6 and 
TNF-α. These cytokines are secreted by activated monocytes in response to local tissue injury 
or bacterial toxins. Once secreted, pro-inflammatory cytokines diffuse into the blood stream, 
where they act both locally, at the site of inflammation, and systemically towards target 
organs. Their serum concentration increases within few hours after the starting stimulus and 
decreases progressively2. Pro-inflammatory cytokines are divided into two groups (IL-1 type 
cytokines and IL-6 type cytokines), which interact with different kinds of receptors of 
hepatocytes. IL-1 type cytokines stimulate different cellular types to release IL-6 cytokines, 
showing a pro-inflammatory action. On the contrary, IL-6 type cytokines seem to act a 
negative feed-back towards the production of IL-1 type cytokines. Il-1 type and IL-6 type 
cytokines show both common and specific functions. 
IL-1 IL-6 TNF-α 
 
- Activation of stroma, 
condrocytes and 
epithelium in 
response to localised 
tissue damage 
 
- Regulation of B-
lymphopoiesis in 
bone marrow 
 
 
- Mediation of tissue 
 
- Induction and 
differentiation of 
cytotoxic T 
lymphocytes 
 
- Stimulation of 
differentiation of  
hematopoietic stem 
cells 
 
- Modulation of 
production of IL-1 
 
- Induction of IL-1 
production 
 
- Participation in cell 
destruction by 
suppressing protein 
synthesis  
 
- Elicit local 
endothelial injury 
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infiltration of 
leukocytes through 
IL-8 
 
- Osteoblast activation 
and bone and 
cartilage degradation 
 
and TNF 
 
 
 
- Induction of hepatic acute phase response 
 
- Fever induction 
 
- Activation of T-, B- and NK cells 
 
- Induction of IL-2 in T-cells 
 
Table 4: main specific and common functions of IL-1, IL-6 and TNF-α2. 
 
 
In dogs and cats, APPs can be classified in major, moderate or negative, according to the 
modification in their plasma concentration when an inflammatory stimulus occurs. Major 
APPs show a plasma concentration ten to one hundred times the physiologic range, while 
moderate APPs show a plasma concentration twice to ten times. Negative APPs, instead, are 
characterized by a plasma concentration below the physiological range. In dogs, CRP and 
SAA are considered major APPs, while Cp, Hg and AGP are considered moderate ones. In 
cats, major APPs enrol AGP and SAA, while Hp is classified as moderate acute phase protein. 
In both canine and feline patients albumin is considered a negative acute phase protein2. The 
response pattern of APPs is, in fact, specie specific, with the exception of albumin, which 
plasma concentration reduces between 10% and 30% in all mammalians3. Generally, SAA 
and CRP show a higher increase in plasma concentration than Hg. In physiologic conditions, 
the basal plasma concentrations of SAA and CRP are undetectable, so the relative increase in 
plasma concentration during acute inflammation is significantly more elevated. However, 
SAA and CRP plasma concentrations are substantially lower than other APPs with negligible 
normal plasma concentrations2. Acute phase response is part of a general defence response 
towards tissue injuries, which involves different APPs. A number of APPs is, in fact, directly 
involved in the protection of the host4 and its functions well understood. Hp, for example, is 
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able to bind hemoglobin released by damaged erythrocytes and, together with hemopexin and 
transferrin, both to alleviate the detrimental effects of free iron and to reduce the availability 
of free iron for invading bacteria. Although the biological function of other APPs has not been 
completely established yet, many APPs showed to be involved in a down-regulation process 
of pro-inflammatory cytokines production and activity in monocytic cells. Due to a relatively 
short half-life in serum and high response in diseased animals, APPs can be considered a valid 
measure of a systemic response to an initiating stimulus at the time of blood sampling. The 
maximum serum concentration of APPs is typically reached within 24 and 48 hours. If no 
further stimulus occurs, a decline in serum concentration and feed-back regulation, leading to 
resolution of inflammation, are seen within four to seven days from the starting process.  
CRP is formed by five no-covalently associated polypeptide subunits, with a total molecular 
size of approximately 115 kDa5. This protein has been discovered in blood of human patients 
in acute phase of pneumococcal pneumonia and its name derives by the ability of CRP to bind 
pneumococcal C-polysaccharide2. The blood concentration of CRP is known to be elevated 
from one hundred to one thousand times within 24 and 48 hours after inflammatory irritation 
and it is widely used in human medicine as a sensitive marker of inflammation. Similarly in 
veterinary medicine, CRP shows high in various inflammatory conditions, such as infections6, 
surgical trauma7, neoplasia8,9, pyometra10, acute pancreatitis11, immune-mediated haemolytic 
anaemia, arthritis, glomerulonephritis and experimental inflammation1. In human medicine 
both traditional and non-traditional risk factors of cardiovascular disease in CKD have been 
identified. Traditional cardiovascular risk factors include advanced age, gender, hypertension, 
diabetes mellitus, smoking, hyperlipidemia, left ventricular hypertrophy, heart failure, 
physical inactivity and are indicated into the Framingham risk equations. Although the high 
prevalence of traditional risk factors, the severity and extend of cardiovascular complications 
in CKD patients underline the role of non-traditional factors.  These factors are not included 
into the Framingham equations and enrol albuminuria, anaemia, disorders of bone and 
mineral metabolism, inflammation and oxidative stress13,14.  
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Traditional risk factors Non-traditional risk factors 
 
- older age 
- male gender 
- hypertension 
- high LDL 
- low HDL 
- diabetes mellitus 
- smoking 
- physical inactivity 
- menopause 
- family history of CVD 
- LVH 
- Heart failure 
 
 
- albuminuria 
- anaemia 
- homocysteine 
- inflammation 
- oxidative stress 
- disorders of mineral metabolism 
- vascular calcification 
- uremic bone disease 
- malnutrition/protein wasting 
- sympathetic activation 
- extracellular fluid volume overload 
- coagulation disorders 
- altered nitric oxide/endothelin balance 
- insulin resistance 
- subclinical hypothyroidism 
- uremic toxins 
- adipokine imbalance 
 
Table 5: traditional and non-traditional risk factors of cardiovascular disease in human CKD 
patients12. 
 
Chronic inflammation has been widely described in people affected by CKD since the early 
stages of the disease and its prevalence increases with the worsening of renal failure. Together 
with oxidative stress and endothelial dysfunction, inflammation represents one of the most 
important contributors of the development and progression of atherosclerosis, which is 
considered the link between CKD and cardiovascular diseases. The inflammatory mechanism 
occurring in CKD patients has a multifactor origin. Even in the absence of overt clinical 
illness, underling diseases may cause acute phase inflammation and predispose patients to 
infections. The prevalence of inflammation tends to increase along with the progression of 
CKD, especially in ESRD patients in which uraemia and impaired immune response amplify 
the inflammatory condition. Uraemia can play a fundamental role in stimulating 
inflammation. Uremic toxins are, in fact, directly responsible for releasing cytokines. 
Guanidines were shown to enhance the production of TNF-α by monocytes and advanced 
glycation-end products (AGE-s) have been reported to increase cytokine release. Furthermore 
the reduction in renal clearance determines an increase in plasma concentration of pro- and 
anti-inflammatory cytokines and other mediators, such as AGE-s. Although it has been 
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questioned which was the overall effect of pro- and anti-inflammatory cytokines retention, the 
net result appears to be an accumulation of pro-inflammatory mediators.  Overhydrated 
patients show elevated plasma levels of several cytokines and endotoxins comparing to stable, 
edema-free people with chronic heart failure. Diuretic treatments, in fact, reported significant 
decreases in plasma endotoxin concentrations. Moreover, the negative correlation between 
serum albumin and excessive extracellular fluid volume suggested that overhydration may 
lead to reduced albumin synthesis by increasing endotoxin and cytokine levels. Up-regulation 
of inflammatory cytokines has also been shown in patients affected by heart failure. 
Myocardial cells are, in fact, able to produce TNF-α in response to increased left ventricular 
pressure and volume overload. In heart failure, myocardial expression of TNF-α and IL-6 can 
also increase due to a chronic β-adrenergic stimulation, determined by an elevated 
symphathetic activity. In haemodialysis patients CRP levels correlate positively with left 
ventricular mass and negatively with ejection fraction. In this class of patients, several studies 
reported a strong correlation between LVH and inflammatory state. Oxidative stress seems to 
be involved in stimulating inflammation and extensive investigations demonstrated a 
bidirectional and synergistic connection between oxidative stress and inflammatory process12. 
A strict relationship between extra-osseous calcifications and inflammatory syndrome has 
been widely demonstrated, showing a significant increase in cardiovascular mortality rate15. 
Chronic inflammatory response precedes the formation of atherosclerotic plaques and 
involves cytokines and other mediators, which can regulate the osteogenic differentiation of 
vascular cells16. Moreover, valvular and perivalvular calcifications of the mitral annulus and 
aortic valve can be easily complicated by infective endocarditis.  
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CHAPTER 10: OXIDATIVE STRESS AND CKD PROGRESSION: ROLE OF α-
TOCHOPHEROL 
 
In human medicine it has been widely demonstrated that cardiovascular diseases represent the 
major cause of morbidity and mortality in CKD patients. In fact, as GFR reduces the 
prevalence and severity of cardiovascular injuries increase1,2. Cardiovascular alterations 
seemed to augment not only in ESRD, but also in early stages of the disease. Among patients 
belonging to IRIS 3 and IRIS 4, the prevalence of cardiovascular diseases is four to five fold 
higher than observed in general population. In human CKD patients, several cardiovascular 
risk factors have been recognized. Particularly, a significant importance has been attributed to 
diabetes, hypertension and obesity. However, cross-sectional studies have demonstrated that 
traditional cardiovascular disease risk factors are not sufficient to determine the extent of 
cardiovascular injury risk in CKD and ESRD patients. This finding have led to the conclusion 
that other risk factors must be involved in the increased prevalence of cardiovascular events in 
CKD population3. Among several factors, oxidative stress was recognized as a powerful risk 
condition for the development of cardiovascular damage in CKD patients. Oxidative stress 
can be defined as a state of imbalance between free radicals production and degradation, with 
a resulting increase and accumulation of free radicals. The more common forms of free 
radicals are represented by reactive oxygen metabolites (ROS) and reactive nitrogen species 
(RNS). The majority of ROS production (about 90%) derives from accidental formation in 
mitochondria during oxygen metabolism. During this process some electrons pass down the 
electron transport chain and leak away from the main path, going directly to reduce oxygen 
molecules to superoxide anion4. In addition, ROS are deliberately synthesized in phagocytic 
cells, vascular wall cells and various other tissue, by the action of NAD(P)H oxidase, 
myeloperoxidase, xanthine oxidase, cycloxygenase and lipoxygenase5. ROS involve different 
compounds like superoxide anion, hydrogen peroxide, hydroxil radical, hypochlorite ion and 
hydroperoxyl radical, which, at low concentrations, are involved in many physiologic 
functions. However, when ROS production is excessive, they can react with lipids, 
carbohydrates, proteins and DNA, altering their structure and function, with subsequent 
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cellular damages. ROS overproduction and its deleterious effects are controlled by an 
antioxidant enzymatic and non-enzymatic system. The antioxidant enzymatic fraction is 
composed by superoxide dismutase (SOD), glutathione peroxidase, glutathione reductase and 
catalase, while the non-enzymatic one involves gluthathione, thiols, ascorbic acid, α-
tochopherol, mixed carotinoids and bioflavonoids. Final result of the antioxidant barrier, of 
both enzymatic and non-enzymatic form, is to eliminate pro-oxidants and free radicals3. In 
human medicine, although a significant correlation between CKD and oxidative stress has 
been widely assessed, the origin of this relationship has to be clarified. The most accepted 
hypothesis derives oxidative stress from a combination of increased ROS production, reduced 
clearance and dysfunction of antioxidant mechanisms. Alterations of several antioxidant 
pathways, as erythrocyte SOD, plasma thiol groups, plasma glutathione and glutathione 
peroxidase, have been reported in CKD patients3. It is also to be noticed that total antioxidant 
capacity of plasma has been demonstrated to be normal or even increased with the 
progression of renal disease6. In CKD numerous biomarkers of oxidative stress have been 
found above normal range and their increase related to the progression of the disease. GFR, in 
fact, has been reported to be inversely associated with some products of lipid and protein 
oxidation. CKD patients are generally characterized by elevated values of lipid oxidation 
compounds, oxidized low-density lipoproteins (LDL), protein oxidation products, F2 
isoprostanes and isolevuglandins and oxidative DNA damage markers3. Furthermore, 
increased activity of NAD(P)H oxidase and subsequent overproduction of superoxide anion in 
circulating peripheral mononuclear cells, have been reported in IRIS 1 and 27. CKD patients 
are also affected by concomitant pathologies, like diabetes and hypertension, which can 
exacerbate oxidative stress. NAD(P)H oxidase, for example, can be activated by 
hyperglycemia, as well as some cytokines and mechanical stress. Similarly, malondialdehyde 
and protein carbonylation have shown increased in hypertensive patients with CKD, 
compared to hypertensive subjects without CKD. Moreover, renin-angiotensin system has 
reported a significant role in NAD(P)H oxidase activation in vascular smooth muscle cells 
and kidney. Another potential source of oxidative stress in CKD patients is represented by 
haemodialysis. This treatment can contribute to oxidative stress in different ways. During 
haemodialysis session, ROS production can be enhanced by the contact of blood with the 
dialysis membrane or to the presence of endotoxins in water used for dialysate preparation. 
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Both conditions are responsible for activation of circulating peripheral mononuclear cells, 
leading to increasing ROS generation. Furthermore, myeloperoxidase activity has been found 
augmented during haemodialysis, especially when bioincopatible membranes have been 
used8. Heparin, commonly used as anticoagulant agent during haemodialysis, has also been 
demonstrated to activate circulating peripheral mononuclear cells. Intravenous administration 
of heparin can also be responsible for displacement of extracellular-superoxide dismutase 
from vascular endothelium, by interfering with the binding of the antioxidant enzyme to type 
C heparin sulphate proteoglycans. Loss of extracellular-superoxide dismutase from vascular 
wall may contribute to endothelial dysfunction. Finally, haemodialysis can also affect the 
antioxidant barrier, by reducing plasma concentration of ascorbic acid and α-tochopherol9. 
Oxidative stress has been connected with cardiovascular diseases by the oxidative hypothesis 
of atherosclerosis. According to this hypothesis the oxidative transformation of LDL would 
represent the starting event of atherosclerosis and it would contribute to its progression. 
Oxidized LDL are responsible for adhesion of circulating monocytes to endothelial cells by 
inducing adhesion molecules (VCAM-1) and specific receptors. Oxidized LDL can also 
stimulate production and release of monocyte chemotactic protein 1 (MCP-1) from 
endothelial cells and smooth muscle cells, resulting in increased migration of monocytes into 
the arterial intima. Furthermore, oxidized LDL show protrombotic activity and increase 
platelet activation and expression of tissue factor and plasminogen activator inhibitor 1 (PAI-
1) on endothelial cells10,11.  
Vitamin E enrols a group of extremely powerful antioxidants composed by four tochopherols 
(α-tochopherol, β-tochopherol, γ-tochopherol and δ-tochopherol) and four tochotrienols (α-
tochotrienol, β-tochotrienol, γ-tochotrienol and δ-tochotrienol), of which α-tochopherol 
represents the most important and abundant molecule12. α-tochopherol is mainly stored in 
vegetables even if small quantities can be found even in fat of animal origin13. After an active 
intestinal absorption, α-tochopherol seems to be mostly stocked in microsomial membranes, 
which represent main intracellular pools. The transfer of α-tochopherol from microsomes to 
mithocondria is mediated by α-tochopherol-transfer proteins (α-TTP). The major affinity of 
α-TTP for α-tochopherol, compared to other isomers, may explain why α-tochopherol is the 
most represented form of Vitamin E in the body, despite the higher concentration of γ-
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tochopherol in food14. In physiologic conditions α-tochopherol absorption depends on the 
quantity of dietary fats introduced and ranges within 30% and 80%, with a high inter-
individual variability. This difference may be explained by inter-individual variability in the 
expression and activity of Vitamin E intestinal receptors15. α-tochopherol is metabolized by 
the liver and it is transported in plasma by lipoproteins16. Its tissue distribution does not 
appear uniform and different organs show different concentration of α-tochopherol. Highest 
concentrations are reached in fat tissue and surrenal glands, while lowest ones are present in 
red blood cells and kidney17. 
Tissue α-tochopherol (µg/g tissue) 
 
Plasma 
 
Red blood cells 
 
Platelets 
 
Fat 
 
Kidney 
 
Liver 
 
Muscle 
 
Ovary 
 
Testis 
 
Uterus 
 
Heart 
 
Surrenal gland 
 
Pituitary gland 
 
 
9.5 
 
2.3 
 
30 
 
150 
 
7 
 
13 
 
19 
 
11 
 
40 
 
9 
 
20 
 
132 
 
40 
 
Tabella 6: α-tochopherol concentration expressed as µg/g of tissue in different organs and tissues 
 
α-tochopherol shows different biological antioxidant and not antioxidant functions. As an 
antioxidant compound, α-tochopherol acts as a chain-breaking molecule towards lipid 
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oxidation, through a rapid and non-enzyme mediated action. During lipid oxidation process, 
in fact, α-tochopherol is able to bind peroxide radicals, avoiding their binding to lipid targets. 
Beside antioxidant action, α-tochopherol is responsible for several functions such as 
inhibiting the phosphorilation of protein C kinase, platelet aggregation and endothelial 
adhesion of monocytes. Recently a modulating gene activity has been discovered18,19. α-
tochopherol is considered the most powerful fat-soluble antioxidant known in nature and it 
works through the inhibition of the oxidation of low density lipoproteins (LDL) by oxidants20. 
Several studies have reported that the protein fraction of LDL (apolipoprotein B100) may be 
carbamylated at lysine or the terminal protein amino acids. Carbamylation is the result of a 
non-enzymatic post-translational modification of a protein by urea-derived cyanate, normally 
elevated in plasma of human CKD patients. It has also demonstrated that carbamylation of 
LDL represents a significant non-traditional risk factor for the onset of cardiovascular 
diseases. According to oxidative hypothesis of atherosclerosis, atherosclerotic plaques would 
be originated by the cooperation of foam cells and macrophages, covered by a fibrous cap. 
Injured endothelial cells, in fact, attract monocytes, which have previously ingested 
carbamylated LDL, originating foam cells21. LDL, in their native state, are not atherogenic 
and they must undergo oxidative modifications before becoming atherogenetic3. Several 
studies have reported a significant increase in carbamylated LDL concentration in uremic 
patients and the elevation in oxidized LDL has been shown to be related with the severity of 
the disease. Strong and independent relationship between oxidized LDL and cardiovascular 
alterations has been reported in CKD population, as well as a large number of evidences have 
suggested oxidized LDL as leading cause of atherosclerosis10. Increase in plasma 
concentrations of carbamylated LDL has been associated with concomitant alteration in 
antioxidant defence22. Anyway, the role of serum α-tochopherol reduction in increasing 
cardiovascular risk in CKD patients is still controversial. In human CKD patients, serum 
levels of α-tochopherol are generally reduced in long-term haemodialysis, as long as other 
nutritional parameters and lipid profile. Many studies regarding α-tochopherol in CKD have 
reported that α-tochopherol alone cannot be considered a mortality risk. Furthermore, α-
tochopherol has not been able to decrease mortality and, at high doses, mortality can even 
increase23,24. Prolonged oral α-tochopherol administration in haemodialysis patients has 
seemed to decrease the activity of the antioxidant enzyme superoxide dismutase and total 
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plasma antioxidant system, showing a pro-oxidant effect25. In other studies, instead, α-
tochopherol supplementation has been associated with beneficial effects on heart diseases and 
on lipid peroxidation. In haemodialysis subjects, oxidized LDL concentration has been 
reported to be significantly decreased after a 16 week α-tochopherol integration26. In mice, 
high concentrations of α-tochopherol supplementation have been demonstrated to 
significantly reduce cisplatin-induced nephrotoxicity, restoring normal levels of the renal 
antioxidant barrier. This effect has seemed to be dose related. Dietary α-tochopherol 
supplementation at the dosage of 500 mg/kg of body weight has shown more effective than 
250 mg/kg in improving antioxidant barrier27. Moreover, dietary integration of α-tochopherol 
(200 IU/kg) has been capable to reverse acquired glomerulosclerosis and tubulointerstitial 
injury in rat models with CKD28. In veterinary medicine, no studies regarding serum levels of 
α-tochopherol in CKD are present. The only study in feline CKD patients, has reported only a 
non-significant tendency to increased values of oxidative status, compared to control group. 
In these patients, the combined administration of α-tochopherol, vitamin C and β-carotene 
has shown a protective action towards oxidative injuries of DNA29. Further investigations 
referring to α-tochopherol concentration in CKD animals and its relationship with the severity 
and the progression of the disease are strongly needed.  	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CHAPTER 11: MATERIALS AND METHODS 
 
Treatment of animals 
The research project involved a total of 301 privately owned dogs of different breed, gender, 
age and weight, at different stages of CKD, referred to the Veterinary Teaching Hospital 
“Mario Modenato” between December 2008 and December 2010 for nephrological 
consultation. 291 patients showed a diagnosis of CKD reported by referring veterinarian, 
while 10 subjects were referred for a GFR evaluation. A total of 125 clinically healthy (CH) 
dogs of different breed, gender, age and weight, presented to the Veterinary Teaching 
Hospital “Mario Modenato” between December 2008 and December 2010 for routine annual 
check-up, was involved as control group, after owners’ informed consent. Each patient was 
submitted to historical record, clinical evaluation and blood sample (5 ml of volume) for 
assessing the standard biochemistry panel used to diagnose CKD. Renal panel involved 
plasma creatinine and urea, serum albumin, total proteins, total calcium, phosphate and 
ionized calcium, together with complete blood count (CBC) and complete urinalysis. After a 
12 hour fasting period, all dogs (both CKD and clinically healthy) were submitted to blood 
sampling (5 ml of volume) and blood was collected both in heparinised tubes (for obtaining 
plasma) and in tubes without anticoagulant agents (for obtaining serum). 10 dogs with plasma 
creatinine within the normal range were submitted to GFR test through the plasma clearance 
of iohexol. CKD patients were classified according to the International Renal Interest Society 
guidelines in IRIS 1, IRIS 2, IRIS 3 and IRIS 4. For each patient, Ca X P product (Ca X P), 
calcium corrected for albumin (tCaAlb) and calcium corrected for total proteins (tCaPt) were 
calculated. Ca X P was assessed by multiplying serum total calcium per phosphate. tCaAlb 
was determined through the following formula: tCaAlb (mg/dl) = total calcium (mg/dl) – 
albumin (g/dl) + 3.5. tCaPt was determined through the following formula: tCaPt (mg/dl) = 
total calcium (mg/dl) – (0.4 x total proteins {g/dl}) + 3.3.All dogs’ owners were asked for 
informed consent, in order to store serum samples for research purposes. 44 of 301 owners of 
CKD patients and 20 of 125 owners of CH dogs accepted to be enrolled in the present 
research project. IRIS 1 group was composed by 13 dogs, IRIS 2 group by 7 dogs, IRIS 3 
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group by 13 dogs and IRIS 4 group by 11 dogs. CH group was composed by 20 dogs. Serum 
of each patient was divided into four parts for the determination of total calcium X phosphate 
product (Ca X P), cardiac troponin I (cTnI), C reactive protein (CRP) and α-tocopherol. 
Control group was composed by 125 subjects for total calcium, ionized calcium, tCaAlb and 
tCaPt and by 20 subjects for Ca X P, cTnI, CRP and α-tocopherol. 
 
Plasma creatinine 
Plasma creatinine was determined at the Laboratory of Clinical Haematology and 
Biochemistry of the Veterinary Teaching Hospital “Mario Modenato” through a commercial 
kit based on a cinetic method, which uses alkaline picrate in the Jaffe reaction. Analysis was 
performed by SLIM® analyzer (SEAC, Firenze, Italia).  
 
Plasma urea 
Plasma urea was determined at the Laboratory of Clinical Haematology and Biochemistry of 
the Veterinary Teaching Hospital “Mario Modenato” through a commercial kit based on a 
cinetic UV method. Urease catalyzes the hydrolysis of urea into carbon dioxide and ammonia, 
which, at the presence of glutamate dehydrogenase, react with ketoglutarate sodium and 
NADH generating NAD and causing a reduction in absorbance. Analysis was performed by 
SLIM® analyzer (SEAC, Firenze, Italia). 
 
Serum albumin 
Serum albumin was determined at the Laboratory of Clinical Haematology and Biochemistry 
of the Veterinary Teaching Hospital “Mario Modenato” through a commercial colorimetric 
kit based on the bromocresol green (BCG) reaction. Analysis was performed by SLIM® 
analyzer (SEAC, Firenze, Italia). 
 
Serum total proteins 
Serum total proteins were determined at the Laboratory of Clinical Haematology and 
Biochemistry of the Veterinary Teaching Hospital “Mario Modenato” through a commercial 
colorimetric kit based on Biuret reaction. In alkaline conditions, proteins link to copper anions 
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forming blue-violet complexes, while peptides link to copper anions forming red complexes. 
Colour intensity is proportional to the concentration of proteins in the sample. Analysis was 
performed by SLIM® analyzer (SEAC, Firenze, Italia). 
 
Serum total calcium 
Total calcium (tCa) was determined at the Laboratory of Clinical Haematology and 
Biochemistry of the Veterinary Teaching Hospital “Mario Modenato” through a colorimetric 
method, which uses a Cresolphthalein Complexone (CPC) diagnostic kit. Analysis was 
performed by SLIM® analyzer (SEAC, Firenze, Italia).  
 
Serum phosphate 
Phosphate was determined at the Laboratory of Clinical Haematology and Biochemistry of 
the Veterinary Teaching Hospital “Mario Modenato” through a direct UV kit based on 
Molybdate reaction. In acid conditions, inorganic phosphate reacts with ammonium 
molybdate forming a coloured complex. Colour intensity is proportional to the concentration 
of phosphate in the sample. Analysis was performed by SLIM® analyzer (SEAC, Firenze, 
Italia). Ca X P was calculated by multiplying total calcium per phosphate. 
 
Serum ionized calcium 
Ionized calcium was determined at the Laboratory of Clinical Haematology and Biochemistry 
of the Veterinary Teaching Hospital “Mario Modenato” through a selective ion 
hemogasanalysis machine STAT PROFILE® pHOx Plus (GEPA, Milano, Italy), which 
measures potential difference of the sample. 
 
Serum cardiac troponin I (cTnI) 
cTnI was assessed by an immunometric method. Blood was collected into tubes without 
anticoagulant and centrifuged at 3000 rpm for 3 minutes to obtain serum. Serum was stored at 
-20°C till analysis. Samples were sent to Vet Med Labor GmbH, Division of IDEXX 
Laboratories – Mörikestraße 28/3, 71636 Ludwigsburg, Deutschland for the determination of 
cTnI. Serum cTnI was determined through immunometric method (IMMUNOLITE 2000® 
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Immunoassay System) using enzyme-amplified chemiluminescence technique. This method 
was based on a solid phase, covered by murine monoclonal anti-troponin I antibodies, and on 
a liquid phase, composed by bovine alkaline-phosphatase linked to goat polyclonal anti-
troponin I antibodies. Serum samples (200 µl) were incubated together with reagent and solid 
phase for 30 minutes. Then samples were washed and centrifuged till the chemiluminescent 
substrate was added. As much intense luminescence was as much enzyme was linked. A value 
of serum cTnI > 0.20 ng/ml was considered pathologic.  
 
Serum C-reactive protein (CRP) 
CRP was assessed by an immunoturbidimetric method. Blood was collected into tubes 
without anticoagulant and centrifuged at 3000 rpm for 3 minutes to obtain serum. Serum was 
stored at -20°C till analysis. Samples were sent to Vet Med Labor GmbH, Division of IDEXX 
Laboratories – Mörikestraße 28/3, 71636 Ludwigsburg, Deutschland for the determination of 
CRP. Serum CRP was determined through a RANDOX immunoturbidimetric kit for CRP 
(Vet Med Lab, IDEXX, Germany). 100 µl of serum were added to assay buffer, which was 
composed by polyethylene glycol (at a maximum of 4%), tris/HCL buffer (20 mmol/l at pH 
7.4) and sodium chloride (150 mmol/l). Then samples were added to antibody reagent, which 
was composed by human anti-CRP antibodies.  
 
Serum α-tochopherol 
α-tochopherol was assessed through a HPLC system by using a Chromosystems-Diagnostic 
Kit HPLC & LC/MS (Munchen, Germany). 200 µl of serum were added to 20 µl of internal 
standard and to 25 µl of precipitation reagent I. Samples were vortex for 30 seconds and 
added with 400 µl of precipitation reagent II. Then samples were vortex for 30 seconds and 
centrifuged at 10000 rpm for 10 minutes. 50 µl of supernatant were submitted to HPLC 
analysis. The HPLC system consisted of a Series 200 Perkin Elmer gradient Pump coupled to 
a Series 200 Perkin Elmer variable UV detector, which was set at 325 nm and 254 nm. HPLC 
was interfaced with a personal computer by using an interface SERIES 600 Perkin Elmer 
(Norwalk, CT, USA). Integration of pikes was performed through Turbochrome Navigator 
software (Perkin Elmer). A chromatographic column (CHROMOSYSTEMS, Munchen, 
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Germany) was used. Instruments showed a wave length of 325 nm, which was switched to 
295 nm after 3.5 minutes. The flux was set at 1.5 ml/min and temperature of the column was 
25°C. 
 
Statistical analysis 
For all 301 patients, belonging to different IRIS stages (IRIS 1, IRIS 2, IRIS 3 and IRIS 4), 
mean values of plasma creatinine and urea, serum albumin, total proteins, total calcium, 
phosphate, ionized calcium, tCaAlb and tCaPt were calculated. Pearson correlation analysis 
(p<0.05) between ionized calcium and total calcium, ionized calcium and tCaAlb, ionized 
calcium and tCaPt was performed in all IRIS stages. For control group subjects (CH), mean 
values of plasma creatinine and urea, serum albumin, total proteins, total calcium, phosphate, 
ionized calcium, tCaAlb and tCaPt were calculated. Correlation analysis (p<0.05) between 
ionized calcium and total calcium, ionized calcium and tCaAlb, ionized calcium and tCaPt 
was performed through Pearson test. 
Average Ca X P, cTnI, CRP and α-tochopherol were calculated for both CKD patients with 
parameters above and below the reference range and for control group.  
Variance analysis (p<0.05) among mean serum values of Ca X P of control group and IRIS 1, 
2, 3 and 4 was determined through ANOVA test. If significant difference among control 
group and IRIS stages was present (p<0.05), Dunnett’s and Tukey’s post-tests were 
performed. Pearson correlation test (p<0.05) between plasma creatinine and Ca X P was 
assessed for patients belonging to IRIS 1, 2, 3 and 4. Contingency analysis between the 
number of subjects with Ca X P ≤ 0.7 and > 0.7 was calculated in each IRIS stage through χ2 
test (p<0.05). Contingency analysis between the number of patients survived and dead in the 
group of dogs with Ca X P ≤ and > 0.7 was calculated in each IRIS stage through χ2 test 
(p<0.05). Survival curve of Kaplan-Meier was determined for patients belonging to the group 
with Ca X P ≤ and > 0.7.  
Variance analysis (p<0.05) among mean serum values of cTnI of control group and IRIS 1, 2, 
3 and 4 was determined through ANOVA test. If significant difference among control group 
and IRIS stages was present (p<0.05), Dunnett’s and Tukey’s post-tests were performed. 
Pearson correlation test (p<0.05) between plasma creatinine and cTnI was assessed for 
patients belonging to IRIS 1, 2, 3 and 4. Contingency analysis between the number of subjects 
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with cTnI ≤ 0.2 and > 0.2 was calculated in each IRIS stage through χ2 test (p<0.05). 
Contingency analysis between the number of patients survived and dead in the group of dogs 
with cTnI ≤ and > 0.2 was calculated in each IRIS stage through χ2 test (p<0.05). Survival 
curve of Kaplan-Meier was determined for patients belonging to the group with cTnI ≤ and > 
0.2.  
Variance analysis (p<0.05) among mean serum values of CRP of control group and IRIS 1, 2, 
3 and 4 was determined through ANOVA test. If significant difference among control group 
and IRIS stages was present (p<0.05), Dunnett’s and Tukey’s post-tests were performed. 
Pearson correlation test (p<0.05) between plasma creatinine and CRP was assessed for 
patients belonging to IRIS 1, 2, 3 and 4. Contingency analysis between the number of subjects 
with CRP ≤ 9.7 and > 9.7 was calculated in each IRIS stage through χ2 test (p<0.05). 
Contingency analysis between the number of patients survived and dead in the group of dogs 
with CRP ≤ and > 9.7 was calculated in each IRIS stage through χ2 test (p<0.05). Survival 
curve of Kaplan-Meier was determined for patients belonging to the group with CRP ≤ and > 
9.7.  
Variance analysis (p<0.05) among mean serum values of α-tochopherol of control group and 
IRIS 1, 2, 3 and 4 was determined through ANOVA test. If significant difference among 
control group and IRIS stages was present (p<0.05), Dunnett’s and Tukey’s post-tests were 
performed. Pearson correlation test (p<0.05) between plasma creatinine and α-tochopherol 
was assessed for patients belonging to IRIS 1, 2, 3 and 4. Contingency analysis between the 
number of subjects with α-tochopherol ≤ 21.6 ppm and > 21.6 ppm was calculated in each 
IRIS stage through χ2 test (p<0.05). Contingency analysis between the number of patients 
survived and dead in the group of dogs with α-tochopherol ≤ and > 21.6 ppm was calculated 
in each IRIS stage through χ2 test (p<0.05). Survival curve of Kaplan-Meier was determined 
for patients belonging to the group with α-tochopherol ≤ and > 21.6 ppm. Statistical analysis 
was performed by using the software GraphPad Prism 4 for Macintosh, USA. 
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CHAPTER 12: RESULTS 
 
 
 
Ionized calcium, total calcium, calcium corrected for albumin (cCaAlb) and 
calcium corrected for total proteins (cCaPt) 
Ionized calcium, total calcium, calcium corrected for albumin (cCaAlb) and calcium corrected 
for total proteins (cCaPt) were determined in 301 CKD dogs and in 125 CH subjects. CKD 
patients showed a mean plasma creatinine of 3.73 ± 3.10 mg/dl. According to plasma 
creatinine, 22 patients were in IRIS stage 1, 83 in IRIS stage 2, 130 in IRIS stage 3 and 66 in 
IRIS stage 4. IRIS 1 dogs showed a mean GFR of 43.28 ± 10.92 ml/min/m2 and an average 
plasma creatinine of 1.04 ± 0.18 mg/dl. Mean plasma creatinine was 1.68 ± 0.20 mg/dl in 
IRIS 2, 3.21 ± 0.82 mg/dl in IRIS 3 and 8.41 ± 3.37 mg/dl in IRIS 4. Mean plasma urea was 
32.19 ± 10.97 mg/dl in IRIS 1, 66.20 ± 38.22 mg/dl in IRIS 2, 153.93 ± 85.28 mg/dl in IRIS 3 
and 284.24 ± 130.04 mg/dl in IRIS 4. Mean serum total calcium was 10.38 ± 0.95 mg/dl in 
IRIS 1, 9.86 ± 1.44 mg/dl in IRIS 2, 10.20 ± 2.04 mg/dl in IRIS 3 and 9.29 ± 2.06 mg/dl in 
IRIS 4. Mean serum phosphate was 4.22 ± 1.48 mg/dl in IRIS 1, 4.64 ± 1.77 mg/dl in IRIS 2, 
6.59 ± 3.67 mg/dl in IRIS 3 and 15.46 ± 9.13 mg/dl in IRIS 4. Mean serum ionized calcium 
was 1.28 ± 0.05 mmol/l in IRIS 1, 1.24 ± 0.09 mmol/l in IRIS 2, 1.19 ± 0.20 mmol/l in IRIS 3 
and 1.06 ± 0.28 mmol/l in IRIS 4. Mean serum albumin was 2.85 ± 0.59 g/dl in IRIS 1, 3.05 ± 
0.74 g/dl in IRIS 2, 2.82 ± 0.79 g/dl in IRIS 3 and 2.74 ± 0.61 g/dl in IRIS 4. Mean serum 
total proteins were 6.99 ± 0.94 g/dl in IRIS 1, 6.78 ± 1.15 mmol/l in IRIS 2, 6.41 ± 1.26 
mmol/l in IRIS 3 and 6.80 ± 1.95 mmol/l in IRIS 4. IRIS 1 patients showed a mean tCaAlb 
value of 11.02 ± 0.85 mg/dl, IRIS 2 patients a mean value of 10.25 ± 2.05 mg/dl, IRIS 3 
patients a mean value of 10.87 ± 1.67 mg/dl and IRIS 4 patients a mean value of 9.98 ± 2.20 
mg/dl. IRIS 1 patients showed a mean tCaPt value of 10.96 ± 1.06 mg/dl, IRIS 2 patients a 
mean value of 10.26 ± 1.44 mg/dl, IRIS 3 patients a mean value of 10.94 ± 1.67 mg/dl and 
IRIS 4 patients a mean value of 9.67 ± 2.29 mg/dl. 
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CH subjects showed an average plasma creatinine of 0.90 ± 0.21 mg/dl, a mean plasma urea 
of 29.31 ± 11.38 mg/dl, a mean serum total calcium of 9.64 ± 0.76 mg/dl, a mean serum 
phosphate of 3.55 ± 0.77 mg/dl, a mean serum ionized calcium of 1.25 ± 0.06 mmol/l, a mean 
serum albumin of 3.32 ± 0.47 g/dl, mean serum total proteins of 6.64 ± 0.62 g/dl, a mean 
tCaAlb of 9.82 ± 0.77 mg/dl and a mean tCaPt of 10.21 ± 0.73 mg/dl.  
 
 CH IRIS 1 IRIS 2 IRIS 3 IRIS 4 
 
CREAT 
(mg/dl) 
 
UREA    
(mg/dl) 
 
TCA       
(mg/dl) 
 
PHOS    
(mg/dl) 
 
ICA     
(mmol/l) 
 
ALB           
(g/dl) 
 
PT              
(g/dl) 
 
TCAALB 
(mg/dl) 
 
TCAPT 
(mg/dl) 
 
 
0.90±0.21 
 
 
29.31±11.38 
 
 
9.64±0.76 
 
 
3.55±0.77 
 
 
1.25±0.06 
 
 
3.32±0.47 
 
 
6.64±0.62 
 
 
9.82±0.77 
 
 
10.21±0.73 
 
1.04±0.18 
 
 
32.19±10.97 
 
 
10.38±0.95 
 
 
4.22±1.48 
 
 
1.28±0.05 
 
 
2.85±0.59 
 
 
6.99±0.94 
 
 
11.02±0.85 
 
 
10.96±1.06 
 
1.68±0.20 
 
 
66.20±38.22 
 
 
9.86±1.44 
 
 
4.64±1.77 
 
 
1.24±0.09 
 
 
3.05±0.74 
 
 
6.78±1.15 
 
 
10.25±2.05 
 
 
10.26±1.44 
 
3.21±0.82 
 
 
153.93±85.28 
 
 
10.20±2.04 
 
 
6.59±3.67 
 
 
1.19±0.20 
 
 
2.82±0.79 
 
 
6.41±1.26 
 
 
10.87±1.67 
 
 
10.94±1.67 
 
8.41±3.37 
 
 
284.24±130.04 
 
 
9.29±2.06 
 
 
15.46±9.13 
 
 
1.06±0.28 
 
 
2.74±0.61 
 
 
6.80±1.95 
 
 
9.98±2.20 
 
 
9.67±2.29 
Tabella 2: mean values  and standard deviatons of plasma creatinine (mg/dl) and urea (mg/dl), serum total 
calcium (mg/dl), phosphate (mg/dl), ionized calcium (mmol/l), albumin (g/dl) and total proteins (g/dl) in CH 
subjects and in CKD patients at different IRIS stages. TCA: total calcium, ICA: ionized calcium, TCAALB: total 
calcium corrected for albumin, TCAPT: total calcium corrected for total proteins. 
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One-way ANOVA (p<0.05) among mean values of ionized calcium of CH subjects and IRIS 
1, IRIS 2, IRIS 3 and IRIS 4 showed a significant difference (p<0.0001, R2=0.14). Tukey’s 
post test showed a significant difference between CH and IRIS 3 (p<0.05) and between CH 
and IRIS 4 (p<0.001), between IRIS 1 and IRIS 4 (p<0.001) and between IRIS 2 and IRIS 4 
(p<0.001) and IRIS 3 and IRIS 4 (p<0.001). No significant difference was found among CH, 
IRIS 1 and IRIS 2 and among IRIS 1, IRIS 2 and IRIS 3. 
	  
Figura 22: One-way ANOVA test (p<0.05) among mean values of ionized calcium in CH subjects and in IRIS 
1, IRIS 2, IRIS 3 and IRIS 4 patients. A significant difference was found (p<0.0001, R2=0.14). Tukey’s post test 
showed a significant difference among CH, IRIS 1 and IRIS 2 (a) and IRIS 3 (b) and IRIS 4 (c).  
ANOVA test    Ionized calcium 
One-way analysis of variance  
P value <0.0001 
P value summary *** 
Are means signif. different? (p<0.05) Yes 
Number of groups 5 
F 16,46 
R2 0,1497 	  
Tukey’s test Mean diff q P value 95% Cl of diff 
CH vs IRIS 1 -0,02405 0,9191 >0.05 -0.1264 to 
0.078 
CH vs IRIS 2 0,01992 1,196 >0.05 -0.04523 to 
0.08 
CH vs IRIS 3 0,06144 4,074 <0.05 0.002443 to 0.1 
CH IRIS 1 IRIS 2 IRIS 3 IRIS 4
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
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1.3 a
a a b
c
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CH vs IRIS 4 0,1949 10,72 <0.001 0.1237 to 0.266 
IRIS 1 vs IRIS 
2 
0,04397 1,597 >0.05 -0.06376 to 
0.15 
IRIS 1 vs IRIS 
3 
0,08549 3,212 >0.05 -0.01864 to 
0.18 
IRIS 1 vs IRIS 
4 
0,2189 7,684 <0.001 0.1075 to 0.330 
IRIS 2 vs IRIS 
3 
0,04152 2,392 >0.05 -0.02639 to 
0.10 
IRIS 2 vs IRIS 
4 
0,1750 8,698 <0.001 0.09627 to 0.25 
IRIS 3 vs IRIS 
4 
0,1334 7,085 <0.001 0.05977 to 0.20 
	  
 
Contingency analysis (p<0.05), through χ2 test, among the number of subjects with ionized 
calcium within, above and below the normal range in CH subjects and in IRIS 1, IRIS 2, IRIS 
3 and IRIS 4 patients showed a significant difference (p<0.0001). All 125 subjects of CH 
group and 22 patients of IRIS 1 showed ionized calcium within the normal range. In IRIS 2 
group, 70 patients showed ionized calcium within the normal range, while 2 patients were 
hypercalcemic and 11 hypocalcemic. In IRIS 3 group, 92 patients showed ionized calcium 
within the normal range, while 5 patients were hypercalcemic and 33 hypocalcemic. In IRIS 4 
group, 25 patients showed ionized calcium within the normal range, while 3 patients were 
hypercalcemic and 38 hypocalcemic. 
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Figura 23: contingency analysis (p<0.05) between the number of subject with ionized calcium within, below 
and above the reference range in CH and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant 
difference (p<0.001) 	  
χ2 TEST IONIZED CALCIUM 
Chi-square, df 112.7, 8 
P value P<0.0001 
P value summary *** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 
 
 
According to the gold standard test (ionized calcium) 22/22 patients of IRIS 1 resulted 
normocalcemic, while no patients were hyper- or hypocalcemic. 4 patients resulted 
hypercalcemic and 18 normocalcemic, when total calcium was used. 16 dogs resulted 
hypercalcemic and 6 normocalcemic, when cCaAlb was used. Finally, 11 patients resulted 
normocalcemic and 11 hypocalcemic, when cCaPt was used. According to the gold standard 
test 70/83 patients of IRIS 2 resulted normocalcemic, 2/83 hypercalcemic and 11/83 
hypocalcemic. 17 patients resulted hypercalcemic, 61 normocalcemic and 5 hypocalcemic, 
when total calcium was used. 28 dogs resulted hypercalcemic, 47 normocalcemic and 8 
hypocalcemic, when cCaAlb was used. Finally, 23 patients resulted hypercalcemic, 56 
normocalcemic and 4 hypocalcemic, when cCaPt was used. According to the gold standard 
test 92/130 patients of IRIS 3 resulted normocalcemic, 5/130 hypercalcemic and 33/130 
CH IRIS 1 IRIS 2 IRIS 3 IRIS 4
0
25
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hypocalcemic. 41 patients resulted hypercalcemic, 69 normocalcemic and 20 hypocalcemic, 
when total calcium was used. 28 dogs resulted hypercalcemic, 30 normocalcemic and 9 
hypocalcemic, when cCaAlb was used. Finally, 31 patients resulted hypercalcemic, 41 
normocalcemic and no one hypocalcemic, when cCaPt was used. According to the gold 
standard test 25/66 patients of IRIS 4 resulted normocalcemic, 3/66 hypercalcemic and 38/66 
hypocalcemic. 9 patients resulted hypercalcemic, 35 normocalcemic and 22 hypocalcemic, 
when total calcium was used. 8 dogs resulted hypercalcemic, 16 normocalcemic and 6 
hypocalcemic, when cCaAlb was used. Finally, 7 patients resulted hypercalcemic, 13 
normocalcemic and 7 hypocalcemic, when cCaPt was used. 
 In IRIS 1 patients, Pearson test (p<0.05) between ionized calcium and total calcium showed 
no significant correlation (p=0.09), Pearson test (p<0.05) between ionized calcium and 
cCaAlb showed no significant correlation (p=0.18), Pearson test (p<0.05) between ionized 
calcium and cCaPt showed no significant correlation (p=0.18). In IRIS 2 patients, Pearson test 
(p<0.05) between ionized calcium and total calcium showed a significant correlation 
(p=0.00), Pearson test (p<0.05) between ionized calcium and cCaAlb showed a significant 
correlation (p=0.00), Pearson test (p<0.05) between ionized calcium and cCaPt showed a 
significant correlation (p=0.00). In IRIS 3 patients, Pearson test (p<0.05) between ionized 
calcium and total calcium showed a significant correlation (p=0.00), Pearson test (p<0.05) 
between ionized calcium and cCaAlb showed a significant correlation (p=0.00), Pearson test 
(p<0.05) between ionized calcium and cCaPt showed a significant correlation (p=0.00). In 
IRIS 4 patients, Pearson test (p<0.05) between ionized calcium and total calcium showed a 
significant correlation (p=0.00), Pearson test (p<0.05) between ionized calcium and cCaAlb 
showed no significant correlation (p=0.22), Pearson test (p<0.05) between ionized calcium 
and cCaPt showed no significant correlation (p=0.31). 
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Figure 24: Pearson correlation analysis between ionized calcium (mmole/l) and total calcium (mg/dl) in IRIS 1 
dogs. No significant correlation was found. Pearson r: 0.36, P value (two-tailed): 0.09, R2: 0.13 
 
Figura 25: Pearson correlation analysis between ionized calcium (mmole/l) and cCaAlb (mg/dl) in IRIS 1 dogs. 
No significant correlation was found. Pearson r: 0.34, P value (two-tailed): 0.18, R2: 0.12 
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Figura 26: Pearson correlation analysis between ionized calcium (mmole/l) and cCaPt (mg/dl) in IRIS 1 dogs. 
No significant correlation was found. Pearson r: 0.34, P value (two-tailed): 0.18, R2: 0.12 
 
Figura 27: Pearson correlation analysis between ionized calcium (mmole/l) and total calcium (mg/dl) in IRIS 2 
dogs. A significant correlation was found. Pearson r: 0.42, P value (two-tailed): 0.00, R2: 0.18 
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Figura 28: Pearson correlation analysis between ionized calcium (mmole/l) and tCaAlb (mg/dl) in IRIS 2 dogs. 
A significant correlation was found. Pearson r: 0.52, P value (two-tailed): 0.00, R2: 0.27 
 
Figura 29: Pearson correlation analysis between ionized calcium (mmole/l) and tCaPt (mg/dl) in IRIS 2 dogs. A 
significant correlation was found. Pearson r: 0.51, P value (two-tailed): 0.00, R2: 0.26 
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Figura 30: Pearson correlation analysis between ionized calcium (mmole/l) and total calcium (mg/dl) in IRIS 3 
dogs. A significant correlation was found. Pearson r: 0.68, P value (two-tailed): 0.00, R2: 0.47 
 
Figura 31: Pearson correlation analysis between ionized calcium (mmole/l) and cCaAlb (mg/dl) in IRIS 3 dogs. 
A significant correlation was found. Pearson r: 0.49, P value (two-tailed): 0.00, R2: 0.24 
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Figura 32: Pearson correlation analysis between ionized calcium (mmole/l) and cCaPt (mg/dl) in IRIS 3 dogs. A 
significant correlation was found. Pearson r: 0.52, P value (two-tailed): 0.00, R2: 0.28 
 
Figura 33: Pearson correlation analysis between ionized calcium (mmole/l) and total calcium (mg/dl) in IRIS 4 
dogs. A significant correlation was found. Pearson r: 0.25, P value (two-tailed): 0.00, R2: 0.06 
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Figura 34: Pearson correlation analysis between ionized calcium (mmole/l) and cCaAlb (mg/dl) in IRIS 4 dogs. 
No significant correlation was found. Pearson r: 0.01, P value (two-tailed): 0.82, R2: 0.00 
 
Figura 35: Pearson correlation analysis between ionized calcium (mmole/l) and cCaAlb (mg/dl) in IRIS 4 dogs. 
No significant correlation was found. Pearson r: 0.14, P value (two-tailed): 0.09, R2: 0.02 
 
 
In CH patients, Pearson test (p<0.05) between ionized calcium and total calcium showed a 
significant correlation (p=0.00), Pearson test (p<0.05) between ionized calcium and cCaAlb 
showed no significant correlation (p=0.82), Pearson test (p<0.05) between ionized calcium 
and cCaPt showed no significant correlation (p=0.09). 
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Figura 36: Pearson correlation analysis between ionized calcium (mmole/l) and total calcium (mg/dl) in CH 
dogs. No significant correlation was found. Pearson r: 0.25, P value (two-tailed): 0.00, R2: 0.06 
 
Figura 37: Pearson correlation analysis between ionized calcium (mmole/l) and cCaAlb (mg/dl) in CH dogs. No 
significant correlation was found. Pearson r: 0.01, P value (two-tailed): 0.82, R2: 0.00 
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Figura 38: Pearson correlation analysis between ionized calcium (mmole/l) and cCaPt (mg/dl) in CH dogs. No 
significant correlation was found. Pearson r: 0.14, P value (two-tailed): 0.09, R2: 0.02 
 
 
 
 
 
 
Ca x P product (Ca x P) 
Calcium x phosphate product (Ca x P) was obtained by multiplying serum total calcium 
(mg/dl) per phosphate (mg/dl). Ca x P was calculated in 22 IRIS 1, 83 IRIS 2, 130 IRIS 3 and 
66 IRIS 4 CKD patients and in 20 CH subjects (control group). Ca x P in CH subjects ranged 
from a minimum of 24.00 to a maximum of 36.00, showing a mean value of 30.22 ± 0.85 SE. 
Ca x P in IRIS 1 subjects ranged from a minimum of 25.20 to a maximum of 70.20, showing 
a mean value of 39.06 ± 3.03 SE. Ca x P in IRIS 2 subjects ranged from a minimum of 17.08 
to a maximum of 47.97, showing a mean value of 34.48 ± 4.73 SE. Ca x P in IRIS 3 subjects 
ranged from a minimum of 23.80 to a maximum of 150.50, showing a mean value of 77.92 ± 
10.17 SE. Ca x P in IRIS 4 subjects ranged from a minimum of 80.64 to a maximum of 
275.20, showing a mean value of 195.80 ± 126.20 SE.  
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One-way ANOVA (p<0.05) among CH subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 
patients showed a significant difference in the mean value of Ca x P (p<0.0001 and R2=0.75). 
Tukey’s post-test showed that mean Ca x P of CH subjects was significantly different 
(p<0.001) from Ca x P of IRIS 3 and IRIS 4 patients. Mean Ca x P of IRIS 1 patients was 
significantly different from Ca x P of IRIS 3 (p<0.05) and IRIS 4 (p<0.001) patients. Mean 
Ca x P of IRIS 2 patients was significantly different from Ca x P of IRIS 3 (p<0.05) and IRIS 
4 (p<0.001) patients. Mean Ca x P of IRIS 3 patients was significantly different (p<0.001) 
from Ca x P of IRIS 4 patients. According to Tukey’s post-test, no significant difference was 
found between CH and IRIS 1 subjects, CH and IRIS 2 subjects, IRIS 1 and IRIS 2 patients. 
 
Figura 39: One-way ANOVA analysis of variance of mean Ca x P among CH subjects and IRIS 1, IRIS 2, IRIS 
3 and IRIS 4 patients. A significant difference in mean Ca x P among different groups was found (p<0.0001, 
R2=0.75). Tukey’s post-test showed a significant difference among CH, IRIS 1, IRIS 2 (a) and IRIS 3 (b) and 
IRIS 4 (c) 
 
ANOVA test   Ca x P  
One-way analysis of variance  
P value <0.0001 
P value summary *** 
Are means signif. different? (p<0.05) Yes 
Number of groups 5 
F 46.33 
R2 0.75 
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Tukey’s test Mean diff q P value 95% Cl of diff 
CH vs IRIS 1 -8.84 1.09 >0.05 -40.97 to 23.29 
CH vs IRIS 2 -4.26 0.42 >0.05 -43.87 to 35.35 
CH vs IRIS 3 -47.70 5.92 <0.001 -79.83 to -
15.57 
CH vs IRIS 4 -165.50 17.50 <0.001 -203.3 to -
127.8 
IRIS 1 vs IRIS 
2 
4.58 0.43 >0.05 -37.70 to 46.87 
IRIS 1 vs IRIS 
3 
-38.85 4.38 <0.05 -74.23 to -
3.478 
IRIS 1 vs IRIS 
4 
-156.70 15.42 <0.001 -197.2 to -
116.2 
IRIS 2 vs IRIS 
3 
-43.44 4.09 <0.05 -85.72 to -
1.156 
IRIS 2 vs IRIS 
4 
-161.30 13.78 <0.001 -208.0 to -
114.6 
IRIS 3 vs IRIS 
4 
-117.80 11.60 <0.001 -158.4 to -
77.32 
 
Pearson correlation analysis (p<0.05) between plasma creatinine and Ca x P showed no 
significant correlation in IRIS 1 (p=0.928, R2=0.00), IRIS 2 (p=0.969, R2=0.00), IRIS 3 
(p=0.541, R2=0.03) and IRIS 4 (p=0.06, R2=0.49) patients. 
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Figura 40: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and Ca x P in 13 CKD 
subjects belonging to IRIS 1. No significant correlation between plasma creatinine and Ca x P was found 
(p=0.928 and R2=0.00) 
PEARSON CORRELATION ANALYSIS IRIS 1 
Number of XY Pairs 13 
Pearson r -0,02784 
95% confidence interval -0.5702 to 0.5314 
P value (two-tailed) 0,9281 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,0007752 	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Figura 41: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and Ca x P in 7 CKD 
subjects belonging to IRIS 2. No significant correlation between plasma creatinine and Ca x P was found 
(p=0.969 and R2=0.00) 
PEARSON CORRELATION ANALYSIS IRIS 2 
Number of XY Pairs 7 
Pearson r -0,01801 
95% confidence interval -0.7609 to 0.7453 
P value (two-tailed) 0,9694 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,0003242 	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Figura 42: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and Ca x P in 13 CKD 
subjects belonging to IRIS 3. No significant correlation between plasma creatinine and Ca x P was found 
(p=0.541 and R2=0.03) 
PEARSON CORRELATION ANALYSIS IRIS 3 
Number of XY Pairs 13 
Pearson r -0,1865 
95% confidence interval -0.6689 to 0.4063 
P value (two-tailed) 0,5417 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,03480 	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Figura 43: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and Ca x P in 11 CKD 
subjects belonging to IRIS 4. No significant correlation between plasma creatinine and Ca x P was found 
(p=0.06 and R2=0.49) 
PEARSON CORRELATION ANALYSIS IRIS 4 
Number of XY Pairs 11 
Pearson r 0,7028 
95% confidence interval -0.003866 to 0.9413 
P value (two-tailed) 0,0519 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,4940 	  
Pearson correlation analysis (p<0.05) between plasma creatinine and Ca x P showed no 
significant correlation in CH (p=0.213, R2=0.08) subjects. 
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Figura 44: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and Ca x P in 20 CH 
subjects. No significant correlation between plasma creatinine and Ca x P was found (p=0.213 and R2=0.08) 
PEARSON CORRELATION ANALYSIS CH 
Number of XY Pairs 20 
Pearson r -0,2908 
95% confidence interval -0.6498 to 0.1743 
P value (two-tailed) 0,2136 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,08455 	  	  
Contingency analysis (p<0.05), through χ2 test, between the number of subjects with Ca x P 
above and below 70 in CH subjects and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients showed 
a significant difference (p<0.0001). All 20 subjects of CH group showed Ca x P below 70. In 
IRIS 1 group, 12 patients showed Ca x P below 70, while 1 patient showed Ca x P above 70. 
In IRIS 2 group, all 7 patients showed Ca x P below 70. In IRIS 3 group, 9 patients showed 
Ca x P below 70, while 4 patient showed Ca x P above 70. In IRIS 4 group, all 11 patients 
showed Ca x P above 70.  
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Figura 45: contingency analysis (p<0.05) between the number of subject with Ca x P below and above 70 in CH 
and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant difference (p<0.001) 
 
χ2 TEST CTNI 
Chi-square, df 44.31, 4 
P value P<0.0001 
P value summary *** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 	  
Contingency analysis (p<0.05), through χ2 test, between the number of survived subjects and 
dead subjects in the group of CKD patients with Ca x P above and below 70 showed a 
significant difference (p<0.0008). In the group of subjects with Ca x P below 70, 17 dogs 
survived, while 10 died after a period of time of 455 days. In the group of subjects with Ca x 
P above 70, only 2 dogs survived, while 15 died after a period of time of 455 days. 
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Figura 46: contingency analysis, through χ2 test, of survived and dead CKD patients in the group of dogs with 
Ca x P below and above 70. A significant difference (p<0.0008) between the groups of subjects was found. In 
group with Ca x P below 70, 17 dogs survived while 10 died. In group with Ca x P above 70, 2 dogs survived 
while 15 died. 
χ2 TEST CA X P 
Chi-square, df 11.15, 1 
P value 0,0008 
P value summary *** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 	  
Log-rank test (p<0.05) between the group of subjects with Ca x P below 70 and the group of 
subjects with Ca x P above 70 showed a significant difference (p<0.0002). In the group of 
patients with Ca x P below 70, 18 dogs survived and 9 died in a 455 day period, while in the 
group of patients with Ca x P above 70, only 2 dogs survived while 15 died. Kaplan-Meier 
survival curve showed a significantly higher percentage of survival (p<0.0002) of CKD 
patients with Ca x P below 70, compared to patients with Ca x P above 70.  
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Figura 47: Kaplan-Meier survival curve between the group of CKD patients with Ca x P below 70 and the 
group of patients with Ca x P above 70. Patients with Ca x P below 70 showed a significantly higher percentage 
of survival (p<0.0002) compared to the other group 
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Cardiac troponin I (cTnI) 
Cardiac troponin I (cTnI) was determined in 13 IRIS 1, 7 IRIS 2, 13 IRIS 3 and 11 IRIS 4 
CKD patients and in 20 CH subjects (control group). All CH subjects showed a serum cTnI 
below 0.20 ng/ml. In IRIS 1 patients, 4/13 subjects presented cTnI above the reference range, 
with a mean value of 0.98 ± 0.28 ng/ml, ranging from a minimum of 0.43 ng/ml and a 
maximum of 1.66 ng/ml. In IRIS 2 patients, 4/7 subjects presented cTnI above the reference 
range, with a mean value of 6.90 ± 6.36 ng/ml, ranging from a minimum of 0.24 ng/ml and a 
maximum of 26.00 ng/ml. In IRIS 3 patients, 11/13 subjects presented cTnI above the 
reference range, with a mean value of 6.19 ± 3.99 ng/ml, ranging from a minimum of 0.22 
ng/ml and a maximum of 41.50 ng/ml. In IRIS 4 patients, 10/11 subjects presented cTnI 
above the reference range, with a mean value of 11.80 ± 5.15 ng/ml, ranging from a minimum 
of 0.43 ng/ml and a maximum of 51.10 ng/ml.  
One-way ANOVA (p<0.05) among CH subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 
patients showed a significant difference in the mean value of cTnI (p<0.02 and R2=0.16). 
Tukey’s post-test showed that mean cTnI of CH subjects was significantly different (p<0.05) 
from cTnI of IRIS 4. According to Tukey’s post-test, no significant difference was found 
among CH and IRIS 1, IRIS 2 and IRIS 3 subjects, among IRIS 1 and IRIS 2, IRIS 3 and 
IRIS 4 subjects, among IRIS 2, IRIS 3 and IRIS 4, among IRIS 3 and IRIS 4 subjects.  
	  
Figura 48: One-way ANOVA analysis of variance of mean cTnI among CH subjects and IRIS 1, IRIS 2, IRIS 3 
and IRIS 4 patients. A significant difference in mean cTnI among different groups was found (p<0.02), 
R2=0.16). Tukey’s post-test showed a significant difference among CH (a) and IRIS 4 (b) patients 	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ANOVA test    cTnI 
One-way analysis of variance  
P value 0,0297 
P value summary * 
Are means signif. different? (p<0.05) Yes 
Number of groups 5 
F 2,892 
R2 0,1639 	  
Tukey’s test Mean diff q P value 95% Cl of diff 
CH vs IRIS 1 -0,2408 0,1049 P > 0.05 -9.373 to 8.892 
CH vs IRIS 2 -3,830 1,354 P > 0.05 -15.09 to 7.427 
CH vs IRIS 3 -5,069 2,209 P > 0.05 -14.20 to 4.063 
CH vs IRIS 4 -10,55 4,362 P < 0.05 -20.17 to -
0.923 
IRIS 1 vs IRIS 
2 
-3,589 1,189 P > 0.05 -15.61 to 8.428 
IRIS 1 vs IRIS 
3 
-4,828 1,911 P > 0.05 -14.88 to 5.226 
IRIS 1 vs IRIS 
4 
-10,31 3,906 P > 0.05 -20.81 to 
0.1961 
IRIS 2 vs IRIS 
3 
-1,239 0,4104 P > 0.05 -13.26 to 10.78 
IRIS 2 vs IRIS 
4 
-6,716 2,157 P > 0.05 -19.11 to 5.678 
IRIS 3 vs IRIS 
4 
-5,477 2,076 P > 0.05 -15.98 to 5.025 
	  
Pearson correlation analysis (p<0.05) between plasma creatinine and cTnI showed no 
significant correlation in CH subjects (p=0.99, R2=0.00) and in IRIS 1 (p=0.06, R2=0.23), 
IRIS 2 (p=0.54, R2=0.07), IRIS 3 (p=0.07, R2=0.26) and IRIS 4 (p=0.57, R2=0.03) patients. 
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Figura 49: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and cTnI (ng(ml) in 13 
IRIS 1 patients. No significant correlation between plasma creatinine and cTnI was found (p=0.06 and R2=0.23) 	  
PEARSON CORRELATION ANALYSIS IRIS 1 
Number of XY Pairs 13 
Pearson r -0,4804 
95% confidence interval -0.7808 to 0.0004068 
P value (two-tailed) 0,0509 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,2308 	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Figura 50: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and cTnI (ng/ml) in 7 IRIS 
2 patients. No significant correlation between plasma creatinine and cTnI was found (p=0.54 and R2=0.07) 
PEARSON CORRELATION ANALYSIS IRIS 2 
Number of XY Pairs 7 
Pearson r 0,2774 
95% confidence interval -0.6014 to 0.8525 
P value (two-tailed) 0,5469 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,07697 	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Figura 51: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and cTnI (ng/ml) in 13 IRIS 
3 patients. No significant correlation between plasma creatinine and cTnI was found (p=0.07 and R2=0.26) 
PEARSON CORRELATION ANALYSIS IRIS 3 
Number of XY Pairs 13 
Pearson r 0,5138 
95% confidence interval -0.05199 to 0.8299 
P value (two-tailed) 0,0725 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,2640 	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Figura 52: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and cTnI (ng/ml) in 11 IRIS 
4 patients. No significant correlation between plasma creatinine and cTnI was found (p=0.57 and R2=0.03) 
PEARSON CORRELATION ANALYSIS IRIS 4 
Number of XY Pairs 11 
Pearson r 0,1882 
95% confidence interval -0.4642 to 0.7082 
P value (two-tailed) 0,5794 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,03542 	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Figura 53: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and cTnI (ng/ml) in 20 CH 
subjects. No significant correlation between plasma creatinine and cTnI was found (p=0.99 and R2=0.00) 
PEARSON CORRELATION ANALYSIS CH 
Number of XY Pairs 20 
Pearson r 0.00001935 
95% confidence interval -0.4426 to 0.4426 
P value (two-tailed) 0.9999 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0.000000000375 	  
Contingency analysis (p<0.05), through χ2 test, between the number of subjects with cTnI 
above and below 0.20 (ng/ml) in CH subjects and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 
patients showed a significant difference (p=0.0001). All 20 subjects of CH group showed 
cTnI below 0.20 (ng/ml). In IRIS 1 group, 9 patients showed cTnI below 0.20 (ng/ml), while 
4 patients showed cTnI above 0.20 (ng/ml). In IRIS 2 group, 4 patients showed cTnI below 
0.20 (ng/ml), while 3 patients showed cTnI above 0.20 (ng/ml). In IRIS 3 group, 2 patients 
showed cTnI below 0.20 (ng/ml), while 10 patients showed cTnI above 0.20 (ng/ml). In IRIS 
4 group, only 1 patient showed cTnI below 0.20, while 10 patients showed cTnI above 0.20 
(ng/ml).  
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Figura 54: contingency analysis (p<0.05) between the number of subject with cTnI below and above 0.20 ng/ml 
in CH and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant difference (p=0.0001) 	  
χ2 TEST CTNI 
Chi-square, df 35.17, 4 
P value P<0.0001 
P value summary *** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 	  
Contingency analysis (p<0.05), through χ2 test, between the number of survived subjects and 
dead subjects in the group of CKD patients with cTnI above and below 0.20 ng/ml showed a 
significant difference (p=0.02). In the group of subjects with cTnI below 0.20 ng/ml, 10 dogs 
survived, while 5 died after a period of time of 455 days. In the group of subjects with cTnI 
above 0.20 ng/ml, only 7 dogs survived, while 21 died after a period of time of 455 days. 
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Figura 55: contingency analysis, through χ2 test, of survived and dead CKD patients in the group of dogs with 
cTnI below and above 0.20 ng/ml. A significant difference (p=0.007) between the groups of subjects was found. 
In group with cTnI below 0.20 ng/ml, 10 dogs survived while 5 died. In group with cTnI above 0.20 ng/ml, 7 
dogs survived while 21 died. 	  
χ2 TEST CTNI 
Chi-square, df 7.094, 1 
P value 0,0077 
P value summary ** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 	  
Log-rank test (p<0.05) between the group of subjects with cTnI below 0.20 ng/ml and the 
group of subjects with cTnI above 0.20 ng/ml showed a significant difference (p<0.0002). In 
the group of patients with cTnI below 0.20 ng/ml, 12 dogs survived and 5 died in a 455 day 
period, while in the group of patients with cTnI above 0.20 ng/ml, 6 dogs survived while 21 
died. Kaplan-Meier survival curve showed a significantly higher percentage of survival 
(p<0.0007) of CKD patients with cTnI below 0.20 ng/ml compared to patients with cTnI 
above 0.20 ng/ml.  
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Figura 56: Kaplan-Meier survival curve between the group of CKD patients with cTnI below 0.20 ng/ml and the 
group of patients with cTnI above 0.20 ng/ml. Patients with cTnI below 0.20 ng/ml showed a significantly 
higher percentage of survival (p<0.0007) compared to the other group 
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C-reactive protein (CRP) 
C-reactive protein (CRP) was determined in 13 IRIS 1, 7 IRIS 2, 13 IRIS 3 and 11 IRIS 4 
CKD patients and in 20 CH subjects (control group). All CH subjects showed a serum CRP 
below 9.7 mg/l, with a mean value of 1.81 ± 0.36 mg/l, within a minimum of 0.00 mg/l and a 
maximum of 5.60 mg/l. In IRIS 1 patients, 4/13 subjects presented CRP above the reference 
range, while 9/13 subjects CRP below the reference range, with a mean value of 7.48 ± 2.77 
mg/l, ranging from a minimum of 0.00 mg/l and a maximum of 22.40 mg/l. In IRIS 2 
patients, 4/7 subjects presented CRP above the reference range, while 3/7 subjects CRP below 
the reference range, with a mean value of 4.28 ± 1.27 mg/l, ranging from a minimum of 0.00 
mg/l and a maximum of 14.7 mg/l. In IRIS 3 patients, 6/13 subjects presented CRP above the 
reference range, while 7/13 subjects CRP below the reference range, with a mean value of 
17.92 ± 5.16 mg/l, ranging from a minimum of 0.80 mg/l and a maximum of 54.50 mg/l. In 
IRIS 4 patients, 10/11 subjects presented CRP above the reference range, while only 1 patient 
CRP below the reference range, with a mean value of 20.15 ± 3.32 mg/l, ranging from a 
minimum of 1.90 mg/l and a maximum of 35 mg/l.  
 
One-way ANOVA (p<0.05) among CH subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 
patients showed a significant difference in the mean value of CRP (p<0.0001 and R2=0.37). 
Tukey’s post-test showed that mean CRP of CH subjects was significantly different (p<0.001) 
from CRP of IRIS 3 and IRIS 4. Tukey’s post-test showed that mean CRP of IRIS 1 subjects 
was significantly different (p<0.05) from CRP of IRIS 4 and that mean CRP of IRIS 2 was 
significantly different from IRIS 3 (p<0.05) and IRIS 4 (p<0.01). According to Tukey’s post-
test, no significant difference was found among CH, IRIS 1 and IRIS 2, among IRIS 1, IRIS 2 
and IRIS 3, and between IRIS 3 and IRIS 4 subjects.  
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Figura 57: One-way ANOVA analysis of variance of mean CRP among CH subjects and IRIS 1, IRIS 2, IRIS 3 
and IRIS 4 patients. A significant difference in mean CRP among different groups was found (p<0.0001, 
R2=0.37). Tukey’s post-test showed a significant difference among CH (a), IRIS 3 and IRIS 4 (b), between IRIS 
1 (a) and IRIS 4 (b) and among IRIS 2 (a), IRIS 3 (b) and IRIS 4 (b) patients 
ANOVA test CRP 
One-way analysis of variance  
P value P<0.0001 
P value summary *** 
Are means signif. different? (p<0.05) Yes 
Number of groups 5 
F 9,423 
R2 0,3707 	  
Tukey’s test Mean diff q P value 95% Cl of diff 
CH vs IRIS 1 -5,668 2,153 P > 0.05 -16.13 to 4.791 
CH vs IRIS 2 -2,470 0,9653 P > 0.05 -12.63 to 7.695 
CH vs IRIS 3 -16,11 6,459 P < 0.001 -26.02 to -
6.201 
CH vs IRIS 4 -18,34 6,967 P < 0.001 -28.80 to -
7.882 
IRIS 1 vs IRIS 
2 
3,198 1,075 P > 0.05 -8.625 to 15.02 
IRIS 1 vs IRIS 
3 
-10,44 3,575 P > 0.05 -22.04 to 1.162 
IRIS 1 vs IRIS 
4 
-12,67 4,169 P < 0.05 -24.75 to -
0.595 
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IRIS 2 vs IRIS 
3 
-13,64 4,779 P < 0.05 -24.98 to -
2.301 
IRIS 2 vs IRIS 
4 
-15,87 5,333 P < 0.01 -27.69 to -
4.048 
IRIS 3 vs IRIS 
4 
-2,231 0,7640 P > 0.05 -13.84 to 9.372 
	  
Pearson correlation analysis (p<0.05) between plasma creatinine and CRP showed no 
significant correlation in CH subjects (p=0.34, R2=0.04) and in IRIS 1 (p=0.08, R2=0.28), 
IRIS 2 (p=0.67, R2=0.01), IRIS 3 (p=0.22, R2=0.13) and IRIS 4 (p=0.09, R2=0.28) patients. 
	  
Figura 58: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and CRP (mg/l) in 13 IRIS 
1 patients. No significant correlation between plasma creatinine and CRP was found (p=0.34 and R2=0.04) 
PEARSON CORRELATION ANALYSIS IRIS 1 
Number of XY Pairs 13 
Pearson r -0,5372 
95% confidence interval -0.8600 to 0.09270 
P value (two-tailed) 0,0884 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,2885 	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Figura 59: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and CRP (mg/l) in 7 IRIS 2 
patients. No significant correlation between plasma creatinine and CRP was found (p=0.67 and R2=0.01) 
PEARSON CORRELATION ANALYSIS IRIS 2 
Number of XY Pairs 7 
Pearson r 0,1340 
95% confidence interval -0.4766 to 0.6575 
P value (two-tailed) 0,6779 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,01797 	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Figura 60: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and CRP (mg/l) in 13 IRIS 
2 patients. No significant correlation between plasma creatinine and CRP was found (p=0.22 and R2=0.13) 
PEARSON CORRELATION ANALYSIS IRIS 3 
Number of XY Pairs 13 
Pearson r -0,3607 
95% confidence interval -0.7606 to 0.2376 
P value (two-tailed) 0,2260 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,1301 	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Figura 61: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and CRP (mg/l) in 11 IRIS 
4 patients. No significant correlation between plasma creatinine and CRP was found (p=0.09 and R2=0.28) 
PEARSON CORRELATION ANALYSIS IRIS 4 
Number of XY Pairs 11 
Pearson r -0,5321 
95% confidence interval -0.8581 to 0.09976 
P value (two-tailed) 0,0920 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,2831 	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Figura 62: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and CRP (mg/l) in 7 CH 
subjects. No significant correlation between plasma creatinine and CRP was found (p=0.34 and R2=0.04) 
PEARSON CORRELATION ANALYSIS CH 
Number of XY Pairs 20 
Pearson r -0,2233 
95% confidence interval -0.6060 to 0.2433 
P value (two-tailed) 0,3439 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,04988 	  
Contingency analysis (p<0.05), through χ2 test, between the number of subjects with CRP 
above and below 9.7 (mg/l) in CH subjects and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients 
showed a significant difference (p=0.0001). All 20 subjects of CH group showed CRP below 
9.7 (mg/l). In IRIS 1 group, 9 patients showed CRP below 9.7 (mg/l), while 4 patients showed 
CRP above 9.7 (mg/l). In IRIS 2 group, 6 patients showed CRP below 9.7 (mg/l), while 1 
patient showed CRP above 9.7 (mg/l). In IRIS 3 group, 7 patients showed CRP below 9.7 
(mg/l), while 6 patients showed CRP above 9.7 (mg/l). In IRIS 4 group, 2 patients showed 
CRP below 9.7 mg/l, while 10 patients showed CRP above 9.7 (ng/ml).  
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Figura 63: contingency analysis (p<0.05) between the number of subject with CRP below and above 9.7 mg/l in 
CH and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant difference (p=0.02) 
χ2 TEST CRP 
Chi-square, df 10.75, 4 
P value 0,0295 
P value summary * 
One- or two-sided NA 
Statistically significant? (alpha<0.05) Yes 	  
Contingency analysis (p<0.05), through χ2 test, between the number of survived subjects and 
dead subjects in the group of CKD patients with CRP above and below 9.7 mg/l showed a 
significant difference (p=0.0009). In the group of subjects with CRP below 9.7 mg/l, 18 dogs 
survived, while 6 died after a period of time of 455 days. In the group of subjects with CRP 
above 9.7 mg/l, only 5 dogs survived, while 15 died after a period of time of 455 days. 
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Figura 64: contingency analysis, through χ2 test, of survived and dead CKD patients in the group of dogs with 
CRP below and above 9.7 mg/l. A significant difference (p=0.0009) between the groups of subjects was found. 
In group with CRP below 9.7, 18 dogs survived while 6 died. In group with CRP above 9.7 mg/l, 5 dogs 
survived while 15 died. 
 
χ2 TEST CRP 
Chi-square, df 10.93, 1 
P value 0,0009 
P value summary *** 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) Yes 	  
Log-rank test (p<0.05) between the group of subjects with CRP below 9.7 mg/l and the group 
of subjects with CRP above 9.7 mg/l showed a significant difference (p<0.0009). In the group 
of patients with CRP below 9.7 mg/l, 18 dogs survived and 6 died in a 455 day period, while 
in the group of patients with CRP above 9.7 mg/l, 5 dogs survived while 15 died. Kaplan-
Meier survival curve showed a significantly higher percentage of survival (p<0.001) of CKD 
patients with CRP below 9.7 mg/l compared to patients with CRP above 9.7 mg/l. 
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Figura 65: Kaplan-Meier survival curve between the group of CKD patients with CRP below 9.7 mg/l and the 
group of patients with CRP above 9.7 mg/dl. Patients with CRP below 9.7 mg/l showed a significantly higher 
percentage of survival (p=0.001) compared to the other group 
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α-tochopherol 
α-tochopherol was determined in 13 IRIS 1, 7 IRIS 2, 13 IRIS 3 and 11 IRIS 4 CKD patients 
and in 20 CH subjects (control group). In CH group, 3/20 subjects showed serum α-
tochopherol below 21.6 ppm, while 17/20 subjects showed α-tochopherol above the reference 
range, with a mean value of 26.56 ± 1.11 ppm, within a minimum of 17.96 ppm and a 
maximum of 35.88 ppm. In IRIS 1 group, 1/13 subject presented α-tochopherol above the 
reference range, while 12/13 subjects α-tochopherol below the reference range, with a mean 
value of 10.71 ± 3.93 ppm, ranging from a minimum of 0.42 ppm and a maximum of 49.84 
ppm. In IRIS 2 group, 2/7 subjects presented α-tochopherol above the reference range, while 
5/7 subjects α-tochopherol below the reference range, with a mean value of 17.48 ± 7.07 
ppm, ranging from a minimum of 0.84 ppm and a maximum of 60.18 ppm. In IRIS 3 group, 
6/13 subjects presented α-tochopherol above the reference range, while 7/13 subjects α-
tochopherol below the reference range, with a mean value of 22.42 ± 3.88 ppm, ranging from 
a minimum of 2.49 ppm and a maximum of 48.49 ppm. In IRIS 4 group, all subjects 
presented α-tochopherol below the reference range, with a mean value of 6.84 ± 1.33 ppm, 
ranging from a minimum of 1.10 ppm and a maximum of 14.88 ppm.  
 
One-way ANOVA (p<0.05) among CH subjects and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 
patients showed a significant difference in the mean value of α-tochopherol (p<0.0002 and 
R2=0.32). Tukey’s post-test showed that mean α-tochopherol of CH subjects was 
significantly different from α-tochopherol of IRIS 1 (p<0.01) and IRIS 4 (p<0.001). Tukey’s 
post-test showed that mean α-tochopherol of IRIS 3 subjects was significantly different 
(p<0.05) from α-tochopherol of IRIS 4. According to Tukey’s post-test, no significant 
difference was found among IRIS 1, IRIS 2, IRIS 3 and IRIS 4 and among IRIS 2, IRIS 3 and 
IRIS 4.  
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Figura 66: One-way ANOVA analysis of variance of mean α-tochopherol among CH subjects and IRIS 1, IRIS 
2, IRIS 3 and IRIS 4 patients. A significant difference in mean α-tochopherol among different groups was found 
(p<0.0002, R2=0.32). Tukey’s post-test showed a significant difference among CH (a), IRIS 1 (b) and IRIS 4 (c) 
and between IRIS 3 (b) and IRIS 4 (c).  	  
ANOVA test α-tochopherol 
One-way analysis of variance  
P value P<0.0002 
P value summary *** 
Are means signif. different? (p<0.05) Yes 
Number of groups 5 
F 6,627 
R2 0,3207 	  
Tukey’s test Mean diff q P value 95% Cl of diff 
CH vs IRIS 1 15,85 5,399 P < 0.01 4.130 to 27.57 
CH vs IRIS 2 9,077 2,699 P > 0.05 -4.350 to 22.50 
CH vs IRIS 3 4,139 1,372 P > 0.05 -7.910 to 16.19 
CH vs IRIS 4 19,71 6,108 P < 0.001 6.827 to 32.59 
IRIS 1 vs IRIS 
2 
-6,774 1,846 P > 0.05 -21.42 to 7.877 
IRIS 1 vs IRIS 
3 
-11,71 3,490 P > 0.05 -25.11 to 1.687 
IRIS 1 vs IRIS 
4 
3,860 1,089 P > 0.05 -10.29 to 18.01 
IRIS 2 vs IRIS 
3 
-4,938 1,322 P > 0.05 -19.85 to 9.977 
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IRIS 2 vs IRIS 
4 
10,63 2,722 P > 0.05 -4.963 to 26.23 
IRIS 3 vs IRIS 
4 
15,57 4,309 P < 0.05 1.144 to 30.00 
	  
 
Pearson correlation analysis (p<0.05) between plasma creatinine and α-tochopherol showed a 
significant correlation in IRIS 2 patients (p=0.00, R2=0.85). No significant correlation 
between plasma creatinine and α-tochopherol was found in CH subjects (p=0.47, R2=0.02), in 
IRIS 1 (p=0.49, R2=0.04), in IRIS 3 (p=0.87, R2=0.00) and in IRIS 4 (p=0.94, R2=0.00) 
patients. 
	  
Figura 67: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and α-tochopherol (ppm) in 
13 IRIS 1 patients. No significant correlation between plasma creatinine and α-tochopherol was found (p=0.49 
and R2=0.04) 
PEARSON CORRELATION ANALYSIS α-tochopherol 
Number of XY Pairs 13 
Pearson r 0,2191 
95% confidence interval -0.4060 to 0.7045 
P value (two-tailed) 0,4939 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,04800 	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Figura 68: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and α-tochopherol (ppm) in 
7 IRIS 2 patients. A significant correlation between plasma creatinine and α-tochopherol was found (p=0.00 and 
R2=0.85) 
PEARSON CORRELATION ANALYSIS α-tochopherol 
Number of XY Pairs 7 
Pearson r 0,9245 
95% confidence interval 0.6306 to 0.9865 
P value (two-tailed) 0,0010 
P value summary ** 
Is the correlation significant? (alpha=0.05) Yes 
R2 0,8547 	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Figura 69: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and α-tochopherol (ppm) in 
13 IRIS 3 patients. No significant correlation between plasma creatinine and α-tochopherol was found (p=0.87 
and R2=0.00) 
PEARSON CORRELATION ANALYSIS α-tochopherol 
Number of XY Pairs 13 
Pearson r 0,05218 
95% confidence interval -0.5655 to 0.6324 
P value (two-tailed) 0,8789 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,002723 	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Figura 70: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and α-tochopherol (ppm) in 
11 IRIS 4 patients. No significant correlation between plasma creatinine and α-tochopherol was found (p=0.94 
and R2=0.00) 
PEARSON CORRELATION ANALYSIS α-tochopherol 
Number of XY Pairs 11 
Pearson r 0,02605 
95% confidence interval -0.6494 to 0.6785 
P value (two-tailed) 0,9470 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,0006784 	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Figura 71: Pearson correlation analysis (p<0.05) between plasma creatinine (mg/dl) and α-tochopherol (ppm) in 
20 CH subjects. No significant correlation between plasma creatinine and α-tochopherol was found (p=0.47 and 
R2=0.02) 
PEARSON CORRELATION ANALYSIS α-tochopherol 
Number of XY Pairs 20 
Pearson r -0,1712 
95% confidence interval -0.5706 to 0.2937 
P value (two-tailed) 0,4705 
P value summary ns 
Is the correlation significant? (alpha=0.05) No 
R2 0,02931 	  	  
Contingency analysis (p<0.05), through χ2 test, between the number of subjects with α-
tochopherol above and below 21.6 (ppm) in CH subjects and in IRIS 1, IRIS 2, IRIS 3 and 
IRIS 4 patients showed a significant difference (p=0.0001). In CH group 3 subjects showed 
α-tochopherol below 21.6 ppm, while 17 subjects α-tochopherol above 21.6 ppm. In IRIS 1 
group, 12 patients showed α-tochopherol below 21.6 ppm, while only 1 patient showed α-
tochopherol above 21.6 ppm. In IRIS 2 group, 5 patients showed α-tochopherol below 21.6 
ppm, while 2 patients showed α-tochopherol above 21.6 ppm. In IRIS 3 group, 7 patients 
showed α-tochopherol below 21.6 ppm, while 6 patients showed α-tochopherol above 21.6 
ppm. In IRIS 4 group, all 11 patients showed α-tochopherol below 21.6 ppm.  
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Figura 72: contingency analysis (p<0.05) between the number of subject with α-tochopherol below and above 
21.6 ppm in CH and in IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant difference (p=0.0001) 
χ2 TEST α-TOCHOPHEROL 
Chi-square, df 30.29, 4 
P value P<0.0001 
P value summary *** 
One- or two-sided NA 
Statistically significant? (alpha<0.05) Yes 	  
Contingency analysis (p<0.05), through χ2 test, between the number of survived subjects and 
dead subjects in the group of CKD patients with α-tochopherol above and below 21.6 ppm 
showed no significant difference. In the group of subjects with α-tochopherol below 21.6 
ppm, 14 dogs survived, while 18 died after a period of time of 455 days. In the group of 
subjects with α-tochopherol above 21.6 ppm, 5 dogs survived, while 6 died after a period of 
time of 455 days. 
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Figura 73: contingency analysis, through χ2 test, of survived and dead CKD patients in the group of dogs with 
α-tochopherol below and above 21.6 ppm. No significant difference between the groups of subjects was found. 
In group with α-tochopherol below 21.6 ppm, 14 dogs survived, while 18 died. In group with α-tochopherol 
above 21.6 ppm, 5 dogs survived, while 6 died. 
χ2 TEST α-TOCHOPHEROL 
Chi-square, df 0.009644, 1 
P value 0,9218 
P value summary ns 
One- or two-sided Two-sided 
Statistically significant? (alpha<0.05) No 	  
Log-rank test (p<0.05) between the group of subjects with α-tochopherol below 21.6 ppm and 
the group of subjects with α-tochopherol above 21.6 ppm showed no significant difference. In 
the group of patients with α-tochopherol below 21.6 ppm, 14 dogs survived and 18 died in a 
455 day period, while in the group of patients with α-tochopherol above 21.6 ppm, 5 dogs 
survived while 6 died. Kaplan-Meier survival curve showed no significant difference in the 
percentage of survival of CKD patients with α-tochopherol below 21.6 ppm compared to 
patients with α-tochopherol above 21.6 ppm. 
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Figura 74: Kaplan-Meier survival curve between the group of CKD patients with α-tochopherol below 21.6 
ppm and the group of patients with α-tochopherol above 21.6 ppm. No significant difference in percentage of 
survival between the two groups of patients was found.  	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CHAPTER 13: DISCUSSION 	  	  
In canine and feline population as well as in humans, CKD plays an important 
epidemiological role, showing an even increasing prevalence. Although different definitions 
are present, CKD refers to a chronic and progressive clinical syndrome, which inexorably 
moves to ESRD and uraemia. Since the seventies, veterinary haemodialysis and renal 
transplantation became a reality in the USA and, at present, these techniques are becoming 
available all over the world. Anyway, the high costs of supplies and materials and the 
reticence of some owners and veterinarians towards these very high tech procedures, have 
been limiting their use to a few number of cases. It is also important to notice that, even in 
human medicine, most recent guidelines suggest to manage CKD patients with diet and 
medical therapy as longer as possible before using haemodialysis or continuous renal 
replacement therapy (CRRT). As a consequence, the importance of early diagnosis has grown 
and new methods have been developed in order to identify CKD as soon as possible. The 
recent development of a renal standardization group (International Renal Interst Society – 
IRIS) led to the formulation of diagnostic guidelines, which should help private practitioners 
in diagnosing and treating CKD. Both feline and canine CKD patients are classified, 
according to plasma creatinine, in four stages of severity. Although IRIS stage 2, 3 and 4 are 
characterized by high plasma values of creatinine, IRIS stage 1 encloses asymptomatic 
patients with plasma creatinine below 1.4 mg/dl. At present, most private practitioners base 
diagnosis of CKD on plasma creatinine and urea. These two parameters have the advantage to 
be extremely cheap and easy to determine, but they have demonstrated late and inaccurate in 
diagnosing CKD. Plasma creatinine can be use to diagnose IRIS 2, 3 and 4 patients but it is 
completely ineffective for earlier stages. Furthermore, as patients with plasma creatinine 
above the reference range have already lost more than 70% of total renal function, IRIS 2, 3 
and 4 represent advanced stages of the disease. So the aim of early diagnosis should be the 
identification of IRIS 1. GFR remains the only test capable to identify IRIS 1 patients. In fact, 
this group of patients is often asymptomatic and characterized by plasma creatinine within the 
normal range. As UP/UC and systolic blood pressure are risk factors, which cannot diagnose 
CKD by themselves, IRIS 1 patients can be detected only through GFR. The GFR 
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determination method in use at the Veterinary Teaching Hospital “Mario Modenato” uses a 
five-sample system (5’, 15’, 60’, 90’ and 180’), based on the plasma clearance of iohexol, 
which was developed in conjunction with the Section of Pharmacology and Toxicology of our 
Department. This simplified method was obtained from a 24 hour reference scheme and it 
was validated both in healthy and in CKD canine patients. The HPLC detection system 
showed very accurate and simple to be performed. The low number of blood samples and 
time required, compared to other plasma clearance methods, significantly increase the 
compliance of both owners and patients. The introduction of GFR test in nephrological 
consultations to assess the effective functional renal mass of patients, led to the identification 
of a growing number of IRIS 1 subjects, which, otherwise would have been undiagnosed. 
Together with early diagnosis of CKD, a deep interest towards prognostic factors developed. 
In human medicine several prognostic factors of CKD have been recognized and studied, in 
order to monitor and predict the progression of the disease. Most factors, in fact, show both a 
prognostic and progressive nature. Modifications of these factors were associated with a faster 
progression of CKD and entry into dialysis. Although the role of these markers in the 
progression of CKD has been widely demonstrated in human medicine, the mechanisms by 
which they act are still being studied. Particularly, CKD progression has been associated with 
alterations in calcium-phosphate metabolism, cardiovascular injury, inflammation and 
oxidative distress. The present study took into consideration one marker for each of these 
pathological conditions, assessing its concentration in different IRIS stages and in clinically 
healthy subjects to evaluate its potential prognostic role. 	  	  
Ionized calcium, total calcium, calcium corrected for albumin (cCaAlb), 
calcium corrected for total proteins (cCaPt) 
As universally known, homeostasis of calcium is primarly regulated by the activity of PTH, 
calcitonin and vitamin D, so parathyroid glands, bones, intestine and kidneys strictly interact 
to maintain physiologic concentration of calcium. As a consequence, any pathological 
condition involving one or more of these organs can deeply affect calcium homeostasis1. The 
importance of mineral metabolism and calcium-phosphate status in human CKD patients was 
documented by an intense scientific, epidemiologic and clinical research, which recently led 
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the Kidney Disease Improving Global Outcomes (KDIGO) group to the formulation of a new 
classification, named Chronic Kidney Disease – Bone and Mineral Disorder (CKD-BMD)2.  
In veterinary medicine, available evidence in spontaneous CKD cats and in experimental 
CKD dogs reported that abnormalities in calcium and phosphate metabolism show a negative 
effect on residual kidney function and survival. In cats, for each 1 mg/dl increase in serum 
phosphate there is an 11.8% increase in the risk of mortality3,4,5. Ionized calcium, total 
calcium, calcium corrected for albumin (cCaAlb) and calcium corrected for total proteins 
(cCaPt) were assessed in all 301 CKD canine patients presented to the Veterinary Teaching 
Hospital “Mario Modenato” in a three year period for nephrologic consultation and in 125 
clinically healthy (CH) subjects. Ionized calcium was considered the gold standard and two 
correction equations, one based on serum albumin and one based on total proteins, were taken 
into consideration. These equations derived from human medicine and were introduced in 
veterinary medicine because of the difficulties many veterinarians have in determining 
ionized calcium. The aim of the present study was to assess calcemic status in IRIS 1, IRIS 2, 
IRIS 3 and IRIS 4 patients and in CH subjects and to test the accuracy of total calcium, 
cCaAlb and cCaPt in predicting ionized calcium. Present results (ANOVA; p<0.05) showed 
that mean concentration of ionized calcium in CH and in the four stages of CKD was 
significantly different (p<0.0001, R2=0.14). In particular, IRIS 3 and IRIS 4 patients showed a 
mean ionized calcium concentration significantly lower, compared to CH subjects and IRIS 1 
and IRIS 2. IRIS 4 patients showed a mean ionized calcium concentration below the reference 
range (1.06 ± 0.03 mmole/l). Furthermore, contingency analysis reported that the number of 
hypocalcemic patients significantly (p<0.0001) increased with the severity of the disease. 
These data were in partial agreement with some previous works6,7 on CKD dogs, which 
reported ionized calcium within the reference range or slightly decreased. Anyway, these 
works considered a lower number of patients and did not identify IRIS 1 subjects by GFR but 
by persistent renal proteinuria. Despite what previously found, one-way ANOVA analysis 
showed that, although mean ionized calcium concentration between CH and CKD was 
significantly different, significance increased dramatically in IRIS 3 and 4. This finding may 
be explained by both the onset of metabolic acidosis and secondary hyperparathyroidism 
(HPTH). Metabolic acidosis is a very common condition in CKD due to the lower renal 
excretion of acid radicals, phosphate and sulphate compounds, as well as reduced renal 
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absorption of bicarbonate and low ammoniagenesis. Calcium, in fact, binds to the albumin 
carboxyl group, that represents the same site at which H+ usually binds. As, during metabolic 
acidosis, H+ radicals do not dissociate easily from carboxyl groups, calcium has less 
opportunities to bind albumin, resulting in an increase in serum concentration8. Higher 
concentrations of ionized calcium were reported in induced acidosis dogs and calves9,10. 
Moreover, metabolic acidosis itself can cause calcium disturbances characterized by urinary 
calcium loss, increase bone calcium absorption and deficient synthesis of vitamin D8. On the 
other hand, the significant increase in the number of hypocalcemic patients in IRIS 3 and 4, 
may be determined by HPTH. High serum phosphate levels inhibit the activity of renal 1-α-
hydroxylase, causing a reduction in vitamin D and ionized calcium concentration. This 
condition stimulates PTH release, which diminishes tubular phosphate absorption and 
increases phosphaturia. Unfortunately, the restore of normal serum levels of vitamin D and 
ionized calcium is only a transitory phenomena7. So, after a first rebalance of calcemia, CKD 
patients are doomed to develop hypocalcemia. The increasing prevalence of hypocalcemia 
with the progression of CKD underlined the importance of measuring ionized calcium, 
especially in IRIS 3 and IRIS 4 patients. The early detection of a hypocalcemic status can 
help practitioners in treating patients and avoiding clinical symptoms. Anyway, the 
assessment of ionized calcium can be sometimes difficult in a routine clinical setting, where 
calcemic status is often determined by measuring total or corrected calcium. In our study 
Pearson correlation analysis between ionized calcium and total calcium, ionized calcium and 
cCaAlb, ionized calcium and cCaPt, showed no significant correlation in IRIS 1 patients. The 
lack of correlation between the gold standard and each of the methods used for predicting 
ionized calcium, underlined the low accuracy of these parameters in a very early stage of the 
disease. As CKD patients can remain in an IRIS 1 stage for a long period of time (from 
months to years), the use of ionized calcium in this group of subjects can show significantly 
important for an accurate assessment of calcemic status. Being able to discover calcium 
disorders in an early phase of CKD can be of fundamental importance, in order to establish 
therapeutic and dietary modifications, which prevent the onset of HPTH and the progression 
of the disease. In agreement with previously reports, both total and corrected (cCaAlb, cCaPt) 
calcium showed inaccurate in predicting ionized calcium. This observation may find 
explanation in the fact that both analyzed equations are based only on serum albumin and 
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total proteins, avoiding to consider other compounds like citrate, phosphate and solphate. 
Calcium may, in fact, form complexes with bicarbonate, lactate, citrate, phosphate and 
oxalate, determining significant modifications in complexed fraction, which cannot be 
discovered by correcting total calcium for albumin or total proteins. Furthermore, alterations 
of normal distribution of calcium into the three serum fractions may occur without causing 
modifications of total calcium. As a consequence the only assessment of serum total calcium 
may result perfectly normal, despite the presence of calcium homeostasis disorders. A 
significant correlation was found both in IRIS 2 and IRIS 3 patients. In IRIS 2, cCaAlb 
(Pearson r=0.52) and cCaPt (Pearson r=0.51) showed a better correlation with ionized 
calcium, compared to total calcium (Pearson r=0.42). On the contrary, in IRIS 3 total calcium 
showed the best correlation (Pearson r=0.68) with ionized calcium, compared to cCaAlb 
(Pearson r=0.49) and cCaPt (Pearson r=0.52). The poorer correlation ability of cCaAlb and 
cCaPt in IRIS 3, compared to IRIS 2, may be due to a higher prevalence of clinical symptoms 
at this stage of the disease. IRIS 3 patients are often very symptomatic and may present 
albumin and serum protein disorders, which can significantly affect the accuracy of cCaAlb 
and cCaPt. Vomiting, malnutrition, diarrhea and proteinuria can be responsible for intense 
protein loss and hypoalbuminaemia. The worsening of clinical status, together with the 
inexorably progression of the disease may be responsible for the lack of correlation between 
ionized calcium and cCaAlb and ionized calcium and CCaPt in IRIS 4. IRIS 4 patients, in 
fact, showed a significant correlation only between ionized and total calcium, while no 
correlation was present between ionized and cCaAlb and ionized and cCaPt. At this stage of 
CKD, the measurement of ionized calcium becomes essential for an accurate assessment of 
calcemic status. The wide fluctuations in serum albumin and total proteins, due to the 
worsening of symptoms, and the high prevalence of hypocalcemia, compared to other stages, 
should be a valid reason to avoid the use of total or corrected calcium.  	  	  
Ca x P product (Ca x P) 
In human medicine, increasing evidences suggested a strict relationship between 
cardiovascular mortality risk and hyperphosphatemia in CKD. Cardiovascular disease 
represents, in fact, the leading cause of death in the majority of CKD subjects, not only before 
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and on dialysis program, but also after successful renal transplantation. An independent 
association between serum phosphate and mortality, as well as between serum phosphate and 
progression of CKD, has been widely demonstrated by numerous studies. For this association 
different mechanisms were supposed. First of all, elevated phosphate levels may directly 
induce vascular injury by stimulating vascular calcification, enhancing mineral deposition in 
the vascular wall and promoting expression of bone-forming transcription factors and 
proteins11. Hyperphosphatemia seems to be associated with increasing myocardial 
hypertrophy, cardiac fibrosis and arterial wall thickening, while high PTH values causes 
intracellular calcium overload and impaired myocardial energy production. Secondly, high 
serum phosphate may increase the production of reactive oxygen species, as previously 
documented in cows12. Another consequence of hyperphosphatemia is represented by 
secondary renal HPTH. The onset of HPTH predisposes CKD patients to renal osteodistrophy 
and to the toxic effects of PTH, as uremic toxin. The increased mortality risk in CKD 
subjects, showing high levels of serum phosphate, may be determined by an elevated Ca x P 
product (Ca x P). In humans, Ca x P levels greater than 70 mg/dl were associated with a 
significantly higher relative risk of death. This data well correlated with previously reports, in 
which Ca x P above 60 and 70 mg/dl was strictly related to high risk of metastatic 
calcifications. Myocardial and pulmonary calcium content in CKD patients with Ca x P above 
70 was markedly higher, as well as the prevalence of valvular calcifications. Arterial 
calcifications, in fact, were linked to elevated Ca x P levels and a coronary artery calcium 
score 2.5 to 5 times higher was found in dialysis patients, compared to non-dialysis ones13. 
Elevated serum phosphate and Ca x P values were both demonstrated significant predictors of 
cardiovascular mortality in CKD human patients. For this reason, actual guidelines 
recommend to maintain phosphate and Ca x P between 3.0 and 5.0 mg/dl and below 55 mg/dl 
respectively14. The aim of the present study was to assess Ca x P in CH and in IRIS 1, IRIS 2, 
IRIS 3 and IRIS 4 patients and to evaluate its relationship towards mortality. In CH group all 
125 patients showed Ca x P values above 70 mg/dl, with a mean value (30.22 ± 0.85 SE) 
significantly (p<0.0001) different from CKD. The mean Ca x P level showed a progressive 
increase of its serum concentration, according to the progression of the disease, even if, 
average Ca x P above the normal value, was found only in late stages. Although no significant 
difference was found, IRIS 1 and IRIS 2, in fact, showed a mean serum Ca x P of 39.06 ± 
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3.03 SE and 34.48 ± 4.73 SE respectively. It is to be noticed that no-one of IRIS 1 patients 
was under low-phosphate diet or therapy, while in IRIS 2 some dogs have already started 
renal diet. This data may be responsible for the higher mean value of Ca x P of IRIS 1 
compared to IRIS 2. Most IRIS 2 patients were, in fact, referred from private practitioners, 
who had already started a renal diet. In IRIS 3 and IRIS 4 patients, instead, mean Ca x P was 
significantly higher than the cut off value of 70 mg/dl. Patients of IRIS 3 and IRIS 4 stage 
showed an average Ca x P of 77.92 ± 10.17 SE and 195.80 ± 126.20 SE respectively. 
ANOVA and Tukey’s post-test identified a significant difference not only among IRIS 3, 
IRIS 4, other stages and CH, but also between IRIS 3 and IRIS 4. Mean Ca x P level showed 
the highest value in IRIS 4 group, where it reached a value more than twice the risk level. 
According to present data and to the fact that the number of hypocalcemic patients increases 
with the progression of the disease, phosphate accumulation and Ca x P alterations seemed to 
develop more in late rather than early stage of CKD. Although a significant increment in Ca x 
P was found according to CKD progression, Pearson test showed no significant correlation 
towards plasma creatinine in anyone of IRIS stages and in CH group. As previously reported 
for hypocalcemia, also Ca x P increase seemed to be independent from plasma creatinine 
modifications and increments in Ca x P concentration did not correspond to the same 
increment in plasma creatinine. A significant difference in the number of patients with Ca x P 
below and above 70 mg/dl was found according to the progression of CKD. The number of 
subjects with Ca x P above 70 mg/dl increased significantly (p<0.0001) with IRIS 
progression. In particular, all patients of IRIS 4 presented Ca x P above reference value. The 
same significant difference (p<0.0008) between the number of survived and dead patients in 
Ca x P group above and below 70 mg/dl was found. The number of dead patients over a 455 
day period was, in fact, significantly higher in Ca x P over 70 group. This finding was in 
complete agreement with previous human reports, which underlined the elevated prognostic 
value of Ca x P. High serum phosphate and Ca x P have been demonstrated to be correlated to 
increased mortality risk and, in renal transplant patients, they represented additional and 
independent risk factors. In the present study, an even more important confirmation of the key 
role of Ca x P in predicting progression and mortality of CKD, derived from log rank analysis 
between the group of subjects with Ca x P below and above 70 mg/dl. Kaplan-Meier curves 
of the two groups of patients were, in fact, significantly different (p<0.0002) from each other. 
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CKD patients with Ca x P above 70 mg/dl showed a percentage of survival significantly 
lower, compared to the other group. This finding may suggest that in dogs, as well as in 
humans, the prognostic relevance of Ca x P in predicting mortality. According to present data, 
alterations of phosphate metabolism and subsequent increase in Ca x P seemed to be more 
characteristic of the late stages of renal disease. Anyway, the significantly lower percentage 
of survival of patients with Ca x P above 70 mg/dl resulted independent from the IRIS stage, 
which the patient belonged to. Early detection of phosphate alterations and Ca x P 
modifications should be taken into consideration, in order to identify patients at higher risk of 
progression of CKD. Early recognition of these high risk patients may help veterinarians in 
correcting calcium-phosphate alterations and in reducing mortality rate. 	  	  
Cardiac troponin I (cTnI) 
A significant relationship between CKD and an increased risk of cardiovascular disease has 
been widely demonstrated in human medicine. The risk of cardiovascular mortality is 
particularly high in the late stages of CKD and in end stage renal disease (ESRD). These 
patients, in fact, showed an increased prevalence of vascular and valvular calcifications, 
arterial stiffness and cardiac fibrosis, which may predispose patients to inadequate coronary 
reserve and cardiac ischemia. Cardiovascular complications represent a very frequent 
condition in CKD, which show different pathogenetic mechanisms1,2. Cardiac diseases 
account for about 45% of all deaths in ESRD patients and, in haemodialysis subjects, about 
20% of cardiac deaths are attributed to acute myocardial infarction3. Identification of such 
mechanisms and risk factors may be of dramatic importance in assessing therapy and 
preserving both cardiac and renal function. In human medicine, different cardiac biomarkers 
were tested and, among them, cardiac troponins T and I had a very important position. Both 
cardiac troponins are frequently elevated in the absence of acute coronary syndrome in 
patients with various degrees of kidney disease. cTnT showed a more frequent increase in 
asymptomatic ESRD patients, compared to cTnI, with a reported prevalence between 30% 
and 80%. In the same class of patients, cTnI reported a percentage of increase between 5% 
and 18%. The prevalence of increase of cTnC and cTnI showed higher values with the 
progression of CKD. Anyway, despite of a lower prevalence of increase in ESRD, cTnI 
	   140	  
showed a very good prognostic marker of cardiovascular complications, due to lower 
incidence of elevation and expression in non-cardiac tissues1. At present, cTnI is considered 
the gold standard measurement to detect myocardial injury and to predict mortality and future 
cardiac events. cTnI serum concentration starts to rise within 2 hours after myocardial 
damage, reaching a peak at 12 – 24 hours. Furthermore, in acute coronary occlusion canine 
models cTnI concentration correlated with infarct size, suggesting a potential role as marker 
of the extent of myocardial damage. Shorter survival times were also found in dogs with 
acquired cardiac disease and cTnI above normal values4. Recently reports in veterinary 
medicine, demonstrated that CKD dogs and cats often present cTnI above physiologic levels. 
The percentage of increase was a little more elevated in dogs (78%) than in cats (72%). 
Patients with myocardial injury showed high values of cTnI, even if obvious ante-mortem 
cardiac involvement was not present. cTnI appeared, in fact, a highly specific marker of 
myocardial damage but not a specific clinical marker of primary cardiac disease or heart 
failure. Moreover mild subclinical heart disease did not result in marked elevation of cTnI and 
hypertension did not correlate with cTnI increase. Although a relationship between high 
levels of cTnI and myocardial injury was demonstrated, the mechanisms of cTnI elevation in 
CKD patients are still unknown. In human patients the most accredited hypothesis of cTnI 
increase in CKD subjects referred to independent and un-associated co-morbidity of coronary 
artery disease. However, because coronary artery disease is not a feature of veterinary 
patients, this hypothesis could not explain the mechanism in companion animals5. In 
veterinary CKD patients, as well as in humans, cTnI elevation appeared more frequent in the 
late stages rather than in early ones. As no data regarding IRIS classification and the survival 
of patients are available, the present study analyzed cTnI concentration in patients belonging 
to all IRIS classes, the correlation towards plasma creatinine and the survival percentage in 
subjects with cTnI above and below the reference value. Considering a physiologic value of 
cTnI of 0.2 ng/ml, the present results showed that all CH subjects had mean cTnI level below 
0.2 ng/ml. On the contrary, CKD patients, belonging to different classes of severity, reported 
a mean value of cTnI above 0.2 ng/ml. Mean cTnI tended to increase according to the 
progression of the disease, showing a value of 0.98 ± 0.28 ng/ml in IRIS 1, 6.90 ± 6.36 ng/ml 
in IRIS 2, 6.19 ± 3.99 ng/ml in IRIS 3 and 11.80 ± 5.15 ng/ml in IRIS 4. One-way ANOVA 
(p<0.05) of these data showed a significant difference (p<0.02) among mean cTnI values of 
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CH, IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients. Although a significant difference was present, 
Tukey’s post-test reported no significant difference among CH, IRIS 1, IRIS 2 and IRIS 3 and 
among IRIS 1, IRIS 2, IRIS 3 and IRIS 4. The only significant difference was between CH 
and IRIS 4 (p<0.05). These findings were in agreement with previous studies in human and 
veterinary medicine, in which the degree of cTnI augmented with the progression of the 
disease. It is to be noticed that, despite some patients presented cTnI below reference, mean 
cTnI concentration was above 0.2 ng/ml even in early, asymptomatic IRIS 1 subjects. 
Contingency analysis (p<0.05), as well, showed a significant (p<0.0001) increase in the 
number of subjects with cTnI above 0.2 ng/ml according to CKD progression. Although the 
significant tendency of cTnI towards increasing mean values with the progression of CKD, 
Pearson test reported no significant correlation between cTnI and plasma creatinine in no one 
of IRIS stages. No relationship between cTnI and plasma creatinine was found. As reported 
for Ca x P, the link between cTnI elevation and CKD progression seemed to be independent 
from plasma creatinine. According to mortality analysis, contingency analysis (p<0.05) 
regarding the number of survived and dead patients between the group of subjects with cTnI 
below and above 0.2 ng/ml, showed a significant difference (p<0.02). The number of dead 
patients was, in fact, significantly higher in the group of subjects with cTnI above 0.2 ng/ml. 
Similarly, log-rank test (p<0.05) showed a significant difference (p<0.0002) between the 
group of patients with cTnI above and below 0.2 ng/ml. CKD subjects with cTnI above 0.2 
ng/ml reported a Kaplan-Meier curve of the percentage of survival significantly lower 
(p<0.0007) than the other group. In agreement with what previously reported in human 
medicine, serum cTnI elevation seemed to be significantly correlated with a higher mortality 
risk and reduction in percentage of survival. cTnI resulted completely independent from the 
plasma creatinine value of CKD patients. Furthermore the prognostic role of cTnI did not 
depend on the severity of the disease (according to IRIS classification) and cTnI appeared an 
independent risk factor of mortality. Anyway, it is essential to say that the prevalence of cTnI 
elevation is significantly higher with the progression of IRIS class. As cTnI has been widely 
demonstrated as a marker of myocardial injury in both animals and humans, the significantly 
higher prevalence of subjects presenting cTnI above 0.2 ng/ml and mean cTnI above the cut 
off value with the progression of CKD, may suggest a role of cardiovascular damage in the 
progression of renal disease. Furthermore, the evidence of patients with cTnI above 0.2 ng/ml 
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even in IRIS 1 patients and their lower survival percentage over a 455 day period, seemed to 
indicate that cardiovascular alterations may start even at the very beginning of CKD. 
Although in human patients no relationship between cTnI increase and obvious ante-mortem 
cardiac involvement was found, on the basis of present the results, it may be advisable to 
submit CKD patients with cTnI above 0.2 ng/ml to clinical and instrumental cardiological 
evaluation. 	  	  	  
C-reactive protein (CRP) 
In human medicine, C-reactive protein (CRP) was associated with the prevalence, progression 
and negative outcome of CKD1. Inflammation and positive phase proteins strongly predicted 
outcome in dialysis patients2. Increased serum levels of several acute phase proteins, such as 
CRP, were documented among different patients affected by CKD. However, a direct 
relationship between inflammatory biomarkers and reduction in GFR was not yet 
demonstrated2. A strong correlation between chronic inflammation and CKD was widely 
reported in humans and several studies underlined the role of inflammation in promoting 
morbidity and mortality in such class of patients. In a CKD condition many causes can be 
responsible for the onset of acute and chronic inflammation. Previous reports identified 
multiple factors, such as decreasing renal function, uraemia, increased susceptibility to 
infections and alterations of immune system. Furthermore, additional factors like repeated 
exposure to dialysis system and subsequent leukocyte activation and production of 
inflammatory cytokines, were detected in patients undergoing haemodialysis3. This class of 
patients showed a significantly higher risk of inflammation compared to other CKD subjects 
and many sources of inflammation were identified. The kind of vascular access type was 
associated with a different mortality risk. Arterio-venous fistula showed the highest infection-
induced mortality risk, followed by artero-venous grafts, permanent catheters and temporary 
catheters. Vascular access inflammation was related both to the initial risk of septicemia and 
unrecognized infections and biofilm deposited on plastic catheters4,5. Finally, haemodialysis 
patients were found to be at risk of inflammation by possible interactions of circulating 
monocytes with dialysis membrane or with bacterial products, lipopolysaccharide and 
bacterial DNA that may be present in dialysate6. In patients undergoing chronic 
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haemodialysis treatment, the repetitive induction of acute phase response seemed to induce a 
chronic micro-inflammatory state, leading to a variety of long-term complications, including 
malnutrition and cardiovascular diseases3. Inflammation was recognized as a condition 
affecting prognosis and outcome, not only in haemodialysis patients but also in CKD 
untreated subjects. Different potential injurious effects of inflammation were reported in 
human medicine. Firstly, clinical evidences showed hypoalbuminemia a powerful risk factor 
for mortality and this condition was attributed both to malnutrition and inflammation. Then, 
the role of hypoalbuminemia, as marker of inflammation, was strongly replaced by CRP. 
Although both albumin and CRP were demonstrated to be independent predictors of all cause 
mortality in haemodialysis patients, CRP contributed more to the risk of death. Whatever the 
cause of inflammation is, an increased synthesis of proinflammatory cytokines and 
leukocytosis occurs. Inflammation determines various modifications such as reduction in 
synthesis of negative acute phase proteins (albumin, pre-albumin, transferrin), decreased iron 
absorption and recycling, increased synthesis of positive acute phase proteins (CRP, SAA, 
fibrinogen, pentraxin, hepcidin, ceruloplasmin) and generation of a proathergenic lipoprotein 
profile (low HDL, oxidized LDL, high triglycerides). All these modifications were recognized 
to be responsible for an increased risk of cardiovascular damage2. Augmented atherosclerotic 
lesions were supposed to be the connection between inflammation and cardiovascular injury. 
In particular, CRP was thought to be an active factor in atherosclerotic lesions, by binding to 
damaged cells, with subsequent activation of innate immune system through complement, 
resulting in foam cells formation. Similarly, CRP is stimulated and attracted by complement 
release and by induction of pro-inflammatory cytokines. Furthermore, in general population, 
CRP was demonstrated to be an important risk factor for cardiovascular outcome, like acute 
myocardial infarction, peripheral vascular disease and all-cause mortality7. At present, no data 
regarding CRP concentration and its relation to mortality risk, are present in canine CKD 
patients. The present study analyzed CRP concentration in CH subjects and in patients 
belonging to all IRIS classes, correlation towards plasma creatinine and survival percentage in 
subjects with CRP above and below the reference value. All CH subjects showed CRP values 
below reference range and their mean concentration was 1.81 ± 0.36 mg/l. One-way ANOVA 
(p<0.05) reported a significant (p<0.0001) difference in mean serum CRP among CH, IRIS 1, 
IRIS 2, IRIS 3 and IRIS 4 patients. IRIS 1 and IRIS 2 patients showed a mean CRP value of 
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7.48 ± 2.77 mg/l and 4.28 ± 1.27 mg/l respectively. Mean CRP concentration in IRIS 3 and 
IRIS 4 was above the reference range, with values of 17.92 ± 5.16 mg/l and 20.15 ± 3.32 mg/l 
respectively. It is interesting to notice that mean serum CRP in late stages of CKD was about 
twice the reference cut off level. Furthermore, Tukey’s post-test underlined that CRP in CH 
subjects was significantly different (p<0.001) from both IRIS 3 and IRIS 4. Similarly, a 
significant (p<0.05) difference was found between mean serum CRP of IRIS 1 and IRIS 4. 
Instead, no significant difference was present among CH, IRIS 1 and IRIS 2, among IRIS 1, 
IRIS 2 and IRIS 3 and between IRIS 3 and IRIS 4. In agreement with previously reports in 
human medicine, in which CRP modifications were found more often in ESRD subjects and 
in patients undergoing haemodialysis, in dogs CRP alterations seemed to verify more 
frequently in late stages of CKD, rather than in early phases. These findings seemed to be 
confirmed even from contingency analysis (p<0.05) regarding the number of subjects with 
CRP above and below 9.7 mg/l in CH and IRIS 1, IRIS 2, IRIS 3 and IRIS 4 dogs. The 
difference in the number of subjects between the two groups was, in fact, significant 
(p<0.0001), showing a significant increase in the number of subjects with the progression of 
renal disease. For CRP, as well as for cTnI and Ca x P, Pearson test (p<0.05) showed no 
significant correlation between CRP and plasma creatinine. Once more a significant increase 
in mean CRP concentration, according to IRIS progression, did not correspond to plasma 
creatinine changes. These data were in complete agreement with several studies in human 
medicine, which reported no correlation between CRP elevations and GFR. In humans, CRP 
was demonstrated an independent and strong predictor of all-cause mortality in haemodialysis 
patients, showing a very high correlation with mortality. In the present study contingency 
analysis (p<0.05) regarding the number of survived and dead subjects in the group of patients 
with CRP above and below 9.7 mg/l reported a significant difference (p<0.0009). The number 
of dead patients was, in fact, significantly higher in the group with CRP above 9.7 mg/l, with 
no regards towards IRIS class. The relationship between CRP and negative outcome of CKD 
was demonstrated even by log-rank test (p<0.05), which showed a significant difference 
between the two groups (p<0.0009). Furthermore, the Kaplan-Meier curve of percentage of 
survival of the group with CRP above reference level was significantly (p<0.001) different 
from the other group. CKD patients with CRP below 9.7 mg/l showed a significantly higher 
percentage of survival. According to present data, in canine patients as well as in humans, 
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CRP seemed to be considered a very good marker of negative outcome and mortality in CKD. 
The significantly reduced percentage of survival of patients presenting CRP above 9.7 mg/l 
appeared independent from the IRIS class, which patients belonged to. This finding seemed to 
underline the independent nature of CRP in predicting negative outcome and may justify its 
determination even in early phases of the disease. 	  	  	  
α-tochopherol 
A strict relationship between negative cardiovascular outcome and oxidative stress was 
widely demonstrated in CKD humans. Particularly, augmented oxidative stress was supposed 
to be the link between inflammation and cardiovascular cellular damage in CKD patients. 
This class of subjects, in fact, showed a disequilibrium between pro and antioxidant 
compounds, which led to a state of increased oxidative stress. Several deficiencies in different 
components of antioxidant defence barrier, together with an increase in pro-oxidant activity, 
were found1. Oxidative stress was particularly elevated in patients undergoing haemodialysis, 
rather than in earlier CKD stages and a strong debate, about the relationship between 
haemodialysis and oxidative stress, is still present. On one hand, membrane bioincopatibility 
and endotoxin challenge, related to dialysis, seemed to worsen oxidative stress. On the other, 
haemodialysis sessions may replace some antioxidant properties2. Anyway it was 
demonstrated that even a single haemodialysis treatment is able to increase lipid peroxides 
and decrease antioxidants3. Furthermore, haemodialysis patients showed an augmented 
incidence of coronary artery disease and mortality, when compared to general population4. 
Atherosclerotic injuries were recognized as the leading cause of cardiovascular alterations in 
ESRD patients and atherosclerotic process seemed to be increased by high oxidative stress5. 
This finding correlated with the acceleration of atherosclerotic lesion onset in diabetic and 
uremic subjects1. Up to 72% of uremic patients, in fact, reported increased intima-media 
thickness of the carotid and femoral arteries, by the presence of atherosclerotic plaques6. 
Oxidized forms of low-density lipoproteins (LDL) were demonstrated to be deeply involved 
in atherogenetic process and high serum concentrations were found in haemodialysis subjects. 
Among different compounds of the antioxidant barrier, α-tochopherol showed an inhibiting 
action towards LDL oxidation1. In CKD patients, elevated serum concentrations of urea-
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derived cyanate are responsible for carbamylation of protein components of LDL. 
Carbamylation of LDL was recognized as a non-traditional risk factor for the development of 
cardiovascular diseases. In such a condition, endothelial cells attract monocytes and ingest 
carbamylated LDL, forming foam cells. This process leads to the formation of atherosclerotic 
plaques, which are composed by macrophages and foam cells, covered by a fibrous cap. A 
significant in vitro effect of α-tochopherol against LDL carbamylation was recently 
demonstrated7. α-tochopherol represents an effective, lipid-soluble, antioxidant of biological 
membrane of cells. Among its functions, α-tochopherol shows a protective action of cellular 
structures towards damages caused by oxygen free radicals and reactive products of lipid 
peroxidation. α-tochopherol is not only a powerful antioxidant, but it also contributes to the 
regulation of metabolic activity and cell proliferation and death of various cellular types, such 
as smooth muscle cells, endothelial cells and leukocytes8. Several studies reported that, 
although α-tochopherol levels were decreased in long-term haemodialysis patients compared 
to general population, this finding was unrelated to the patients’ prognosis. Previous human 
reports showed that α-tochopherol integration was not able to reduce mortality and, in same 
cases, may also act as a pro-oxidant agent9. Furthermore, α-tochopherol level was a mortality 
risk factor only linked to other factors, such as nutritional parameters10. On the other hand, 
other studies reported a protective effect of α-tochopherol to prevent renal oxidative damage. 
The onset of antioxidant renal effect seemed to be related and dependent on dose and duration 
of treatment11. In human CKD patients, infact, a 14-week oral supplementation of α-
tochopherol at a dosage of 600 mg/day resulted effective8. In veterinary medicine, the dietary 
supplementation of 200 IU/kg of α-tochopherol was found to reverse established 
glomerulosclerosis and tubulo-interstitial injury in CKD rats12 and was demonstrated an 
effective antioxidant in different animal species. A significant antioxidant activity of an 
association of α-tochopherol, vitamin C and β-carotene was reported in CKD cats13. As no 
data are currently available about α-tochopherol concentration in CKD canine patients 
belonging to different IRIS stages, the present study analyzed the serum concentration of α-
tochopherol in CH and CKD patients at various degree of severity. Furthermore, correlation 
analysis towards plasma creatinine and mortality in the group of patients with α-tochopherol 
levels above and below reference was assessed. In CH subjects mean α-tochopherol value 
	   147	  
was above the reference value (26.56 ± 1.11 ppm), while in IRIS 1 and IRIS 2 patients mean 
serum value was 10.71 ± 3.93 ppm and 17.48 ± 7.07 ppm respectively. IRIS 4 patients, 
instead, showed a mean value above reference range 22.42 ± 3.88 ppm. One-way ANOVA 
(p<0.05) among CH, IRIS 1, IRIS 2, IRIS 3 and IRIS 4 showed a significant difference 
(p<0.0002) and Tukey’s post-test identified a significant difference between mean α-
tochopherol of CH and IRIS 1 (p<0.01) and between CH and IRIS 4 (p<0.001). Moreover, 
mean α-tochopherol of IRIS 3 was significantly (p<0.05) different from IRIS 4. Instead, no 
significant difference was found among IRIS 1, IRIS 2, IRIS 3 and IRIS 4 and among IRIS 2, 
IRIS 3 and IRIS 4. Interestingly, the highest mean value of α-tochopherol were found in IRIS 
1 and in IRIS 4, while IRIS 2 and 3 showed a significantly lower concentration. On the basis 
of human data, it is difficult to interpreter present results, because significantly reduced 
concentrations of α-tochopherol were mainly reported in ESRD and haemodialysis patients. It 
can be hypothesized that the finding of lower α-tochopherol concentrations in very early and 
late stages of CKD may be due to a more intense consumption of antioxidant compounds in 
these phases. So, it would be extremely interesting to measure even reactive oxygen 
metabolite production, in order to perform a correlation analysis with the concentration of α-
tochopherol. According to Pearson correlation analysis (p<0.05), no significant correlation 
was found between serum α-tochopherol and plasma creatinine, with the exception of IRIS 2 
(p<0.00). In IRIS 2 patients, in fact, α-tochopherol seemed to reduce according to the increase 
in plasma creatinine. It is to be said that the low number of patients enrolled in IRIS 2 may 
have influenced results. Further studies should be necessary. Contingency analysis (p<0.05) 
referring to the number of subjects with α-tochopherol below and above 21.6 ppm among 
CH, IRIS 1, IRIS 2, IRIS 3 and IRIS 4 patients, showed a significant difference (p<0.0001). 
The number of patients with α-tochopherol above the reference significantly reduced with 
progression of IRIS stage and in IRIS 4 no patients presented α-tochopherol above 21.6 ppm. 
In agreement with previous studies conducted in human medicine, α-tochopherol 
concentration significantly decreased with the progression of CKD. In the present study, 
contingency analysis (p<0.05) regarding the number of survived and dead subjects in the 
group of patients with α-tochopherol below and above 21.6 ppm showed no significant 
difference. Similarly, both log-rank test (p<0.05) and Kaplan-Meier curve showed no 
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significant difference in the percentage of survival between dogs with α-tochopherol below 
and above 21.6 ppm. Although a significant decrease in α-tochopherol was found according 
to progression of CKD, no relationship towards mortality risk was found. In agreement with 
several human studies, α-tochopherol did not seem a good marker of negative outcome. 
Anyway, the significant reduction in its serum concentration with CKD progression, should 
let think about an oral integration of α-tochopherol, in order to reduce renal oxidative 
damage. 
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